Administration (pdf) - Antimicrobial Agents and Chemotherapy ...
03.03.2013 • Views
Share Embed Flag

Administration (pdf) - Antimicrobial Agents and Chemotherapy ...

Administration (pdf) - Antimicrobial Agents and Chemotherapy ...

Administration (pdf) - Antimicrobial Agents and Chemotherapy ...

SHOW MORE
SHOW LESS
ePAPER READ
DOWNLOAD ePAPER
aac.asm.org

Create successful ePaper yourself

Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.

START NOW

Robert C. Moellering, Jr.,<br />

Editor in Chief (1995)<br />

New Engl<strong>and</strong> Deaconess Hospital<br />

Boston, Mass.<br />

Michael Barza, Editor (1995)<br />

New Engl<strong>and</strong> Medical Center<br />

Hospitals<br />

Boston, Mass.<br />

George L. Drusano, Editor (1998)<br />

University of Maryl<strong>and</strong> School of<br />

Medicine<br />

Baltimore, Md.<br />

Robert D. Abbott (1993)<br />

Vincent T. Andriole (1993)<br />

Peter C. Appelbaum (1994)<br />

Gordon L. Archer (1995)<br />

Devron Averett (1993)<br />

Masanori Baba (1995)<br />

Frank Balis (1994)<br />

Arthur L. Barry (1995)<br />

John G. Bartlett (1993)<br />

Arnold S. Bayer (1994)<br />

Michel G. Bergeron (1995)<br />

Richard F. Bergstrom (1994)<br />

Karen K. Biron (1993)<br />

Jurg Blaser (1994)<br />

Gerald P. Bodey (1995)<br />

Karen Bush (1994)<br />

Claude Carbon (1995)<br />

Suzanne Chamberl<strong>and</strong> (1995)<br />

Henry F. Chambers (1994)<br />

Sarah H. Cheeseman (1995)<br />

Anthony Chow (1994)<br />

Donald M. Coen (1993)<br />

Patrice Courvalin (1994)<br />

William A. Craig (1993)<br />

William L. Current (1993)<br />

Michael H. Cynamon (1995)<br />

William E. Dismukes (1993)<br />

Gary V. Doern (1993)<br />

Michael N. Dudley (1995)<br />

David Durack (1994)<br />

Theodore Eickhoff (1994)<br />

ANTIMICROBIAL AGENTS AND<br />

CHEMOTHERAPY<br />

VOLUME 37 0 DECEMBER 1993 * NUMBER 12<br />

Thomas D. Gootz, Editor (1995)<br />

Pfizer Inc.<br />

Groton, Conn.<br />

Frederick G. Hayden, Editor<br />

(1995)<br />

University of Virginia Health<br />

Sciences Center<br />

Charlottesville, Va.<br />

EDITORIAL BOARD<br />

George M. Eliopoulos (1994)<br />

John N. Galgiani (1993)<br />

N. H. Georgopapadakou (1994)<br />

Dale N. Gerding (1994)<br />

Allan Godfrey (1993)<br />

Sherwood L. Gorbach (1995)<br />

Stephen B. Greenberg (1995)<br />

Scott M. Hammer (1995)<br />

Margaret R. Hammerschlag (1995)<br />

Robert E. W. Hancock (1995)<br />

W. Lee H<strong>and</strong> (1995)<br />

H. Hunter H<strong>and</strong>sfield (1995)<br />

Leonid B. Heifets (1993)<br />

David C. Hooper (1993)<br />

Michael R. Jacobs (1993)<br />

George A. Jacoby (1995)<br />

Susan E. Jensen (1994)<br />

James H. Jorgensen (1993)<br />

A. W. Karchmer (1994)<br />

Donald Kaye (1994)<br />

Robert E. Kessler (1993)<br />

George S. Kobayashi (1994)<br />

Donald J. Krogstad (1995)<br />

Philip Todd Lavin (1995)<br />

Marc LeBel (1994)<br />

Stephen A. Lerner (1995)<br />

Stuart B. Levy (1995)<br />

David R. Luke (1993)<br />

Gerald L. M<strong>and</strong>ell (1995)<br />

J. Joseph Marr (1995)<br />

Henry Masur (1993)<br />

Gary R. Matzke (1995)<br />

Douglas Mayers (1994)<br />

Antone A. Medeiros (1993)<br />

Michael Miller (1993)<br />

Henry W. Murray (1993)<br />

John D. Nelson (1995)<br />

Harold C. Neu (1995)<br />

Franklin A. Neva (1995)<br />

Wright Nichols (1995)<br />

Charles H. Nightingale (1993)<br />

Lawrence A. Pachla (1993)<br />

Joseph S. Pagano (1993)<br />

Thomas R. Parr, Jr. (1994)<br />

James E. Pennington (1995)<br />

T. J. Perun (1995)<br />

Brent Petty (1995)<br />

Philip A. Pizzo (1994)<br />

Ronald Polk (1993)<br />

Catherine P. Reese (1995)<br />

Richard C. Reichman (1995)<br />

Douglas D. Richman (1993)<br />

Allan Ronald (1993)<br />

John P. Rosazza (1995)<br />

John Rotschafer (1995)<br />

Robert H. Rubin (1993)<br />

Merle S<strong>and</strong>e (1994)<br />

W. Eugene S<strong>and</strong>ers, Jr. (1993)<br />

W. Michael Scheld (1995)<br />

Raymond F. Schinazi (1995)<br />

Robert T. Schooley (1993)<br />

Richard S. Schwalbe (1994)<br />

Barbara E. Murray, Editor (1997)<br />

University of Texas Health Science<br />

Center<br />

Houston, Tex.<br />

Herbert A. Kirst, Editor (1996)<br />

Lilly Research Laboratories<br />

Indianapolis, Ind.<br />

Chinstine C. S<strong>and</strong>ers, Editor (1994)<br />

Creighton University School of<br />

Medicine<br />

Omaha, Neb.<br />

Charles Shipman, Jr. (1994)<br />

David M. Shlaes (1994)<br />

Thomas R. Shryock (1995)<br />

Robert W. Sidwell (1993)<br />

Fritz Sorgel (1995)<br />

Philip J. Spagnuolo (1994)<br />

P. Frederick Sparling (1993)<br />

David P. Speert (1994)<br />

Spotswood Lee Spruance<br />

(1995)<br />

Harold St<strong>and</strong>iford (1994)<br />

David A. Stevens (1995)<br />

Charles W. Stratton (1994)<br />

Stephen E. Straus (1993)<br />

Alan M. Sugar (1995)<br />

Richard B. Sykes (1994)<br />

Francis C. Szoka, Jr. (1995)<br />

Francis P. Tally (1993)<br />

Diane E. Taylor (1993)<br />

Fred C. Tenover (1994)<br />

Clyde Thornsberry (1995)<br />

Alex<strong>and</strong>er Tomasz (1994)<br />

Roger D. Toothaker (1994)<br />

Thomas Walsh (1995)<br />

Bernard Weisblum (1994)<br />

Peter F. Weller (1995)<br />

Richard J. Whitley (1993)<br />

Richard Wise (1995)<br />

James Woodworth (1993)<br />

Lowell S. Young (1994)<br />

Geoffrey J. Yuen (1995)<br />

Barbara H. Iglewski, Chairman, Publications Board<br />

Linda M. Illig, Director, Joumals<br />

Kathleen M. Whalen, Production Editor<br />

<strong>Antimicrobial</strong> <strong>Agents</strong> <strong>and</strong> <strong>Chemotherapy</strong>, an interdisciplinary publication of the American Society for Microbiology (ASM), 1325<br />

Massachusetts Ave., N.W., Washington, DC 20005-4171, is devoted to the dissemination of knowledge relating to all aspects of antimicrobial,<br />

antiviral, antiparasitic, <strong>and</strong> anticancer agents <strong>and</strong> chemotherapy. Instructions to authors are published in the January issue each year; reprints<br />

are available from the editors <strong>and</strong> the Journals Division. <strong>Antimicrobial</strong><strong>Agents</strong> <strong>and</strong> <strong>Chemotherapy</strong> is published monthly, one volume per year.<br />

The nonmember print subscription prices are $250 (U.S.) (Canadians add 7% GST) <strong>and</strong> $294 (other countries) per year; single copies are $40<br />

(Canadians add 7% GST). The member print subscription prices are $49 (U.S.) (Canadians add 7% GST) <strong>and</strong> $84 (other countries; single<br />

copies are $10 (Canadians add 7% GST). For prices of CD-ROM versions, contact the Subscriptions Unit, ASM. Correspondence relating to<br />

scriptions, defective copies, missing issues, <strong>and</strong> availability of back issues should be directed to the Subscriptions Unit, ASM;<br />

correspondence relating to reprint orders should be directed to the Reprint Order Unit, ASM; <strong>and</strong> correspondence relating to disposition of<br />

submitted manuscripts, proofs, <strong>and</strong> general editorial matters should be directed to the Journals Division, American Society for Microbiology,<br />

1325 Massachusetts Ave., N.W., Washington, DC 20005-4171. Phone: (202) 737-3600.<br />

Claims for missing issues from residents of the United States, Canada, <strong>and</strong> Mexico must be submitted within 3 months after publication<br />

of the issues; residents of all other countries must submit claims within 6 months of publication of the issues. Claims for issues missing<br />

because of failure to report an address change or for issues "missing from files" will not be allowed.<br />

Second-class postage paid at Washington, DC 20005, <strong>and</strong> at additional mailing offices.<br />

POSTMASTER: Send address changes to<strong>Antimicrobial</strong> <strong>Agents</strong> <strong>and</strong> <strong>Chemotherapy</strong>, ASM, 1325 Massachusetts Ave., N.W., Washington,<br />

DC 20005-4171.<br />

Made in the U.S.A. Printed on acid-free paper.<br />

ISSN 0066-4804<br />

Copyright © 1993, American Society for Microbiology. CODEN: AMACCQ<br />

All Rights Reserved.<br />

The code at the top of the first page of an article in this journal indicates the copyright owner's consent that copies of the article may be<br />

made for personal use or for personal use of specific clients. This consent is given on the condition, however, that the copier pay the stated<br />

per-copy fee through the Copyright Clearance Center, Inc., 27 Congress St., Salem, MA 01970, for copying beyond that permitted by Sections<br />

107 <strong>and</strong> 108 of the U.S. Copyright Law. This consent does not extend to other kinds of copying, such as copying for general distribution, for<br />

advertising or promotional purposes, for creating new collective works, or for resale.

Alcouloumre, Marcia S., 2628<br />

Allen, Stanley D., 2716<br />

Aoki, Yuhko, 2656, 2662<br />

Arisawa, Mikio, 2656, 2662<br />

Ateshkadi, Arasb, 2650<br />

Bacheler, Lee T., 2606<br />

Balzarini, Jan, 2540<br />

Baqar, Shahida, 2688<br />

Barmada, S., 2678<br />

Beauchamp, Denis, 2727<br />

Becker, S. A. W. E., 2638<br />

Bell, Constance A., 2668<br />

Benchimol, Marlene, 2722<br />

Bentorcha, Fairouze, 2593<br />

Bergeron, Michel G., 2727<br />

Bergeron, Yves, 2727<br />

Berlutti, F., 2618<br />

Blais, Johanne, 2571<br />

Blom, Jens, 2550<br />

Bodeau, Amy L., 2710<br />

Borin, Marie T., 2650<br />

Bradford, Patricia A., 2578<br />

Brion, N., 2674<br />

Cantoni, Lavinia, 2527<br />

Carelli, Maria, 2527<br />

Carey, Patrick M., 2650<br />

Carias, Lenore L., 2760<br />

Cesana, M., 2545<br />

Chamberl<strong>and</strong>, Suzanne, 2571<br />

Chen, Ming, 2550<br />

Christensen, S0ren Br0gger,<br />

2550<br />

Cohen, Michael A., 2563<br />

Colturani, F., 2545<br />

Comodi-Ballanti, M. R., 2618<br />

Corbett, Anita H., 2599<br />

Cory, Michael, 2668<br />

Craig, William A., 2650<br />

Dal Pizzol, Virginia, 2693<br />

Dazer, Maureen E., 2563<br />

de Aquino Almeida, Joao<br />

Carlos, 2722<br />

Debyser, Zeger, 2540<br />

de Cespedes, Gilda, 2593<br />

De Clercq, Erik, 2540<br />

de Lalla, Fausto, 2693<br />

Delbos, Frangoise, 2593<br />

Desmyter, Jan, 2540<br />

de Souza, W<strong>and</strong>erley, 2722<br />

Dhindsa, Harinder S., 2754<br />

Domagala, John M., 2563<br />

Ducharme, Murray P., 2706..<br />

Dunne, W. Michael, Jr., 2522<br />

Dworkin, R., 2678<br />

Dykstra, Christine C., 2668<br />

Edwards, Barbara A., 2754<br />

Edwards, David J., 2706<br />

Edwards, John E., Jr., 2628<br />

Fairley, Terri A., 2668<br />

Faleschini, E., 2545<br />

Fallani, Stefania, 2693<br />

Fich, Karen, 2550<br />

Finegold, S. M., 2638<br />

Frachet, B., 2674<br />

Fraimow, Henry S., 2736<br />

Franzini, P., 2545<br />

French, Pamela, 2736<br />

Fukasawa, Masatomo, 2743<br />

Fukatsu, Hiroshi, 2756<br />

Galgiani, John N., 2517<br />

Garber, Sena, 2606<br />

Garcia, M. M., 2638<br />

Gaspar, Erzsebet, 2593<br />

Ghannoum, Mahmoud A.,<br />

2628<br />

Ghezzi, Pietro, 2527<br />

Gilbert, D., 2678<br />

Gongalves, Noemia<br />

Rodrigues, 2722<br />

Goody, Roger, 2612<br />

Grewal, Jaswinder, 2645<br />

Guerry, Philippe, 2599<br />

H<strong>and</strong>, Debra L., 2557<br />

H<strong>and</strong>, W. Lee, 2557<br />

Hansen, Lori M., 2699<br />

Hara, Kohei, 2762<br />

Hashizume, Terutaka, 2756<br />

Hesse, Werner H., 2622<br />

Hirata, Michimasa, 2534<br />

Hirata, Takahiro, 2656<br />

Hirsh, Dwight C., 2699<br />

Holy, Antonin, 2540<br />

Hoogkamer, Johannes F. W.,<br />

2622<br />

Hooper, David C., 2588<br />

Hoosen, Anwar A., 2733<br />

Horaud, Thea, 2593<br />

Howell, John M., 2754<br />

Hub<strong>and</strong>, Michael D., 2563<br />

Hughes, George S., 2650<br />

Ibrahim, Ashraf S., 2628<br />

Imbimbo, B. P., 2545<br />

Immendoerfer, Ulrike, 2612<br />

Jackson, M. Keven, 2716<br />

Jacoby, George A., 2760<br />

Jindrich, Jindrich, 2540<br />

Johnson, Curtis A., 2650<br />

Jones, Ronald N., 2747<br />

Kaku, Mitsuo, 2762<br />

Kamiyama, Tsutomu, 2656<br />

Kaplan, Sheldon L., 2522<br />

Kaufhold, Achim, 2740<br />

Keyhani, Afsaneh, 2584<br />

Kharazmi, Arsalan, 2550<br />

Kharsany, Ayesha B. M.,<br />

2733<br />

Koenig, Bernhard, 2612<br />

Koga, Hironobu, 2762<br />

Kohlhepp, S., 2678<br />

Kohno, Shigeru, 2762<br />

Author Index<br />

Kondoh, Masumi, 2662<br />

Lam, Patrick Y.-S., 2606<br />

Larrick, James W., 2534<br />

Lee, K., 2638<br />

Leggett, J., 2678<br />

Le Gros, V., 2674<br />

Lemmich, Else, 2550<br />

Leser, Ulrike, 2612<br />

Levy, Stuart B., 2699<br />

Lins, Ulysses, 2722<br />

Lombardi, F., 2545<br />

Louchahi, K., 2674<br />

Maass, Gerhard, 2612<br />

Manavathu, Elias K., 2645<br />

Marshall, Steven A., 2747<br />

Marshall, Steven H., 2760<br />

Mason, Edward O., Jr., 2522<br />

Matsuda, Kouji, 2756<br />

Maurin, M., 2633<br />

McMurry, Laura M., 2699<br />

McNamara, Patrick J., 2706<br />

McQueen, Teresa J., 2584<br />

Mehta, Reeta T., 2584<br />

Meservey, Mark A., 2563<br />

Milocchi, Fabio, 2693<br />

Mitsutake, Kotaro, 2762<br />

Miyasaki, Kenneth T., 2710<br />

Miyazaki, Haruko M., 2762<br />

Miyazaki, Yoshitsugu, 2762<br />

Morikawa, Keiko, 2684<br />

Morikawa, Shigeru, 2684<br />

Mueller, Barbara, 2612<br />

Nadelmann, Lynda, 2550<br />

Naiman, Noreen A., 2668<br />

Nakada, Naoki, 2656<br />

Nakagawa, Susumu, 2756<br />

Nakamura, Yumiko, 2662<br />

Nakayama, Noboru, 2662<br />

Nervetti, G., 2545<br />

Ng, Eva Y., 2588<br />

Nicastro, G., 2545<br />

Novelli, Andrea, 2693<br />

Okamoto, Osamu, 2756<br />

Oliary, J., 2674<br />

Oseko, Fumimaro, 2684<br />

Osheroff, Neil, 2599<br />

Otto, Michael J., 2606<br />

Pacheco, Nancy D., 2688<br />

Passariello, C., 2618<br />

Pellizzer, Giampietro, 2693<br />

Periti, Piero, 2693<br />

Petitjean, O., 2674<br />

Pfaff, Eberhard, 2612<br />

Pflieger, Philippe, 2599<br />

Pohl, Jan, 2710<br />

Potgieter, Elsa, 2740<br />

Privitera, G., 2545<br />

Raoult, D., 2633<br />

Rayner, Marlene M., 2606<br />

Reid, Carol D., 2606<br />

Rice, Louis B., 2760<br />

Rigon, Antonio, 2693<br />

Rol<strong>and</strong>, Gregory E., 2563<br />

Rollwagen, Florence M., 2688<br />

Rolston, Kenneth V., 2584<br />

Rosenbaum, Beverly, 2584<br />

Rosenberg, Ivan, 2540<br />

Sanada, Minoru, 2756<br />

S<strong>and</strong>ers, Christine C., 2578<br />

Sansano, Sebastiano, 2622<br />

Sawada, Masashi, 2684<br />

Scarnati, Helen, 2606<br />

Schindler, Jay J., 2716<br />

Selan, L., 2618<br />

Selsted, Michael E., 2628<br />

Shafer, William M.j, 2710<br />

Shimada, Hisao, 2656<br />

Shimomoura, Yuko, 2534<br />

Sironi, Marina, 2527<br />

Soussy, Claude J., 2588<br />

Stair, Thomas O., 2754<br />

Stecca, Clara, 2693<br />

Stoeckel, Klaus, 2706<br />

Sumita, Yoshihiro, 2743<br />

Summanen, P., 2638<br />

Sutton, Lorraine, 2760<br />

Tagliabue, G., 2545<br />

Tanaka, Nobuo, 2756<br />

Tardif, Carole, 2571<br />

Tardif, Manon, 2727<br />

Tarr<strong>and</strong>, Jeffrey J., 2584<br />

Taylor, Diane E., 2645<br />

Thaller, M. C., 2618<br />

The<strong>and</strong>er, Thor G., 2550<br />

Thormar, Halldor, 2540<br />

Tidwell, Richard R., 2668<br />

Tod, M., 2674<br />

Tomono, Kazunori, 2762<br />

Trieu-Cuot, Patridk, 2593<br />

Van Den Ende, Jan, 2733<br />

van der Meer, Jos W. M.,<br />

2527<br />

Venuti, Elaine, 2736<br />

Viola, Renato, 2693<br />

Visconti, M., 2545<br />

Vogels, Maria T. E., 2527<br />

Warren, Reed P., 2716<br />

Watanabe, Junko, 2656<br />

Wexler, H. M., 2638<br />

Winslow, Dean L., 2606<br />

Wolfson, John S., 2588<br />

Wright, Susan C., 2534<br />

Yoder, Steven L., 2563<br />

Yoshida, Masao, 2534<br />

Yoshihara, Fumie, 2662<br />

Zheng, Hui, 2534<br />

Zhong, Jian, 2534<br />

Zimmerli, Werner, 2622<br />

Zimmerman, Stephen W.,<br />

2650

ACKNOWLEDGMENT<br />

The following persons served as invited special reviewers for the journal during 1993, <strong>and</strong> their help is greatly appreciated.<br />

L. B. Adams<br />

Kenneth E. Aldridge<br />

N. E. Allen<br />

Raza Aly<br />

David Amacher<br />

S. G. B. Amyes<br />

Koen Andries<br />

Michael Apicella<br />

George Aronoff<br />

Eurico Arruda<br />

M. Arthur<br />

Cyrus J. Bacchi<br />

Johan S. Bakken<br />

R. H. Baltz<br />

Jan Balzarini<br />

John Barrett<br />

R. J. Baumann<br />

J. M. Becker<br />

Robert Belshe<br />

John Bennett<br />

Michael Bennish<br />

Herbert Benson<br />

Richard Berger<br />

Brigitte Berger-Bachi<br />

Ed Bernard<br />

Robert Betts<br />

J. Biehle<br />

John Bilello<br />

John C. Boothroyd<br />

John Boyce<br />

Itzhak Brook<br />

K. N. Brown<br />

Michael R. W. Brown<br />

Daniel Butler<br />

Frank M. Calia<br />

Wayne Campbell<br />

Stephen A. Chartr<strong>and</strong><br />

Ming Chen<br />

V. J. Chen<br />

Ambrose L. Cheung<br />

Ian Chopra<br />

Sunwen Chou<br />

T.-C. Chou<br />

Ming Chu Hsu<br />

Joanna Clancy<br />

Robert A. Clark<br />

Thomas G. Cleary<br />

Donald Clewell<br />

Myron Cohen<br />

S. T. Cole<br />

Edward Connor<br />

J. W. Costerton<br />

F. T. Counter<br />

Jorge Crosa<br />

Clyde Crumpacker<br />

Eric Cundliffe<br />

C. J. Czuprynski<br />

Richard Davey<br />

William Davis<br />

Fern<strong>and</strong>o de la Cruz<br />

A. Deldar<br />

V. Deretic<br />

Louis Diamond<br />

William Drew<br />

David A. Dubnau<br />

Richard Duma<br />

Gary Dunny<br />

Frank Dutko<br />

Paul H. Edelstein<br />

John E. Edwards, Jr.<br />

J. M. Ehret<br />

Anton F. Ehrhardt<br />

Ingvar Eliasson<br />

Emilio Emini<br />

Janet Englund<br />

Alejo Erice<br />

James Evermann<br />

Bruce Farber<br />

P. B. Fern<strong>and</strong>es<br />

Giora Feuerstein<br />

Scott Filler<br />

Roberta Fontana<br />

S. G. Franzblau<br />

Jean Marie Frere<br />

Robert A. Fromtling<br />

Phillip Furman<br />

P. R. J. Gangadharam<br />

R. H. Gelber<br />

John Gerin<br />

Clarence Gibbs<br />

B. Gicquel<br />

Hagain Ginsburg<br />

Arthur Girard<br />

R. P. Gladue<br />

Richard V. Goering<br />

Simeon Goldblum<br />

Mark Goldman<br />

Don Goldmann<br />

E. Goldstein<br />

W. Manford Gooch<br />

Michael Gottlieb<br />

Eduardo Gotuzzo<br />

J. R. Graybill<br />

Max Grogl<br />

Richard Guerrant<br />

S. Gundmundsson<br />

Laurent C. Gutmann<br />

Richard Hafner<br />

Ruth M. Hall<br />

W. H. Hall<br />

S<strong>and</strong>ra H<strong>and</strong>werger<br />

D. J. Hardy<br />

Alan Hay<br />

M. P. Hayes<br />

Kevin Hazen<br />

J. V. Heck<br />

Fred Henderson<br />

M. J. Henry<br />

Erik Hewlett<br />

Martin Hirsch<br />

Joachim Volker Holtje<br />

Jay Hoofnagle<br />

Thomas Hooton<br />

Thea Horaud<br />

Sally Hubert<br />

Joel Huff<br />

Walter Hughes<br />

Joseph R. Iaconis<br />

C. B. Inderlied<br />

William Jacobs<br />

J. L. Johnson<br />

R. C. Johnson<br />

Victoria Johnson<br />

Warren D. Johnson<br />

R. N. Jones<br />

Thomas C. Jones<br />

Colin Jordan<br />

Allen B. Kaiser<br />

Edward Kaplan<br />

Sheldon Kaplan<br />

G. E. Kenney<br />

Douglas S. Kernodle<br />

Louis Kirchhoff<br />

Saul Kit<br />

S. J. Klebanoff<br />

Jerome Klein<br />

Michael Kleinberg<br />

Mark S. Klempner<br />

Tamsin Knox<br />

Joseph Kovacs<br />

R. B. Kundsin<br />

S. Kuwahara<br />

M. T. Labro<br />

Br<strong>and</strong>on Larder<br />

Karl L. M. Lavrijsen<br />

John M. Leedom<br />

Francois LeGoffic<br />

Paul Lietman<br />

Philip D. Lister<br />

Hans Liu<br />

Benjamin Luft<br />

Paul T. Magee<br />

Dennis Maki<br />

Michael H. Malamy<br />

G. G. Marconi<br />

Thomas J. Marrie<br />

Anthony Maxwell<br />

John McBride<br />

Robert McCabe<br />

J. W. McFarl<strong>and</strong><br />

James McSharry<br />

John Mellors<br />

Rolf Menzel<br />

Jay Merluzzi<br />

R. B. Merrifield<br />

Wayne Meyers<br />

Louis H. Miller<br />

Marvin J. Miller<br />

Hiroaki Mitsuya<br />

Harry L. T. Mobley<br />

Keiko Morikawa<br />

J. Glenn Morris, Jr.<br />

Gene Morse<br />

J. W. Murphy<br />

Kzumi Nakashima<br />

Yuziro Namba<br />

Thalia Nicas<br />

Hiroshi Nikaido<br />

David Nix<br />

C. E. Nord<br />

J. Staffan Normark<br />

M. N. Novilla<br />

Frank C. Odds<br />

Richard Odom<br />

John W. Ogle<br />

James G. Olson<br />

Andrew Onderdonk<br />

Michael J. Otto<br />

Tim Palzkill<br />

L. W. Parks<br />

Sally Parsons<br />

Rudi Pauwels<br />

Richard D. Pearson<br />

Jean-Claude Pechere<br />

J. R. Perfect<br />

C. Perronne<br />

Edward Pesanti<br />

Lance Peterson<br />

William Petri<br />

Michael A. Pfaller<br />

Larry K. Pickering<br />

Michael Polis<br />

Richard Pollard<br />

D. A. Preston<br />

Richard Proctor<br />

Steven J. Projan<br />

Paul Quie<br />

John P. Quinn<br />

J. A. Radding<br />

A. Rahman<br />

Robert M. Rakita<br />

R. N. Rao<br />

G. J. Ras<br />

Nolin Rastogi<br />

Jonathan I. Ravdin<br />

Thomas Rea<br />

Michael Rein<br />

Jack Remington<br />

J. A. Retsema<br />

John H. Rex<br />

Louis B. Rice<br />

Y. Rikihisa<br />

Michael Rinaldi<br />

G. D. Roberts<br />

Keith Rodvold<br />

Julian I. Rood<br />

Henry Rosen<br />

T. Rosen<br />

Martin Rosenbert<br />

Philip Rosenthal<br />

Paul Roy<br />

Daniel Sahm<br />

Robert Salata<br />

Louis D. Saravolatz<br />

S. T. Schlossman<br />

Dennis Schmatz<br />

Frederick R. J. Schmidt<br />

Jerome Schwartz<br />

Karen J. Shaw<br />

Gerald Shockman<br />

G. D. Sides<br />

Donald Smee<br />

Arnold L. Smith<br />

James W. Smith<br />

Jean-Pierre Sommadossi<br />

Stephen Spector<br />

Brian G. Spratt<br />

Allen C. Steere<br />

Joyce Sutcliffe<br />

K. Takayama<br />

Kenneth S. Thomson<br />

John Threlfall<br />

Margaret Tisdale<br />

Edmund Tramont<br />

Kenneth Tumecki<br />

Elaine I. Tuomanen<br />

J. R. Turner<br />

David Tyrrell<br />

B. Ullman<br />

M. Vaara<br />

Jos van der Meer<br />

Ralph van Furth<br />

Mark Wainberg<br />

David H. Walker<br />

R. J. Wallace, Jr.<br />

Edward Walsh<br />

Peter Walzer<br />

C. C. Wang<br />

Richard Weiss<br />

Eric Westin<br />

Hannah M. Wexler<br />

Richard Reinhard Wirth<br />

Brian Wispelway<br />

E. Wolinsky<br />

Gary Wormser<br />

D. M. Yajko<br />

Oto Zak<br />

Michael Zasloff

a<br />

U<br />

AMIERICAN SOCIETY FOR MICROBIOLOGY<br />

AND<br />

NATIONAL CENTER FOR INFECTIOUS DISEASES<br />

1994 POSTDOCTORAL RESEARCH<br />

ASSOCIATES PROGRAM<br />

Up to ten associate positions will be awarded by the American Society for Microbiology<br />

for full-time research on infectious diseases which cause significant public health problems.<br />

Associates will perform research in residence at the National Center for Infectious Diseases<br />

(NCID) which is headquartered at the Centers for Disease Control <strong>and</strong> Prevention (CDC)<br />

in Atlanta, GA. In addition to Atlanta, NCID operates laboratories in Ft. Collins, CO,<br />

Anchorage, AK, <strong>and</strong> San Juan, Puerto Rico.<br />

Eligible fields of study include: Bacterial <strong>and</strong> Mycotic Diseases, Viral <strong>and</strong> Rickettsial<br />

Infections, Nosocomial Infections, HIV/AIDS, Vector-borne Infectious Diseases, Sexually<br />

Transmitted Diseases, <strong>and</strong> Parasitic Diseases.<br />

The program is intended for individuals who have held a doctorate degree (Ph.D., Sc.D.,<br />

or M.D.) since, but not earlier than, May 1, 1991. Exceptions may be made for those<br />

with more experience. The programn is open to both U.S. <strong>and</strong> foreign citizens. Qualified<br />

applicants will receive consideration without regard to race, creed, color, age, sex, or<br />

national origin. Diversity among associates is encouraged. The program provides an<br />

annual stipend ranging from $28,000 to $33,000 <strong>and</strong> up to $2,000 for professional<br />

development.<br />

The application deadline is February 1, 1994. The Postdoctoral Research Program is<br />

administered by the American Society for Microbiology. All inquiries regarding this<br />

program should be addressed to: Coordinator, Postdoctoral Research Program, American<br />

Society for Microbiology, 1325 Massachusetts Avenue, N.W., Washington, D.C. 20005;<br />

(202) 942-9299.<br />

ASM ODO/NOID|<br />

AMERICAN SIETY CENTERS POR DISEASE CONTROL/NATIONAL CENTER FOR INFEc11OLIS DIS.ESES<br />

FOR MICROBIOLOGY AND PREVENION<br />

- I -<br />

0 U.<br />

U

Abdalla, Salah, 138<br />

Abe, Shigeru, 2228<br />

Acharya, Gopal, 2418<br />

Adam, D., 1620<br />

Adkinson, N. Franklin, Jr.,<br />

1463<br />

Agacfidan, Ali, 1746<br />

Aggarwal, Sunil K., 818<br />

Agrawal, Krishna C., 818<br />

Aguado, J. M., 2490<br />

Aguirre, Tania, 580<br />

AIDS Clinical Trials Group<br />

Virology Committee<br />

Resistance Working Group,<br />

1095<br />

Ajiki, Yoko, 1749<br />

Akahane, Kazumi, 1764<br />

Akalin, H. E., 1637<br />

Akalin, H. Erdal, 1831<br />

Akao, Mitsutaro, 1313<br />

Akashi, Akira, 287, 1826<br />

Akova, M., 1637<br />

Akova, Murat, 1831<br />

Aksnes, Arne, 2024<br />

Alam, N. H., 1572<br />

Alcouloumre, Marcia S., 2628<br />

Alder, Jeffrey, 864, 1329<br />

Aldridge, Kenneth E., 1986<br />

Aliu, Yusuf O., 1050<br />

Allard, J. P., 2239<br />

Allegra, Carmen J., 1227<br />

Allen, S. D., 1696<br />

Allen, Stanley D., 2716<br />

Allouch, P., 737<br />

Alos, Ignacio, 2059<br />

Alpert, Nathaniel M., 1270,<br />

2144<br />

Alteri, Enrica, 2087<br />

Althaus, Irene W., 1127<br />

Amicosante, Gianfranco, 1324<br />

Amirault, Pascal, 1790<br />

Amsterdam, Daniel, 896<br />

Anaissie, Elias J., 51<br />

Anderson, Kevin P., 1945<br />

Andremont, A., 1432<br />

Andrews, Charla, 178<br />

Aoki, Hiroyuki, 2173<br />

Aoki, Yuhko, 2656, 2662<br />

Appelbaum, P. C., 1649<br />

Arai, Sumio, 287, 1826<br />

Arakawa, Yoshichika, 984<br />

Arduino, Jean-Marie, 1095<br />

Argenson, Jean Noel, 1214<br />

Arika, Tadashi, 363, 785<br />

Arisawa, Mikio, 2656, 2662<br />

Arison, Byron, 1737<br />

Aristoff, Paul A., 1127<br />

Arlet, Guillaume, 2020<br />

Armstrong, Donald, 398, 2323<br />

Aronovitz, Gerson H., 159<br />

Artaza, M. A., 1587<br />

Arthur, Michel, 78, 1563<br />

Arts, Eric J., 1305<br />

Ashdown, Leslie R., 905<br />

Ashtekar, Dilip R., 183<br />

Ashton, Sarah H., 393<br />

Ateshkadi, Arasb, 2650<br />

Atzori, Chiara, 1492<br />

Averett, Devron R., 441<br />

Awan, Aftab R., 2478<br />

Aymard, M., 2239<br />

Azad, Raana F., 1945<br />

Babich, John, 2144<br />

Babst, Anna F., 1552<br />

Bacheler, Lee T., 2606<br />

Back, Arthur F., 1552<br />

Bader, John P., 754<br />

Baginski, Rainer, 750<br />

Bajaksouzian, Saralee, 1799<br />

Bakken, Johan S., 1171<br />

Balfour, Henry H., Jr., 357,<br />

835<br />

Ballet, Jean-Jacques, 889<br />

Ballow, Charles H., 1065,<br />

1073<br />

Baltaian, Manik, 1614<br />

Balzarini, J., 332<br />

Balzarini, Jan, 2540<br />

Bamberger, David M., 203<br />

B<strong>and</strong>o, Kaori, 957<br />

Baqar, Shahida, 2688<br />

Baquero, F., 1982<br />

Baquero, Fern<strong>and</strong>o, 2059,<br />

2427<br />

Baquero, Maria-Rosario, 2059<br />

Barbadora, Karen, 1238<br />

Barbhaiya, R. H., 1180<br />

Barbour, Alan G., 1115, 1704<br />

Bargiggia, Stefano, 2212<br />

Barker, Patrick J., 84<br />

Barko, Nir, 2483<br />

Barluzzi, Roberta, 2422<br />

Barmada, S., 2678<br />

Barone, Joseph A., 778<br />

Barrios, Alcira Angelo, 859<br />

Barrow, William W., 652<br />

Barry, A. L., 893<br />

Barry, Arthur L., 14<br />

Barry, Beatrix, 1599<br />

Bartizal, Ken F., 39<br />

Bartlett, John A., 2449<br />

Bartlett, Marilyn S., 39, 1543,<br />

2166<br />

Bartos, Linda, 512<br />

Barza, Michael, 931<br />

Barzen, Georg, 1367<br />

Basco, Leonardo K., 924<br />

Bastone, Elisa B., 914<br />

Batra, Kumar K., 1025<br />

Bauchet, J., 633<br />

Bauer, Friedrich Eckhard,<br />

2153<br />

Bauer, Gerhard, 115<br />

Bayer, Arnold S., 546, 2030<br />

Bazmi, Hengameh Z., 875<br />

Beam, Thomas R., Jr., 896<br />

Beauchamp, Denis, 2727<br />

Beaudouin, Robert, 1264<br />

Beck, Francis, 1873<br />

Becker, S. A. W. E., 2638<br />

Beckett, Laurel A., 1095<br />

Beijnen, Jos H., 1426<br />

Bell, Constance A., 2668<br />

Beller, Jean-Paul, 1873<br />

Bellido, J. L. Mufioz, 911<br />

Benchimol, Marlene, 2722<br />

Bender, Rudolf, 1659<br />

Bengtsson, Stellan, 2200<br />

Bennett, Diane, 613<br />

Bennett, L. Lee, Jr., 1004<br />

Bennett, Peter M., 153<br />

AUTHOR INDEX<br />

VOLUME 37<br />

i<br />

Bennett, Sam, 825<br />

Bennett, W. M., 347<br />

Benson, Constance A., 1444<br />

Benson, John M., 1343<br />

Bentorcha, Fairouze, 2593<br />

Berger, L. C., 1713<br />

Bergeron, Michel G., 2727<br />

Bergeron, Yves, 2727<br />

Berggren, Terriel, 2033<br />

Berkowitz, Barry A., 393<br />

Berlutti, F., 2618<br />

Bernan, Valerie, 1624<br />

Bernard, E., 921<br />

Bernard, Edward M., 398,<br />

2323<br />

Bertasso, A., 559<br />

Berti, Marisa, 741<br />

Bertr<strong>and</strong>, Kevin P., 1624<br />

Bethell, Richard C., 1473<br />

Bethune, Linda, 746<br />

Betriu, Carmen, 1717<br />

Beumer, Henriette, 885<br />

Beveridge, Terry J., 715<br />

Beyer, Jorg, 1367<br />

Bhatt, Arun D., 183<br />

Bhattacharya, M. K., 1197<br />

Bhattacharya, Prabhat Kumar,<br />

2459<br />

Bhattacharya, S. K., 1197<br />

Bienen, E. Jay, 1082<br />

Bierman, Robert H., 778<br />

Bilello, John A., 115<br />

Billard, Lynne, 825<br />

Billhardt, Uta-Maria, 1659<br />

Binczewski, Brian, 1238<br />

Bindra, Rani R., 1360<br />

Birmingham, Mary C., 1065,<br />

1073<br />

Biron, Karen K., 19<br />

Bischofberger, Norbert, 2247<br />

Bistoni, Francesco, 2422<br />

Bj0rneklett, Arvid, 2443<br />

Black, Paul L., 71<br />

Black, Roberta J., 1095<br />

Blahy, Olga M., 1576<br />

Blais, Johanne, 1701, 2571<br />

Blanchet, Francoise, 1790<br />

Blasi, Elisabetta, 2422<br />

Blatter, Marianne, 1971<br />

Blazquez, J., 1982<br />

Blazquez, Jesus, 2059<br />

Blom, Jens, 2550<br />

Blum, Hubert E., 1539<br />

Bodeau, Amy L., 2710<br />

Bodey, Gerald P., 51, 2504<br />

Bodey, G. P., 729<br />

Bodmer, Thomas, 2054<br />

Body, Barbara A., 39<br />

Bogaki, Mayumi, 839<br />

Bohm, Rudolf, 1370<br />

Boivin, Guy, 357<br />

Bolan, Gail A., 1670<br />

Bold, Guido, 2087<br />

Bollen, A., 142<br />

Bombardelli, Ezio, 1492<br />

Bond, Lynne, 474<br />

Bongaerts, G. P. A., 2017<br />

Bonnay, M., 1432<br />

Bonnem, Eric, 512<br />

Bonner, Daniel P., 213, 1289<br />

Bonnesen, Shari Powers, 1614<br />

Bonnet, M., 1015<br />

Bordon, Florence, 1247<br />

Borin, Marie, 1137<br />

Borin, Marie T., 2650<br />

Borner, Klaus, 1835<br />

Borroto-Esoda, Katyna, 1720<br />

Borsch, Carina M., 128<br />

Bosso, John A., 1414<br />

Bostian, Keith A., 377<br />

Bouchard, Celine, 1373<br />

Boucher, Charles, 1390<br />

Boucher, Charles A. B., 1525,<br />

2231<br />

Boudinot, F. Douglas, 1343<br />

Boudjema, Karim, 1873<br />

Boulerice, Francois, 1305<br />

Bourget, Philippe, 54<br />

Bourneix, C., 1432<br />

Bouvet, Olivier, 464<br />

Bouza, Emilio, 1200<br />

Bova, Carol A., 178<br />

Bowden, Raleigh A., 1360<br />

Bowdon, Bonnie J., 1004<br />

Boyce, Steven T., 1890<br />

Boyd, Malcolm R., 642<br />

Boyd, Michael R., 754, 1037<br />

Bradford, Patricia A., 251,<br />

1989, 2578<br />

Bradley, Suzanne F., 2003<br />

Brake, W. B., 1713<br />

Br<strong>and</strong>icourt, Olivier, 970<br />

Brasseur, Philippe, 889<br />

Bray, Patrick G., 1318<br />

Brazeau, Gayle A., 246<br />

Breslin, Barbara J., 2407<br />

Bressolle, Francoise, 464<br />

Bril-Bazuin, C., 2318<br />

Brion, N., 737, 2674<br />

Broccali, Gianpietro, 2212<br />

Brockmeyer, N. H., 1010<br />

Broder, Samuel, 810<br />

Brogard, J. M., 1488<br />

Brook, I., 1882<br />

Brook, Itzhak, 997, 1452, 1531<br />

Brookshire, Kenneth W., 213<br />

Brouwer, J. T., 595<br />

Brown, Barbara A., 1850<br />

Brown, Prince, 613<br />

Brown, Richard B., 1<br />

Brown, Sheldon T., 398, 2323<br />

Bruch, Suzanne, 2449<br />

Bruggeman, Cathrien A., 218<br />

Brumfitt, W., 1558<br />

Bruneton, Jean, 859<br />

Brunnemann, Sherry R., 93<br />

Bruno, Antonella, 1492<br />

Bryskier, Andre, 1560<br />

Bubp, Jeff, 1137<br />

Buckheit, Robert W., Jr., 754<br />

Burger, David M., 1426<br />

Burstein, Esther, 2483<br />

Busch, Janice, 775<br />

Bush, Karen, 851, 1989<br />

Busso, Mariano, 1127<br />

Butler, T., 1572<br />

Butler, Thomas, 2418<br />

Buu-Hoi, A., 2159<br />

Byrnes, Vera W., 947, 1576<br />

Cacalano, Grace, 667<br />

Cahill-Feehan, Carol, 1693

ii AUTHOR INDEX<br />

Cal, Stanley X., 1869<br />

Caliendo, Angela M., 1480<br />

Callahan, Ronald J., 1270<br />

Callaway, James E., 1614<br />

Calvat, Sylvie, 281<br />

Cambau, Emmanuelle, 1247<br />

Cameron, Janet, 1390<br />

Cameron, Janet M., 2231<br />

Cameron, Miriam L., 2449<br />

Cammack, Nick, 1390, 2231<br />

Cammarata, Catherine, 1986<br />

Campbell, D. A., 1180<br />

Campbell, Lee Ann, 8<br />

Canfield, Craig, 1417<br />

Cannon, Deborah L., 875<br />

Cantin, Line, 1993<br />

Canton, Rafael, 2059<br />

Cantoni, Lavinia, 2527<br />

Carbon, Claude, 1790, 2466<br />

Carelli, Maria, 2527<br />

Carey, Patrick M., 2650<br />

Carias, Lenore L., 610, 1061,<br />

2760<br />

Carret, G., 1685<br />

Cars, Otto, 2200<br />

Carsenti-Etesse, H., 921<br />

Carter, Stephen G., 144<br />

Cartwright, Frank D., 1726<br />

Casadevall, Arturo, 1383<br />

Casetta, A., 2159<br />

Cassileth, Peter A., 474<br />

Cataldo-Caputzal, Lucille,<br />

1556<br />

Cavalieri, Stephen J., 1171<br />

Cave, Andre, 859<br />

Cekleniak, Natalie, 1624<br />

Cercenado, E., 1604<br />

Cercenado, Emilia, 1200<br />

Cesana, M., 2545<br />

Cesana, Marina, 2298<br />

Chachaty, E., 1432<br />

Chamberl<strong>and</strong>, Suzanne, 1701,<br />

1993, 2571<br />

Chambers, Henry F., 1144<br />

Chan, Chor-Bun, 2007<br />

Chan, C. Y., 1001<br />

Chan, Marion Man-Ying, 1909<br />

Ch<strong>and</strong>rasekar, P. H., 1927<br />

Chapelsky, Martha, 775<br />

Chaplain, C., 737<br />

Chastre, Jean, 281<br />

Chavalitshewinkoon, Porntip,<br />

403<br />

Cheeseman, Sarah H., 178<br />

Chen, Ming, 2550<br />

Cheng, A. F. B., 1001<br />

Cheng, Yung-chi, 1420<br />

Chichino, Guido, 1492<br />

Chimata, Minoru, 229<br />

Chimirri, A., 1497<br />

Chin, Nai-Xun, 566<br />

Chio, Li-Chun, 1914<br />

Chiodini, Rodrick J., 1645<br />

Chopra, Ian, 153<br />

Chow, Andrew T., 1468<br />

Chow, Joseph W., 134, 1187,<br />

2474<br />

Chow, Yung-Kang, 1480<br />

Christensen, S0ren Br0gger,<br />

2550<br />

Chu, Chung K., 875<br />

Chuah, See Kean, 1711<br />

Chuard, Christian, 625<br />

Citron, Diane M., 1150<br />

Clanton, David J., 754<br />

Clark, Nancye C., 2311<br />

Clarkson, Allen B., Jr., 1082<br />

Clavier, Francoise, 970<br />

Clecner, Bya, 1373<br />

Cleel<strong>and</strong>, Roy, 2144<br />

Clement, Jacob, 864, 1329<br />

Clemons, Karl V., 1177, 2224<br />

Clewell, Don B., 134, 2474<br />

Coates, Jonathan A. V., 1473<br />

Cochereau-Massin, I., 633<br />

Coen, Donald M., 19<br />

Coene, Marie-Claire, 2101<br />

Coffey, Tracey J., 1938<br />

Cohen, Louise G., 2187<br />

Cohen, Michael A., 2563<br />

Cohen, Myron S., 950<br />

Cohen, Yves, 692<br />

Colaizzi, John L., 778<br />

Cole, Stewart T., 414<br />

Coleman, Ruth A., 2027<br />

Colina, F., 2490<br />

Coll, Ramon, 868<br />

Collatz, Ekkehard, 1247<br />

Collins, Linda, 2009<br />

Collins, Linda A., 598, 1364<br />

Colturani, F., 2545<br />

Comodi-Ballanti, M. R., 2618<br />

Condra, Jon H., 947, 1576<br />

Conejo, Carmen, 187<br />

Conly, J. M., 574<br />

Connelly, Michele C., 2247<br />

Connor, Edward, 532<br />

Connor, James, 532<br />

Conway, Anthony J., 2033<br />

Cook, James A., 393<br />

Cooke, N. J., 804<br />

Cooksey, Robert C., 1348,<br />

2311<br />

Cookson, Barry, 681<br />

Cooley, Timothy P., 1480<br />

Cools, Willy, 2101<br />

Cooper, Brian W., 234<br />

Cooper, Chester R., Jr., 2407<br />

Cooreman, M. P., 1506<br />

Corbett, Anita H., 2599<br />

Corey, Lawrence, 975<br />

Correa-Coronas, Rafael, 474<br />

Correia, John A., 1270, 2144<br />

Cory, Michael, 2668<br />

Cosgrove, Yvonne T., 8<br />

Costa, Yannick, 1896<br />

Costa-Perira, Rabi, 183<br />

Costerton, J. W., 2000<br />

Coudron, Philip E., 1447<br />

Courvalin, Patrice, 78, 1456,<br />

1563, 1896, 2093, 2119<br />

Cowsert, Lex M., 171<br />

Cox, H., 1924<br />

Cozens, Robert, 2087<br />

Craig, William A., 2650<br />

Crane, Deborah D., 357<br />

Crawford, Jack T., 1348<br />

Cretton, Erika M., 1816<br />

Crooke, Rosanne M., 1945<br />

Cruceyra, Antonio, 1717<br />

Crumpacker, Clyde S., 1095<br />

Cui, X., 2496<br />

Cunningham, Francesca E.,<br />

1343<br />

Curfs, Jo H. A. J., 276<br />

Currens, Michael J., 1037<br />

Curvale, Georges, 1214<br />

Cynamon, M. H., 2344<br />

Daffe, Mamadou, 1536<br />

Dal Bo, Lorenzo, 2212<br />

Dale, Glenn E., 1400<br />

Dal Pizzol, Virginia, 2693<br />

Dalton, Harry, 2193<br />

Damiani, Aldo, 106<br />

Dan, M., 293<br />

D<strong>and</strong>ekar, Kishor A., 1160<br />

D'Aquila, Richard T., 1095,<br />

1480<br />

Davidson, Ross J., 1154<br />

Davies, Julian, 2379<br />

Davis, Michelle, 19<br />

Day, C. A., 2506<br />

Day, D. F., 2506<br />

Dayer, P., 2132<br />

Dazer, Maureen E., 2563<br />

de Anta, Teresa Jimenez, 138<br />

de Aquino Almeida, Joao<br />

Carlos, 2722<br />

de Beco, Virginie, 281<br />

Debyser, Zeger, 2540<br />

de Cespedes, Gilda, 2593<br />

Decker, William D., 754<br />

De Clercq, E., 332<br />

de Clercq, Erik, 218, 2540<br />

de Graaff, J., 1184<br />

de Jonge, Boudewijn L. M.,<br />

342<br />

de la Coussaye,<br />

Jean-Emmanuel, 464<br />

de Lalla, Fausto, 2693<br />

Delbos, Frangoise, 2593<br />

del C. Ceinos, Maria, 1728<br />

Delehanty, John, 975<br />

Dellamonica, P., 921<br />

Delouis, Christine, 54<br />

Del Valle, O., 1587<br />

Demain, Arnold L., 84<br />

DeMuria, Deborah, 2187<br />

Denaro, Maurizio, 741<br />

Denny, William, 403, 991<br />

De Rosa, Franco, 1679<br />

Derouin, Francis, 2371<br />

De Sarro, A., 1497<br />

De Sarro, G. B., 1497<br />

Desmyter, Jan, 2540<br />

De Souza, W<strong>and</strong>erley, 580,<br />

2722<br />

DeStefano, M. S., 2344<br />

Dever, Lisa L., 1115, 1704<br />

DeVore, Kimberly M., 1480<br />

Dhindsa, Harinder S., 2754<br />

Diasio, Christoph R., 1771<br />

Diaz, M. Dolores, 1200<br />

Dieck, Harold A., 1082<br />

Digranes, Asbj0rn, 2024<br />

Dijkstra, Jan, 2293<br />

Dionne, Gervais, 130<br />

DiPiro, Joseph T., 1343, 1463<br />

Doherty, Catherine, 123<br />

Doherty, Patrick, 1737<br />

Domagala, John M., 2563<br />

Dombret, Marie-Christine, 281<br />

Donabedian, Susan, 134<br />

Donabedian, Susan M., 2474<br />

Donowitz, G. R., 2261<br />

Donta, I., 308<br />

Doury, Jean-Claude, 924<br />

Downey, Kathleen M., 1127<br />

ANTIMICROB. AGENTS CHEMOTHER.<br />

Downs, Mary Beth, 71<br />

Drancourt, Michel, 1214<br />

Dreyer, Geoffrey B., 71<br />

Driver, Vickie B., 1945<br />

Drusano, George L., 115, 483<br />

Drusano, G. L., 2496<br />

DuBois, J., 574<br />

Dubois, Jacques, 1373<br />

Ducharme, Murray P., 2706<br />

Duchateau, V., 1860<br />

Dudley, Michael N., 1723,<br />

1756<br />

Dueweke, Thomas J., 1127<br />

Dullenkopf, Klaus, 1367<br />

Dumas, J. C., 1232<br />

Duncanson, F. P., 1580<br />

Dunn, David L., 357<br />

Dunne, W. Michael, Jr., 2522<br />

Dupeyron, Jean-Pierre, 501<br />

Dupont, Marie-Ange, 1536<br />

Duport, Catherine, 962<br />

Durack, David T., 903<br />

Durant, J., 921<br />

Dutko, Frank J., 297<br />

Dutta, P., 1197<br />

Duval, Jean, 78, 789, 1896,<br />

2119, 2466<br />

Dworkin, R., 2678<br />

Dykstra, C. C., 1713<br />

Dykstra, Christine C., 2668<br />

Dylewski, Joseph, 1373<br />

Earnhardt, K. I., 2261<br />

Echols, Roger, 1670, 2193<br />

Edelstein, Martha A. C., 908<br />

Edelstein, Paul H., 908<br />

Edlund, Charlotta, 1665<br />

Edmonds, Kay, 1799<br />

Edmund, Michael, 1238<br />

Edwards, Barbara A., 2754<br />

Edwards, David J., 2706<br />

Edwards, Fitzroy F., 398,<br />

2323<br />

Edwards, John E., Jr., 546,<br />

2628<br />

Egan, William, 1420<br />

Ehrett, Stuart, 1630<br />

Eledjam, Jean-Jacques, 464<br />

Eling, Wyn<strong>and</strong> M. C., 276<br />

Eliopoulos, C. T., 366<br />

Eliopoulos, George M., 507,<br />

598, 1364, 2009<br />

Eliopoulos, G. M., 366, 1604<br />

Elliott, T. B., 1882<br />

Ellner, Jerrold J., 1799, 1807<br />

Elsea, Sarah H., 2179<br />

El Solh, N., 2159<br />

Emge, Thomas J., 1909<br />

Emini, Emilio A., 947, 1576<br />

Emori, Masako, 722<br />

Engel, Lee S., 1856<br />

Enoxacin Prophylaxis Study<br />

Group, 474<br />

Entenza, J., 921<br />

Entenza, Jose, 1971<br />

Erice, Alejo, 357, 835<br />

Erickson, John, 810<br />

Eron, Joseph J., 1480<br />

Espinel-Ingroff, Ana, 39<br />

Esteve, Montserrat, 868<br />

Etter, L., 2432<br />

Etter, Laura, 1061<br />

Fabre, David, 464

VOL. 37, 1993<br />

Fadat, G., 1955<br />

Faessler, Alex, 2087<br />

Fagon, Jean-Yves, 281<br />

Fairley, Terri A., 2668<br />

Faleschini, E., 2545<br />

Falkenstein-Paul, Hildegard,<br />

696<br />

Fallani, Stefania, 2693<br />

Fantin, Bruno, 2466<br />

Farinotti, Robert, 281<br />

Farmer, Susan W., 453<br />

Farzadegan, H., 360<br />

Farzadegan, Homayoon, 429<br />

Fass, Robert J., 2080, 2348<br />

Faurisson, F., 633<br />

Feibusch, Evan L., 106<br />

Ferencz, Nicholas, 818<br />

Fern<strong>and</strong>ez, Herv6, 54<br />

Ferraro, Mary Jane, 598, 1364<br />

Ferraro, M. J., 366<br />

Fey, P. D., 2432<br />

Fich, Karen, 2550<br />

Fichtl, Richard E., 1504<br />

Field, Hugh J., 2478<br />

Fields, Marc T., 203<br />

Fierer, Joshua, 2293<br />

Figgitt, David, 403, 991<br />

Filadoro, Francesco, 1958<br />

Finegold, S. M., 2638<br />

Finegold, Sydney M., 2509<br />

Fischman, Alan J., 1270, 2144<br />

Fishman, Jay A., 1543<br />

Flaherty, John, 1137<br />

Fl<strong>and</strong>rois, J. P., 1685<br />

Flexner, C., 360<br />

Flor, Soledad C., 1468<br />

Fluckiger, Ursula, 1971<br />

Foca, Alfredo, 393<br />

Focht, Josef, 2298<br />

Foleno, Barbara D., 301<br />

Fong, Dunne, 1909<br />

Foo, Hsin-Hsin, 2500<br />

Foor, Forrest, 84<br />

Ford, Harry, Jr., 810<br />

Ford, Jeanne, 2193<br />

Forrest, Alan, 1065, 1073,<br />

2187<br />

Fothergill, Annette W., 2307<br />

Fouda, Hassan G., 314<br />

Fournet, Alain, 859<br />

Fournier, Genevieve, 2020<br />

Foweraker, J. E., 804<br />

Fox, Maureen C., 171<br />

Foy, Jilanna, 1436<br />

Frachet, B., 2674<br />

Fraimow, Henry S., 2736<br />

Francioli, Patrick, 1971<br />

Francioli, Patrick B., 207<br />

Franzblau, Scott G., 1997<br />

Franzini, P., 2545<br />

Freifeld, Alison, 495<br />

French, Pamela, 2736<br />

Fresnadillo, M. J., 911<br />

Frey, Carrie, 39<br />

Frick, Lloyd W., 2285<br />

Fridl<strong>and</strong>, Arnold, 2247<br />

Friedl<strong>and</strong>, Ian R., 1630<br />

Froelich-Ammon, Stacie J.,<br />

646<br />

Fromtling, Robert A., 39<br />

Frost, R. Wayne, 2106<br />

Fu, K. P., 301<br />

Fuchs, P. C., 893<br />

Fuchs, Peter C., 14<br />

Fujii, K., 67<br />

Fujisawa, Chiho, 2173<br />

Fujita, Y., 1043<br />

Fukasawa, Masatomo, 2743<br />

Fukatsu, Hiroshi, 2756<br />

Fukuoka, Takashi, 322<br />

Fukuoka, Yoshikazu, 384<br />

Fukutomi, Yasuo, 2265<br />

Fulton, David R., 1655<br />

Fung-Tomc, Joan, 213, 1289<br />

Furfine, Eric S., 2285<br />

Furman, Phillip A., 1720, 2285<br />

Furudera, Takenori, 1826<br />

Furuya, Nobuhiko, 675<br />

Gadgil, Shrikant D., 314<br />

Gaffar, Maria C., 778<br />

Galgiani, John N., 39, 2126,<br />

2517<br />

Galim<strong>and</strong>, Marc, 1456, 1896,<br />

2093, 2119<br />

Gallati, Harald, 2418<br />

Galtier, Marc, 464<br />

Galvez, Antonio, 148<br />

Gamage, Swarna, 403, 991<br />

Gambertoglio, John, 1137<br />

Gangeness, David, 1171<br />

Gao, Qing, 130, 1390<br />

Garber, Sena, 2606<br />

Garcia, I., 2490<br />

Garcia, Isabel, 187<br />

Garcia, Jesus, 868<br />

Garcia, M. M., 2638<br />

Garcia-Rodriguez, J. A., 911<br />

Gardner, Mark J., 314<br />

Gargallo-Viola, Domingo, 868<br />

Garneau, Valerie, 1701<br />

Garon, Claude F., 46<br />

Gaspar, Erzsebet, 2593<br />

Gasser, I., 1587<br />

Gastafiares, Maria-Jose, 2427<br />

Gatti, Giorgio, 1137<br />

Gaudebout, Claude, 970<br />

Gaudreau, Christiane, 1174<br />

Geggel, Robert L., 1655<br />

Gehanno, Pierre, 1599<br />

Geisel, Janet, 393<br />

Geleziunas, Romas, 1305<br />

Gelfusa, Vincenzo, 1190<br />

George, Robert C., 681<br />

George, William J., 818<br />

Georgii, Aletta, 2064<br />

Georgopapadakou, N. H.,<br />

559, 2045<br />

Gerard, Geoffrey C., 1334<br />

Gerbaud, Guy, 1456, 2093<br />

Gerlach, E. H., 1696<br />

Gerok, Wolfgang, 1539<br />

Ghaleh, Bijan, 1777<br />

Ghannoum, Mahmoud A.,<br />

546, 2628<br />

Ghezzi, Maria Cristina, 1958<br />

Ghezzi, Pietro, 2527<br />

Ghione, Mario, 1492<br />

Ghosh, Dilip Kumar, 2459<br />

Giamarellou, Helen, 308<br />

Gibert, Claude, 281<br />

Gikas, Achilleas, 51<br />

Gilbart, James, 32<br />

Gilbert, D., 2678<br />

Gilbert, Deborah, 1723<br />

Gilbert, Deborah H., 1756<br />

Gilbert, D. N., 347<br />

Gilja, Odd Helge, 2024<br />

Gillespie, S. H., 2493<br />

Gillil<strong>and</strong>, Susan S., 436, 1377<br />

Gillum, J. Gregory, 2193<br />

Gilman, Thomas M., 93<br />

Gilmore, James D., 1452<br />

Giroux, M., 1232<br />

Glauser, Michel P., 207, 1971<br />

Gleaves, Curt A., 1360<br />

Goering, R. V., 2432<br />

Goetz, Matthew B., 1334<br />

Goh, Khye Seng, 652, 1560<br />

Gohara, Yukiko, 287, 1826<br />

Gold, H. S., 1604<br />

Goldman, Hy, 1305<br />

Goldman, Mark E., 947<br />

Goldstein, Beth P., 741<br />

Goldstein, Ellie J. C., 1150<br />

Goldstein, Neil H., 297<br />

Gollapudi, Sastry V., 1711<br />

Golub, Lorne M., 592<br />

Gomez, Maria, 1717<br />

Gomez, R., 2490<br />

Gomez-Jimenez, J., 1587<br />

Gomez-Lus, Rafael, 138<br />

Gonc,alves, Noemia<br />

Rodrigues, 2722<br />

Gong, Yi-Fei, 2247<br />

Gooch, W. Manford, III, 159<br />

Gooding, Beth Briggs, 349<br />

Goody, Roger, 2612<br />

Goos, M., 1010<br />

Gootz, Thomas D., 646, 2179<br />

Gordillo, Manuel E., 1203<br />

Gorrens, Jos, 2101<br />

Gorzynski, Eugene A., 896<br />

Goss, Thomas F., 1073<br />

Gotlib, Leah, 1576<br />

Goto, Sachiko, 60<br />

Govan, John, 123<br />

Grady, Robert W., 1082<br />

Graham, Donald J., 1576<br />

Grasso, S., 1497<br />

Green, Michael, 1238<br />

Grewal, Jaswinder, 2645<br />

Griffith, Jeffrey K., 1253<br />

Griggs, D. J., 662<br />

Grill, Susan, 1420<br />

Groothuis, Jessie R., 1655<br />

Grosset, Jacques, 407, 692,<br />

1690<br />

Gu, Ligang, 2265<br />

Gu, Zhengxian, 130, 1390<br />

Guay, David R. P., 436<br />

Guay, Gordon G., 191<br />

Gueret, Dominique, 970<br />

Guerillot, F., 1685<br />

Guerra, Isabel, 148<br />

Guerry, Philippe, 2599<br />

Guinea, Jesus, 868<br />

Gulakowski, Robert J., 754<br />

Gulnik, Sergei, 810<br />

Gunther, Michael R., 950<br />

Gupta, Pramod, 864, 1329<br />

Gupta, Rachna, 882<br />

Gur, D., 1637<br />

Gur, Deniz, 1831<br />

Gutmann, L., 1406<br />

Gutmann, Laurent, 1247, 1387<br />

Haag, Jo Jean, 1670<br />

Hackbarth, Corinne J., 1144<br />

AUTHOR INDEX iii<br />

Hakusui, Hideo, 2173<br />

Halinen, Sirkka, 592<br />

Hall, Geraldine, 39<br />

Hall, J. E., 1713<br />

Hall, Joseph, 592<br />

Hall, L. M. C., 1637<br />

Hall, M. C., 662<br />

Halstensen, Alfred, 2024<br />

Halushka, Perry V., 393<br />

Hamer, Davidson H., 931<br />

Hamilton, H., 1620<br />

Hamilton, Robert G., 1463<br />

Hamilton-Miller, J. M. T.,<br />

1558<br />

Hamzeh, Fayez M., 602<br />

Hancock, Robert E. W., 453<br />

H<strong>and</strong>, Debra L., 2557<br />

H<strong>and</strong>, W. Lee, 2557<br />

Hansen, Lori M., 2699<br />

Hansen, Sharon L., 1334<br />

Hanson, Linda H., 1177, 2224<br />

Hanssen, Brenda R., 265<br />

Hara, Kohei, 2762<br />

Hardie, J. M., 2493<br />

Harding, G. K. M., 574<br />

Hare, Roberta S., 2074<br />

Hare, R. S., 708<br />

Hariprashad, June, 1504<br />

Harrington, Joan A., 918<br />

Harrison, Barbara, 1444<br />

Harvey, Kevin, 2193<br />

Harvey, Tracey, 1711<br />

Hase, Toyoji, 363<br />

Hasegawa, Takaaki, 1781<br />

Hasegawa, Takashi, 2217<br />

Haselbeck, Bob, 1614<br />

Hashimoto, Nobuo, 901<br />

Hashizume, Terutaka, 2756<br />

Hattori, Hiroaki, 839<br />

Hattox, Susan E., 178<br />

Hausler, Alex, 84<br />

Havenith, Mick, 218<br />

Hawkey, P. M., 804<br />

Hayakawa, Isao, 2112<br />

Hayashi, Hideya, 810<br />

Hayashi, Ryogo, 100<br />

Hayden, Frederick G., 297<br />

Hayes, Michael M., 2500<br />

Hayman, Alan C., 246<br />

Hayran, Murat, 1831<br />

Healy, Niamh, 1473<br />

Heifets, Leonid, 111, 1380,<br />

2364<br />

Heijtink, R. A., 595<br />

Heikkila, Elina, 1297<br />

Heisig, Peter, 696<br />

Heller, Allen H., 2193<br />

Hemming, Val G., 1655<br />

Hendrix, Craig W., 429<br />

Hengels, K. J., 1506<br />

Hengge, U. R., 1010<br />

Henry, N. K., 554<br />

Herndon, Betty L., 203<br />

Herrero, J. A., 2490<br />

Hesse, Werner H., 2622<br />

Heudes, Didier, 1790<br />

Hewitt, Ross G., 512<br />

Heykants, Jos, 2224<br />

Hickey, Sheila, 1630<br />

Hidaka, T., 67<br />

Hidaka, Takayoshi, 722<br />

Hikida, Muneo, 199<br />

Hill, Bertha C., 2311

iv AUTHORINDEX<br />

Hill, Craig L., 1707<br />

Hill, Edgar, 975<br />

Hill, James M., 1856<br />

Hille, Heidemarie, 2153<br />

Hilligoss, Donald M., 314<br />

Hintermann, Gilberto, 84<br />

Hiraga, Y., 1043<br />

Hirakata, Yoichi, 675<br />

Hiramatsu, Keiichi, 1219,<br />

2278<br />

Hirata, Michimasa, 2534<br />

Hirata, Takahiro, 2656<br />

Hirsch, Martin S., 1480<br />

Hirsh, Dwight C., 2699<br />

Hiscott, John, 130<br />

Hiscox, Steven A., 1473<br />

Hitchcock, C. A., 1962<br />

Hitchcock, Michael J. M.,<br />

1816<br />

Hizi, Amnon, 1037<br />

Hjeln, Ulrika, 1285<br />

H,o, Chi-Tang, 1909<br />

Ho, Dah Hsi, 2504<br />

Ho, May, 2418<br />

Hoban, Daryl J., 1154<br />

Hobden, Jeffery A., 1856<br />

Hocquemiller, Reynald, 859<br />

Hoepelman, Andy I. M., 885<br />

Hoffman, Jacob M., 947<br />

Hoffner, Sven E., 1285<br />

H0iby, E. Arne, 2024<br />

Holder, Ian A., 1890<br />

Holy, A., 332<br />

Holy, Antonin, 2540<br />

Honore, Nadine, 414<br />

Hoogkamer, Johannes F. W.,<br />

2622<br />

Hoogkamp-Korstanje,<br />

J. A. A., 2017<br />

Hook, Edward W., III, 1670<br />

Hooper, David C., 2588<br />

Hoosen, Anwar A., 2733<br />

Hopkins, Sam, 1720<br />

Horaud, Thea, 2593<br />

Hori, Satoshi, 2278<br />

Horii, Toshinobu, 984<br />

Horiuchi, Sankichi, 2486<br />

Hoshino, Kazuki, 2112<br />

Hostetler, John S., 2224<br />

Houck, Herbert J., 613<br />

Hougen, Thomas, 1655<br />

Howell, John M., 2754<br />

Howells, R. E., 2337<br />

Howells, Robert E., 1318<br />

Huang, Hua-Bin, 566<br />

Huang, Jun-Li, 1370<br />

Huang, Wai Mun, 457<br />

Huart, Alain, 1777<br />

Hub<strong>and</strong>, Michael D., 2563<br />

Hughes, George S., 2650<br />

Hughes, Stephen H., 1037<br />

Hughes, Walter T., 1417<br />

Huhn, Dieter, 1367<br />

Huls, Christine E., 1414<br />

Huovinen, Pentti, 1158, 1297<br />

Husson, M., 1860<br />

Ibrahim, Ashraf S., 546, 2628<br />

Ichiyama, Satoshi, 984<br />

Iijima, Masako, 322<br />

lizawa, Yuji, 100<br />

Ikeda, Yasushi, 384<br />

Ilksoy, Nurcan, 875<br />

Imada, Akira, 100<br />

Imagawa, Yatsuka, 2486<br />

Imbimbo, B. P., 2545<br />

Imbimbo, Bruno P., 637, 2212<br />

Imboden, Paul, 2054<br />

Imhoff, Tracy, 2030<br />

Immendoerfer, Ulrike, 2612<br />

Imtiaz, Uzma, 2438<br />

Inagaki, Yoshio, 2486<br />

Inamatsu, T., 1043<br />

Inciardi, John F., 1025<br />

Ingman, Tuula, 592<br />

Inomata, Norikazu, 199<br />

Inoue, Eiko, 1547<br />

Inukai, Masatoshi, 980<br />

Ioannides-Demos, Lisa L.,<br />

914<br />

Irvin, James D., 835<br />

Isaacson, David M., 301<br />

Ishida, Hiroko, 2112<br />

Ishida, Mariko, 2327<br />

Islam, A., 1572<br />

Isono, Fujio, 980<br />

Israel, Debra, 2139, 2193<br />

Ito, Hideaki, 839<br />

Itoh, Tomoo, 2327<br />

Iwagaki, Akitaka, 164<br />

Iwahi, Tomoyuki, 100, 769<br />

Iwasaki, Shigeo, 1313<br />

Iwatani, Wakao, 785<br />

Jackson, M. Keven, 2716<br />

Jackson, W. E., 1882<br />

Jacoberger, Bernadette, 1873<br />

Jacobs, Michael R., 1799,<br />

1807<br />

Jacobs, M. R., 1649<br />

Jacobs, William R., Jr., 1348<br />

Jacobus, David P., 1417<br />

Jacobus, Nilda V., 2270<br />

Jacoby, George A., 2760<br />

Jansen, Robert W., 441<br />

Janssen, David A., 2003<br />

Jantos, Christian, 846<br />

Japour, Anthony J., 1095<br />

Jarvinen, Helina, 1158<br />

Jarvis, Ken, 1329<br />

Jarvis, Kenneth, 864<br />

Jayanetra, P., 2000<br />

Jeanfavre, Deborah Durham,<br />

1693<br />

Jefson, Martin R., 646<br />

Jehl, F., 1488<br />

Jehl, Francois, 501<br />

Ji, Baohong, 407<br />

Jin, Y. F., 662<br />

Jindrich, J., 332<br />

Jindrich, Jindrich, 2540<br />

John, Joseph F., 1334<br />

Johnson, C. C., 2069<br />

Johnson, Curtis A., 2650<br />

Johnson, David E., 483<br />

Johnson, Elma, 1264<br />

Johnson, E. M., 1962<br />

Johnson, James R., 2033<br />

Johnson, Lance C., 441<br />

Johnson, Victoria A., 1095<br />

Jones, R. N., 1696<br />

Jones, Robert B., 1670<br />

Jones, Ronald N., 349, 2747<br />

Jones, S. K., 1713<br />

Jorgensen, James H., 1115,<br />

1704<br />

Kaatz, Glenn W., 128, 1086<br />

Kabir, I., 1572<br />

Kadurugamuwa, Jagath L.,<br />

715<br />

Kageyama, Seiji, 810<br />

Kaiser, Allen B., 702<br />

Kaku, Mitsuo, 2762<br />

Kakuta, Sachiko, 229<br />

Kallenius, Gunilla, 1285<br />

Kalvakuntla, Laxman, 729<br />

Kam, Kai-Man, 2007<br />

Kamchonwongpaisan,<br />

Sumalee, 1108<br />

Kamide, Ryoichi, 2217<br />

Kamiyama, Tsutomu, 2656<br />

Kamwan, Chantana, 2407<br />

Kaplan, Edward L., 159<br />

Kaplan, Joan C., 1480<br />

Kaplan, Sheldon L., 2401,<br />

2522<br />

Kar, Kalipada, 2459<br />

Kar, Sujata, 2459<br />

Karayiannakos, P., 308<br />

Karlowsky, James A., 1154<br />

Karp, Judith E., 1847<br />

Kato, Haru, 957<br />

Kato, Katsuyoshi, 1781<br />

Kato, Michiyuki, 1764<br />

Kato, Naoki, 957<br />

Kato, Nobuo, 984, 1781<br />

Katsuta, Mitsuo, 322<br />

Kauffman, Carol A., 2003<br />

Kaufhold, Achim, 2740<br />

Kaul, Sanjeev, 1160, 1816<br />

Kawada, Harumi, 1749<br />

Kazanjian, Powel H., 2187<br />

Keirns, James J., 178<br />

Kellam, Paul, 1525<br />

Kenny, George E., 1726<br />

Kernodle, Douglas S., 702<br />

Kessler, Joseph A., 144<br />

Keusch, Gerald, 1056<br />

Keyhani, Afsaneh, 246, 2584<br />

Kharazmi, Arsalan, 2550<br />

Khardori, Nancy, 729, 882<br />

Kharsany, Ayesha B. M.,<br />

2733<br />

Kibbler, C. C., 2493<br />

Kidd, Lauren B., 1816<br />

Kiehn, Timothy E., 2323<br />

Kierszenbaum, Felipe, 2235<br />

Killmar, John, 1417<br />

Kimura, Masashi, 801<br />

Kimura, Sadao, 2228<br />

King, Anna, 746<br />

Kinowski, Jean-Marie, 464<br />

Kinsman, Oonagh S., 1243<br />

Kinzig, M., 1860<br />

Kishimoto, Toshio, 801<br />

Kishore, Alugupalli R., 240<br />

Kiso, Yoshiaki, 810<br />

Kitzis, Marie-Dominique, 1387<br />

Kleim, Jorg-Peter, 1659<br />

Kiemens, S. P., 2344<br />

Kleter, G. E. M., 595<br />

Klietmann, Wolfgang, 2298<br />

Klimkait, Thomas, 2087<br />

Klimm, K., 366<br />

Kiopman, Gilles, 1799, 1807<br />

Klugman, Keith P., 1938<br />

Knapp, C. C., 1696<br />

Knapp, Joan S., 1552<br />

Kobayashi, Teruaki, 2042<br />

ANTIMICROB. AGENTS CHEMOTHER.<br />

Koehler, Joy M., 905<br />

Koenig, Bernhard, 2612<br />

Koeppe, Peter, 1835, 2153<br />

Koffel, Jean-Claude, 1873<br />

Koga, Hironobu, 1877, 2762<br />

Koga, Tetsufumi, 1749<br />

Koh, Julia G., 778<br />

Kohlhepp, S., 2678<br />

Kohlhepp, S. J., 347<br />

Kohnen, P. W., 347<br />

Kohno, Shigeru, 1877, 2762<br />

Kojima, Tsuyoshi, 839<br />

Koks, Cornelis H. W., 1426<br />

Kolek, Benjamin, 213, 1289<br />

Kolenda, Herbert, 1518<br />

Kondoh, Masumi, 2662<br />

Konttinen, Yrjo T., 592<br />

Kopp, U., 224<br />

Koranyi, Katalin I., 314<br />

Kort, Jens J., 115<br />

Korting, Hans C., 2064<br />

Kotani, Hitoshi, 2500<br />

Kotnik, V., 1786<br />

Koup, Richard A., 178<br />

Kovacs, Joseph A., 1227,<br />

1674<br />

Krahenbuhl, James L., 2265<br />

Krausgrill, P., 1506<br />

Kreeger, John M., 1645<br />

Krinke, Alison J., 2454<br />

Kristensen, Gun, 1665<br />

Kruse, James A., 1927<br />

Krusell, Allan R., 1132<br />

Kubat, Tina, 1171<br />

Kuebelbeck, Virginia, 835<br />

Kumar, Ashir, 159<br />

Kuo, Cho-Chou, 8<br />

Kurata, Tadashi, 2173<br />

Kuritzkes, Daniel R., 1095<br />

Kurtzberg, Joanne, 144<br />

Kusne, Shimon, 1238<br />

Kuwahara-Arai, Kyoko, 1219<br />

Kuwano, Koichi, 287, 1826<br />

Kuypers, Frans, 1108<br />

Labia, Roger, 939, 962<br />

LaBombardi, Vincent J., 1556<br />

Lachance, Nathalie, 1174<br />

Lacroix, Jean-Michel, 2037<br />

Ladizensky, Esther, 2483<br />

Lafredo, Stephen C., 301<br />

Lagrange, Philippe H., 2020<br />

Lahiri, M., 1197<br />

Lai, Cham-Fai, 2007<br />

Lai, Jiunu, 1614<br />

Laizure, S. Casey, 448<br />

Lal<strong>and</strong>e, Valerie, 407<br />

Lam, Joseph S., 715<br />

Lam, K., 2000<br />

Lam, Patrick Y.-S., 2606<br />

Lambert, C., 1860<br />

Lambert, Dennis M., 71<br />

Lambert, Thierry, 1456, 2093<br />

Lamer, Christian, 281<br />

Lamothe, Francois, 1174<br />

Lamp, Kenneth C., 605, 1931<br />

L<strong>and</strong>man, David, 1904<br />

Lane, James, 532, 1095, 1127<br />

Laneelle, Gilbert, 1536<br />

Lang, Marc, 2087<br />

Lang, R., 2333<br />

Lange, Joep M. A., 1525<br />

Lantero, Marta, 2427

VOL. 37, 1993<br />

Larder, Brendan A., 1525<br />

Larrick, James W., 2534<br />

Larsson, Alison J., 1377<br />

Last-Barney, Kathleen, 1693<br />

Lastilla, Marco Gregorio, 1679<br />

Lavoie, Suzanne R., 1447<br />

Lawlor, Michael T., 234<br />

Lawrence, A. Jean, 1869<br />

Lawrence, Theresa, 896<br />

Lawrence, William D., 512<br />

Lazard, Thierry, 692, 1690<br />

Lazardi, Keyla, 580<br />

Lazdins, Janis, 2087<br />

Lazzaroni, Marco, 2212<br />

LeBlanc, Barbara, 2504<br />

Le Bras, J., 1955<br />

Le Bras, Jacques, 924, 970<br />

Lebsack, M. E., 775<br />

Leclercq, Rol<strong>and</strong>, 78, 789,<br />

1896, 2119, 2466<br />

Lee, Hsi-Ming, 592<br />

Lee, K., 2638<br />

Lee, Ving J., 851, 2270<br />

Lee, Yun-Sang, 2007<br />

Leemann, T., 2132<br />

Leggett, J., 2678<br />

Le Gros, V., 737, 2674<br />

Lei, Shau-Ping, 1614<br />

Leibowitch, Jacques, 2206<br />

Le Jeune, Ludo, 2101<br />

Lemeteil, Denis, 889<br />

Lemmich, Else, 2550<br />

Lentino, Joseph R., 339<br />

Lepine, Guylaine, 2037<br />

Lepocher, H., 1410<br />

Lerner, Stephen A., 2438<br />

Lertora, Juan J. L., 818<br />

Leser, Ulrike, 2612<br />

Leske, Valeria L., 835<br />

Lettieri, John T., 2106<br />

Levin, James M., 1444<br />

Levison, M. E., 2069<br />

Levitsky, Sidney, 2106<br />

Levy, Stuart B., 825, 2699<br />

Lew, Daniel P., 625<br />

Lew, D. P., 2132<br />

Lewin, Clement, 123<br />

Lewis, Mark G., 71<br />

Li, Cong, 2030<br />

Li, M. S. K., 1001<br />

Li, Ronald C., 371, 523<br />

Li, Shu C., 914<br />

Liebman, Howard A., 1480<br />

Lietman, Paul S., 429, 602<br />

Lim, Seung T., 1264<br />

Lima, Viera, 1108<br />

Lindley, Ivan J. D., 276<br />

Lindquist, S., 224<br />

Lindstrom, Terry D., 265<br />

Lindy, Otso, 592<br />

Lins, Ulysses, 2722<br />

Liotta, Dennis C., 875, 1720,<br />

2206, 2285<br />

Lipke, Peter N., 1264<br />

Littlejohn, Tim G., 761<br />

Liu, Tiepu, 1771<br />

Liu, Yu-Ying, 2144<br />

Livermore, David G., 1243<br />

Livermore, D. M., 1637<br />

Livni, E., 1270, 2144<br />

Livornese, L. L., 2069<br />

Lizasoain, M., 2490<br />

Lloyd, Robert M., Jr., 875<br />

Lo, Kuen-Kong, 2007<br />

Lo, Shyh-Ching, 2500<br />

Lockwood, Graham, 297<br />

LoCoco, John M., 301<br />

Lode, Hartmut, 1835<br />

Lombardi, F., 2545<br />

Loncle, V., 2159<br />

Long, William J., 1576<br />

Lonks, John R., 1742<br />

Lopardo, Horacio A., 1728<br />

Lopez-Berestein, Gabriel, 246<br />

Lorscheider, Fritz L., 825<br />

Lortholary, Olivier, 1790<br />

Louchahi, K., 737, 2674<br />

Louis, F. J., 1955<br />

Louis, J.-P., 1955<br />

Lowdin, Elisabeth, 2200<br />

Lu, Zhihong, 1771<br />

Lumbreras, C., 2490<br />

Lupia, Raul H., 818<br />

Luthy, Ruedi, 1056<br />

Maass, Gerhard, 2612<br />

Macalintal, Clarissa, 851<br />

Maderazo, Eufronio G., 1132<br />

Maeda, Akio, 1313<br />

Mael<strong>and</strong>, Arild, 2443<br />

Magallanes, Marcus, 2293<br />

Magnuson, Terry, 1610<br />

Mahr, Gerhard, 1518<br />

Majerus, P., 142<br />

Majumder, Sarmila, 2235<br />

Malanoski, Gregory J., 598,<br />

2009<br />

Maldonado, Rosa A., 1353<br />

Maldonado, Rosa Amelia, 580<br />

Malessa, R., 1010<br />

Maliszewski, Maureen L., 512<br />

Mallet, D., 1410<br />

Mallie, Jean-Pierre, 1510<br />

Mamber, Stephen W., 213<br />

Mamman, Mohammed, 1050<br />

Manavathu, Elias K., 2438,<br />

2645<br />

Mancini, Carlo, 1958<br />

Mann, Paul A., 2074<br />

Mansat, V., 1232<br />

Mant, Tim G. K., 637<br />

Mao, Jinghe, 950<br />

Maqueda, Mercedes, 148<br />

Maraki, Sofia, 51<br />

Marceau-Day, M. L., 2506<br />

Marchan, Edgar, 580<br />

Marchbanks, C. R<strong>and</strong>all,<br />

1723, 1756<br />

Marchesi, Francine, 2054<br />

Marco, Francesc, 138<br />

Marcos, Angeles, 138<br />

Margolick, Joseph B., 429<br />

Marichal, Patrick, 2101<br />

Mariotte, Sophie, 939<br />

Markham, Richard B., 429<br />

Markowitz, Sheldon M., 1447<br />

Marler, J. K., 1122<br />

Marlin, Steven D., 1693<br />

Marrakchi-Benjaafar, S., 633<br />

Marshall, Bonnie, 825<br />

Marshall, Steven A., 2747<br />

Marshall, Steven H., 2760<br />

Martel, A. Y., 574<br />

Martin, Andrea, 1278<br />

Martin, David H., 1670, 1986<br />

Martin, J. Louise, 1720<br />

Martin, Stephan, 1278<br />

Martinez, Anthony, 1674<br />

Martinez, J. L., 1982<br />

Martinez-Bueno, M., 148<br />

Martinez-Vazquez, J. M.,<br />

1587<br />

Martino, Piero, 1190<br />

Marutani, Kiyoshi, 2217<br />

Marx, Gerald R., 1655<br />

Marzella, Louis, 120<br />

Mason, Edward O., Jr., 2401,<br />

2522<br />

Massidda, Orietta, 1324<br />

Masuda, Nobuhisa, 322<br />

Masukawa, Yoshikazu, 199<br />

Matera, Giovanni, 393<br />

Materman, E., 1620<br />

Mathez, Dominique, 2206<br />

Matsubara, Shuzo, 1826, 2217<br />

Matsuda, Kouji, 2756<br />

Matsumoto, Fumio, 2217<br />

Matsumoto, Keizo, 164<br />

Matsumoto, Masahiko, 2217<br />

Mattie, H., 2318<br />

Matumoto, Masahiko, 1826<br />

Mauel, Jacques, 991<br />

Maurin, M., 1410, 2633<br />

Maxwell, Anthony, 126<br />

Mayers, Douglas L., 1095,<br />

1127<br />

Mayhall, C. Glen, 1334<br />

Mazzolla, Rosanna, 2422<br />

McClure, Harold M., 1816<br />

McCracken, George H., Jr.,<br />

1630<br />

McEntee, M. F., 360<br />

McGahren, Jim, 1624<br />

McGlynn, Marion, 1624<br />

McGrath, Betty J., 1723, 1931<br />

McGuirk, Paul R., 646, 2179<br />

McKiel, Joan R., 1756<br />

Mc.Koy, Judith, 1264<br />

McLaughlin, Margaret M.,<br />

178<br />

McLean, Allan J., 914<br />

McLinn, Samuel E., 159<br />

McMahon, James B., 754,<br />

1037<br />

McMillan, Angela, 875<br />

McMurry, Laura M., 2699<br />

McNally, Eugene J., 1693<br />

McNamara, Patrick J., 2706<br />

McQueen, Teresa J., 2584<br />

McWhinney, P. H. M., 2493<br />

Mechlinski, Witold, 778<br />

Medeiros, Antone A., 1742<br />

Meenhorst, Pieter L., 1426<br />

Mehl, Paul, 2470<br />

Mehta, Reeta T., 2584<br />

Meichsner, Christoph, 1659<br />

Meissner, H. Cody, 1655<br />

Mellors, John W., 875<br />

Menard, Robert, 78<br />

Menck, Sylvia, 1518<br />

Menninger, John R., 2027<br />

Merluzzi, Vincent J., 1693<br />

Merz, William G., 1847, 2407<br />

Meservey, Mark A., 2563<br />

Meshnick, Steven R., 1108<br />

Meyer, A. P., 2318<br />

Michel-Bri<strong>and</strong>, Yvon, 962<br />

Mierzwa, Ronald, 2074<br />

Mikami, Yuzuru, 1313<br />

AUTHOR INDEX v<br />

Miksits, Klaus, 1367<br />

Milatovic, D., 1620<br />

Miller, Carole B., 1847<br />

Miller, George H., 2074<br />

Miller, G. H., 708<br />

Miller, Jeffry, 2139<br />

Millet, V., 2239<br />

Milocchi, Fabio, 2693<br />

Mimoto, Tsutomu, 810<br />

Minamimura, Masashi, 1547<br />

Mirabelli, Christopher K., 171<br />

Mitra, U., 1197<br />

Mitsuhashi, Susumu, 793,<br />

1547<br />

Mitsutake, Kotaro, 2762<br />

Mitsuya, Hiroaki, 810<br />

Mitten, Michael, 1329<br />

Mitten, Mike, 864<br />

Miyasaki, Kenneth T., 2710<br />

Miyazaki, Haruko M., 2762<br />

Miyazaki, Shuichi, 60<br />

Miyazaki, Yoshitsugu, 2762<br />

Miyoshi, Akio, 2217<br />

Mobarakai, Neville K., 1904<br />

Mobashery, Shahriar, 2438<br />

Mochizuki, Hidenori, 2412<br />

Moellering, R. C., Jr., 366,<br />

1604<br />

Moellering, Robert C., Jr.,<br />

507, 598, 1364, 2009<br />

Moguilevsky, N., 142<br />

Mol<strong>and</strong>, Ellen S., 260<br />

Molina, Judith, 1353<br />

Molinas, Catherine, 78<br />

Molitoris, Eric, 2509<br />

Moloo, Shamshudeen K.,<br />

1163<br />

Moncada, Jeanne, 1746<br />

Mondain, V., 921<br />

Monteil, H., 1488<br />

Monteil, Henri, 501<br />

Montgomerie, John Z., 1334<br />

Moody, Julia A., 2454<br />

Moore, Carol, 1264<br />

Mor, Natan, 111, 1380, 2364<br />

Moreno, E., 2490<br />

Morgan, U. M., 328<br />

Morikawa, Keiko, 270, 2684<br />

Morikawa, Shigeru, 270, 2684<br />

Morisaki, Naoko, 1313<br />

Morris, Anne B., 1<br />

Morrison, Donald, 681<br />

Morrison, Paul J., 637<br />

Morrison, Susan, 532<br />

Morse, Gene D., 512<br />

Moskovitz, Bruce L., 778<br />

Mourton, Tracy, 1610<br />

Moynihan, Melinda, 2179<br />

Mroczkowski, Tomasz F.,<br />

1670<br />

Mueller, Barbara, 2612<br />

Muffat-Joly, Martine, 1599<br />

Muller, Hans-Jochen, 1835<br />

Mulligan, Maury E., 1334<br />

Mummaw, Nancy, 89<br />

Munayyer, H., 708<br />

Munioz, Patricia, 1200<br />

Mufioz, Victoria, 859<br />

Murakami, Kimihiro, 2412<br />

Murakawa, Yohko, 810<br />

Murphy, Noel B., 1163, 1167<br />

Murray, Barbara E., 1203,<br />

1966

vi AUTHORINDEX<br />

Murray, Gilles, 1373<br />

Murray, Henry W., 1504<br />

Murray, P. R., 1696<br />

Muth, Peter, 1518<br />

Muthiani, Anthony M., 1167<br />

Myers, Dorothea E., 835<br />

Myers, Roy A. M., 120<br />

Mylvaganam, Haima, 2024<br />

Naas, Thierry, 939, 962<br />

Nabeshima, Toshitaka, 1781<br />

Nadai, Masayuki, 1781<br />

Nadelmann, Lynda, 2550<br />

Naesens, L., 332<br />

Nagamuta, Masahiro, 2217<br />

Nagano, Hiroyuki, 2217<br />

Nagase, Mitsumasa, 229<br />

Nagata, Kumiko, 769<br />

Nagatake, Tsuyoshi, 164<br />

Nagrajan, K., 183<br />

Nahata, Milap C., 314<br />

Naidu, A. Satyanarayan, 240<br />

Naidu, Smita S., 240<br />

Naiman, N. A., 1713<br />

Naiman, Noreen A., 2668<br />

Nakada, Naoki, 2656<br />

Nakae, Taiji, 2385<br />

Nakagawa, Susumu, 2756<br />

Nakamura, Mika, 839<br />

Nakamura, Shinichi, 839<br />

Nakamura, Yumiko, 2662<br />

Nakano, Shigeyuki, 2042<br />

Nakaya, Rintaro, 2486<br />

Nakayama, Noboru, 2662<br />

Namavar, F., 1184<br />

Narayan, O., 360<br />

Narayanan, Ven L., 754<br />

Narita, Hirokazu, 384<br />

Narita, Teruo, 322<br />

Nash, Donald R., 1850<br />

Nasr, Mohamed, 2166<br />

Nateghpour, M., 2337<br />

Nau, Rol<strong>and</strong>, 1518<br />

Ndifor, Anthony M., 1318<br />

Ndoutamia, Guelmbaye, 1163<br />

Nelson, Donald J., 2285<br />

Nelson, Jeffrey A., 1444<br />

Nelson, Kenrad E., 2407<br />

Nerhood, Lynda, 429<br />

Nervetti, G., 2545<br />

Neu, Harold C., 566<br />

Neumann, Theresa, 2244<br />

Neumann, Theresa M., 1670<br />

Neyfakh, Alex<strong>and</strong>er A., 128<br />

Ng, Eva Y., 2588<br />

Ngoma, Michel, 901<br />

Ngu, Jacob L., 1318<br />

Nguyen, Hieu, 729<br />

Nguyen, Minh-Hong, 875<br />

Nicastri, Emanuele, 1190<br />

Nicastro, G., 2545<br />

Nicolas, Marie-Helene, 939<br />

Nicolas, M. H., 1406<br />

Nicolle, L. E., 574<br />

Nightingale, Charles H., 234<br />

Nightingale, Stephen D., 1869<br />

Nikaido, Hiroshi, 322, 1393<br />

Niki, Yoshihito, 801<br />

Nimmo, G., 1924<br />

Nishikawa, Sae, 2042<br />

Nishikawa, T., 1043<br />

Nishiki, Katsuyuki, 199<br />

Nishimoto, Mitsunobu, 287<br />

Niu, Wei Wei, 667<br />

Nix, David E., 371, 523, 775,<br />

1065, 1073<br />

Nochy, Dominique, 1790<br />

Nolte, Frederick B., 39<br />

Nomizu, Motoyoshi, 810<br />

Noordergraaf, J. H., 317<br />

Nord, Carl Erik, 1665<br />

Norden, C. W., 1580<br />

Nordl<strong>and</strong>er, E., 1977<br />

Nordmann, P., 1406<br />

Nordmann, Patrice, 939, 962<br />

Noriega, A. R., 2490<br />

Norman, Allyn, 775<br />

Normark, S., 224<br />

Norwegian Yeast Study<br />

Group, 2443<br />

Noskin, Gary A., 2470<br />

Novelli, Andrea, 2693<br />

Oberg, Bo, 1370<br />

O'Brien, Julie A., 947<br />

O'Callaghan, Richard J., 1856<br />

Odds, Frank C., 39, 685<br />

Odenholt-Tornqvist, Inga,<br />

2200<br />

Offensperger, Silke, 1539<br />

Offensperger, Wolf-Bernhard,<br />

1539<br />

Ogawa, Nobuya, 2042<br />

Oguma, T., 1043<br />

Ohashi, Masayuki, 2412<br />

Ohdo, Shigehiro, 2042<br />

Ohmichi, M., 1043<br />

Ohno, Akira, 675<br />

Ohshima, Yumi, 2173<br />

Ohshita, Yoshihiro, 2278<br />

Ohta, Michio, 984<br />

Ohya, Satoshi, 322<br />

Oishi, Kazunori, 164<br />

Oizumi, Kotaro, 287<br />

Okamoto, Osamu, 2756<br />

Okamura, Noboru, 2486<br />

Okazaki, Osamu, 2173<br />

Okonogi, Kenji, 100<br />

Oleske, James, 532<br />

Oliary, J., 2674<br />

Ollert, Markus W., 2064<br />

Olsen, Kurt, 1630<br />

Onuki, Youichi, 2327<br />

Opravil, Milos, 1056<br />

Osada, Yasuaki, 2112<br />

Osborne, A. J., 2069<br />

Oseko, Fumimaro, 270, 2684<br />

Osheroff, Neil, 646, 2179,<br />

2599<br />

Osmon, D. R., 554<br />

Ossi, Michael J., 159<br />

Otabe, Yohko, 2217<br />

Otero, J. R., 2490<br />

Otteni, Jean-Claude, 1873<br />

Otto, Michael J., 2606<br />

Ou, Ching-Nan, 2401<br />

Paccaly-Moulin, Anne, 407<br />

Pacheco, Nancy D., 2688<br />

Pachucki, Constance T., 339<br />

Paessens, Arno, 1659<br />

Pagano, Joseph S., 144<br />

Pahissa, A., 1587<br />

Painter, Barbara, 1756<br />

Painter, George, 1720<br />

Painter, George R., 2285<br />

Pal, Kollol, 1693<br />

Pangon, B., 737<br />

Pankuch, G. A., 1649<br />

Paradiso, Linda, 474<br />

Pares, Marta, 868<br />

Paris, Maria, 1630<br />

Park, Matthew K., 120<br />

Parker, Anita C., 1028, 2391<br />

Parker, William B., 1004<br />

Parniak, Michael A., 1390<br />

Paschalides, Panagiotis, 495<br />

Pascual, Alvaro, 187<br />

Pasculle, A. William, 1238<br />

Passariello, C., 2618<br />

Patchen, M. L., 1882<br />

Patel, Jayesh A., 339<br />

Patel, S., 2493<br />

Patterson, Jan Evans, 134<br />

Patterson, Thomas F., 2307<br />

Patton, Dorothy L., 8<br />

Patton, Melissa, 2244<br />

Paulfeuerborn, Wolfgang, 1835<br />

Paulsen, Ian T., 761<br />

Pav, Joseph W., 178<br />

Pavicic, M. J. A. M. P., 1184<br />

Payares, Gilberto, 580, 1353<br />

Pearson, Bridget A., 1473<br />

Pedemonte, Ronald, 754<br />

Pefanis, Angelos, 308, 507<br />

Pelaez, Teresa, 1200<br />

Pellizzer, Giampietro, 2693<br />

Peng, Tao, 2126<br />

Penn, Charles R., 1473<br />

Pennell, Andrew T., 1343<br />

Penni, Adrio, 1190<br />

Perea, Evelio J., 187<br />

Peregrine, Andrew S., 1050,<br />

1163, 1167<br />

Perfect, John R., 903, 2449<br />

Periti, Piero, 2693<br />

Perri, Mary Beth, 134, 1187,<br />

2474<br />

Perronne, Christian, 692, 1690<br />

Perry, Caroline R., 32<br />

Perry, Greg, 637<br />

Peter, Jean-Daniel, 501<br />

Petersen, Peter J., 2270<br />

Petitjean, O., 737, 2674<br />

Petteway, Stephen R., Jr., 71<br />

Pettinger, Mary B., 1360<br />

Petty, Brent G., 429<br />

Pfaff, Eberhard, 2612<br />

Pfaller, M. A., 893<br />

Pfaller, Michael A., 14, 39<br />

Pfefferkom, Elmer R., 2358<br />

Pflieger, Philippe, 2599<br />

Phan, Lienhanh, 2241<br />

Philippon, Alain, 2020<br />

Phillips, Ian, 746<br />

Phillips, Robert, 1373<br />

Picazo, Juan J., 1717<br />

Pichichero, Michael E., 159<br />

Piddock, L. J. V., 662<br />

Pilkiewicz, Frank G., 1869<br />

Piperacillin-Tazobactam Skin<br />

<strong>and</strong> Skin Structure Study<br />

Group, 1580<br />

Piras, Marta M., 580<br />

Piras, Romano, 580<br />

Piret, Jacqueline, 84<br />

Pitha, P., 360<br />

Pitsakis, P. G., 2069<br />

Pitzurra, Lucia, 2422<br />

Pizzo, Philip A., 495<br />

ANTIMICROB. AGENTS CHEMOTHER.<br />

Pocidalo, Jean-Jacques, 692,<br />

1599, 1690<br />

Pocidalo, J. J., 633<br />

Pohl, Jan, 2710<br />

Poiesz, Bernard, 512<br />

Polk, Ronald, 2193<br />

Polk, Ron E., 2139<br />

Pollack, Jay R., 1171<br />

Pollack, Matthew, 164<br />

Poncioni, Bernard, 2087<br />

Ponglertnapagorn, Preecha,<br />

164<br />

Poppe, Susan M., 1127<br />

Porro, Gabriele Bianchi, 2212<br />

Portmann, R., 293, 2132<br />

Potgieter, Elsa, 2740<br />

Pottecher, Thierry, 501<br />

Pourtois, M., 142<br />

Powell, Francoise, 1227<br />

Powell, Marie, 1264<br />

Pozzi, Luann M., 19<br />

Pradier, C., 921<br />

Pramanik, A. J., 1264<br />

Prange, Hilmar W., 1518<br />

Prichard, Lynn E., 540<br />

Prichard, Mark N., 540<br />

Prince, Alice, 667<br />

Prince, R<strong>and</strong>all A., 1414<br />

Privitera, G., 2545<br />

Proenca, Rui, 667<br />

Progulske-Fox, Ann, 2037<br />

Prosser, Barbara L., 2144<br />

Pryka, R<strong>and</strong>y D., 2106<br />

Pudney, Mary, 2371<br />

Puel, J., 1232<br />

Pulverer, Gerhard, 750<br />

Pussard, Eric, 970<br />

Pye, G. W., 1962<br />

Quale, John M., 1904<br />

Queener, Sherry F., 1543,<br />

1914, 2166<br />

Quemard, Annaik, 1536<br />

Quinn, John P., 1989<br />

Quinquis, Valerie, 54<br />

Quint, W. G. V., 595<br />

Quintero, Julio C., 1576<br />

Quintiliani, Richard, 234<br />

Radstrom, Peter, 761<br />

Raffi, Francois, 1777<br />

Ragual, Rhonda J., 1334<br />

Rainey, Petrie M., 1842<br />

Ralph, Ray, 403, 991<br />

Ramiliarisoa, Olivao, 924<br />

R<strong>and</strong>, Kenneth H., 613<br />

Rankin, Catherine D., 144<br />

Ransijn, Adriana, 991<br />

Raoult, D., 491, 1410, 2633<br />

Raoult, Didier, 1214, 1733<br />

Raponi, Giammarco, 1958<br />

Rasaily, R., 1197<br />

Rasmussen, Beth A., 851,<br />

1989<br />

Rastogi, Nalin, 652, 1560<br />

Rather, Philip N., 2074<br />

Rather, P. N., 708<br />

Rathod, Pradipsinh K., 1102<br />

Ravens, U., 1010<br />

Ray, Stephen, 1270<br />

Rayner, Marlene M., 2606<br />

Reardon, John E., 918<br />

Reboli, Annette C., 1334<br />

Reichart, Cindy, 2244

VOL. 37, 1993<br />

Reichelderfer, Patricia S.,<br />

1095<br />

Reid, Carol D., 2606<br />

Reig, Roser, 138<br />

Reilly, J., 1180<br />

Renard, S., 1432<br />

Rende-Fournier, Rosanna,<br />

2119<br />

Resconi, Anna, 741<br />

Resnick, Lionel, 1127<br />

Reuhl, Kenneth R., 419<br />

Reusser, Fritz, 1127<br />

Reynoldson, J. A., 328<br />

Rhodes, Audrey, 1576<br />

Ribera, E., 1587<br />

Ribner, Bruce S., 1334<br />

Rice, Louis B., 610, 1061,<br />

2760<br />

Rice, Roselyn J., 1552<br />

Rich, Josiah, 2187<br />

Richardson, Judith F., 1219<br />

Richman, Douglas D., 1207<br />

Ricketts, Anthony P., 2358<br />

Riess, Gunther, 1659<br />

Rigon, Antonio, 2693<br />

Riml<strong>and</strong>, David, 1334<br />

Rinaldi, Michael G., 39, 1383,<br />

1847, 2307<br />

Ringwald, Pascal, 924<br />

Ripamonti, Franca, 741<br />

Risse, Gisa, 1367<br />

Rittel, Werner, 183<br />

Robbins, Brian L., 2247<br />

Robert, Alex<strong>and</strong>re, 1510<br />

Robert, Marta, 868<br />

Roberts, Glenn D., 39<br />

Roberts, William L., 1842<br />

Robillard, Norman J., 1756<br />

Rodriguez-Creixems, Marta,<br />

1200<br />

Rodvold, Keith A., 436, 2106<br />

Roesel, Johannes L., 2087<br />

Rogers, Marc B., 2391<br />

Rogge, Mark C., 1468<br />

Roilides, Emmanuel, 495<br />

Rol<strong>and</strong>, Gregory E., 2563<br />

Rollwagen, Florence M., 2688<br />

Rolston, Kenneth, 882<br />

Rolston, Kenneth V., 2584<br />

Rolston, Kenneth V. I., 2504<br />

Rom<strong>and</strong>, St6phane, 2371<br />

Romero, Donna L., 1127<br />

Ronco, Esthel, 962<br />

Rondel, Richard K., 2298<br />

Rose, Lucy M., 1004<br />

Rosen, Mark, 483<br />

Rosenbaum, Beverly, 729,<br />

882, 2584<br />

Rosenberg, Ivan, 2540<br />

Roser, Roberto, 868<br />

Rosner, Judah L., 2251<br />

Rosner, Manfred, 1659<br />

Roth, Elizabeth, 1576<br />

Roth, Richard S., 1543<br />

Rothstein, David M., 191,<br />

1624<br />

Rotschafer, John C., 436,<br />

1377, 2454<br />

Rotstein, Coleman, 896<br />

Rouse, M. S., 554<br />

Rouse, Philippa, 2231<br />

Rouveau, Martine, 2020<br />

Roy, Tapon, 178<br />

Rozenberg-Arska, Maja, 885<br />

Rubeglio, Etelvina A., 1728<br />

Rubin, Robert H., 619, 1270,<br />

2144<br />

Rubinstein, E., 2333<br />

Ruble, Cheryl A., 1086<br />

Ruffing, Thomas L., 947<br />

Ruhnke, Markus, 2153<br />

RV-43 Study Group, The,<br />

1095<br />

Ryan, D. Michael, 1473<br />

Rybak, Michael J., 605, 1931<br />

Ryzlak, Maria T., 419<br />

Saari, Herkko, 592<br />

Sacks, Steven, 637<br />

Safrin, Sharon, 975, 2241<br />

Sagiv, R., 293<br />

Saha, M. R., 1197<br />

Saissi, Gilbert, 464<br />

Saito, A., 1043<br />

Saito, H., 67, 1259<br />

Saito, Hajime, 722<br />

Saleh-Mghir, A., 633<br />

Saletan, Stephen L., 1869<br />

Samonis, George, 51<br />

Samuels, D. Scott, 46<br />

Sanada, Minoru, 2756<br />

Sanchez, Ana, 1717<br />

S<strong>and</strong>ers, Christine C., 251,<br />

260, 1375, 2578<br />

S<strong>and</strong>ers, Paula L., 448<br />

S<strong>and</strong>ers, W. Eugene, Jr., 260<br />

S<strong>and</strong>s, Michael, 1<br />

S<strong>and</strong>ven, Per, 2443<br />

Sangaletti, Ornella, 2212<br />

Sannerud, Kim J., 835<br />

Sansano, Sebastiano, 2622<br />

Sant<strong>and</strong>er, Celina, 1728<br />

Santora, Julie, 512<br />

Saral, Rein, 1847<br />

Sardana, Vinod V., 947, 1576<br />

Saric, Muhamed, 1082<br />

Sato, K., 67, 1259<br />

Sato, Katsumasa, 722<br />

Sato, Kenichi, 2112<br />

Satoh, Hiroshi, 769<br />

Satta, Giuseppe, 1324<br />

Savani, Dora V., 903<br />

Sawada, Masashi, 2684<br />

Scaglia, Massimo, 1492<br />

Scarnati, Helen, 2606<br />

Scavone, Joseph M., 2187<br />

Schaberg, Dennis R., 2003<br />

Schachter, Julius, 1746<br />

Schacker, Tim, 975<br />

Schaeverbeke, Jean, 1510<br />

Schaeverbeke, Madeleine,<br />

1510<br />

Schafer-Korting, Monika,<br />

2064<br />

Schaffner, Carl P., 419<br />

Schalm, S. W., 595<br />

Schedletzky, Holger, 696<br />

Schell, Wiley A., 2449<br />

Schentag, Jerome J., 371, 523,<br />

1065, 1073<br />

Schiefer, Hans Gerd, 846<br />

Schinazi, Raymond F., 875,<br />

1707, 2206<br />

Schindler, Jay J., 2716<br />

Schipper, Pauline, 1525, 2231<br />

Schlabach, Abner J., 1576<br />

Schleif, William A., 947, 1576<br />

Schloegel, M., 1488<br />

Schmidheini, Tobias, 2054<br />

Schmidts, Hans-Ludwig, 846<br />

Schneider, Christine L., 1576<br />

Schneider, Peter, 2087<br />

Schols, D., 332<br />

Schrenzel, J., 2132<br />

Schulman, Marvin, 1737<br />

Schultz, Robert J., 754<br />

Schulze, Andrea, 750<br />

Schuurman, Rob, 2231<br />

Scotti, Roberto, 741<br />

Sedman, Allen J., 775<br />

See, Darryl M., 1593<br />

Segal, Jack L., 93<br />

Segatore, Bernardetta, 1324<br />

Segreti, John, 1444<br />

Seifert, Harald, 750<br />

Seifert, Michael, 2153<br />

Seilheimer, Dan K., 1414<br />

Selan, L., 2618<br />

Selsted, Michael E., 2628<br />

Semmel, Marianne, 26<br />

Seo, Susan M., 1086<br />

Seta, Nathalie, 1790<br />

Setacci, Domenico, 1324<br />

Setogawa, Tomoichi, 722<br />

Shaddix, Sue C., 1004<br />

Shafer, William M., 2710<br />

Shafran, S. D., 574<br />

Shaharabany, Miriam, 1037<br />

Shannon, William M., 1004<br />

Shapiro, Theresa A., 1193<br />

Shasha, B., 2333<br />

Shaw, Karen J., 2074<br />

Shaw, K. J., 708<br />

Shawar, Ribhi, 882<br />

Shimada, Hideyo, 2042, 2327<br />

Shimada, Hisao, 2656<br />

Shimada, J., 1043<br />

Shimada, K., 1043<br />

Shimizu, K., 1043<br />

Shimomoura, Yuko, 2534<br />

Shimomura, Masahiko, 229<br />

Shimoyama, Takashi, 769<br />

Shinnick, Thomas M., 1348<br />

Shipkowitz, N. L., 864<br />

Shipman, Charles, Jr., 540<br />

Shirasaka, Takuma, 810<br />

Shlaes, David M., 610, 1061,<br />

1238<br />

Shlaes, D. M., 2432<br />

Shlaes, J. H., 2432<br />

Shyu, W. C., 1180<br />

Siadak, Anthony, 164<br />

Siegert, Wolfgang, 1367<br />

Sijbesma, Rint, 1707<br />

Silve, Gaby, 1536<br />

Silver, Lynn L., 377<br />

Silverman, Edward G., 1869<br />

Simon, Sanford, 592<br />

Sinclair, Ian, 1270<br />

Singh, Kavindra B., 1203<br />

Singlas, Eric, 1777<br />

Sirisanthana, Thira, 2407<br />

Sironi, Marina, 2527<br />

Sjostedt, Svante, 1665<br />

Skold, Ola, 761<br />

Skumik, Mikael, 1297<br />

Skurray, Ronald A., 761<br />

Slavin, Monica A., 1360<br />

Slocombe, Brian, 32<br />

AUTHOR INDEX vii<br />

Sluchak, Julia A., 1927<br />

Smaoui, Hatem, 1510<br />

Smith, Anthony M., 1938<br />

Smith, C. Jeffrey, 1028, 2391<br />

Smith, Colin, 1243<br />

Smith, James W., 2166<br />

Smith, Marilyn S., 144<br />

Smithuis, F. M., 1977<br />

Snoeck, R., 332<br />

Snydman, David R., 1655<br />

So, Antero G., 1127<br />

Soejima, Rinzo, 801<br />

Soike, Kenneth F., 1370<br />

Soler, Paul, 281<br />

Sommadossi, Jean-Pierre,<br />

1816<br />

Sonke, R. Lee, 532<br />

Sonoda, Fuminari, 164<br />

Soong, Seng-jaw, 1771<br />

Sorgel, F., 1860<br />

Sorgel, Fritz, 1518<br />

Sorsa, Timo, 592<br />

Soussy, Claude J., 2588<br />

Spector, Thomas, 602, 918<br />

Sperber, Steven J., 106<br />

Spicer, W. John, 914<br />

Spitzer, Eric D., 1383<br />

Spratt, Brian G., 1938<br />

Springer, Timothy A., 1278<br />

Srdanov, Gordana, 1707<br />

Srinivas, Ranga V., 2247<br />

Stair, Thomas O., 2754<br />

Stals, Frans S., 218<br />

Stanat, Sylvia C., 19<br />

St<strong>and</strong>iford, Harold C., 483,<br />

1334<br />

Stanislawski, Lena, 26<br />

Stanislawski, Marc, 26<br />

Stark, Christina A., 1665<br />

Staszewski, Schlomo, 1576<br />

Staunton, Donald E., 1278<br />

Stecca, Clara, 2693<br />

Steckelberg, J. M., 554<br />

Steele, Lorraine C., 1850<br />

Steele, Paul, 1436<br />

Steib, Annick, 1873<br />

Steide, Jean-Alex, 1264<br />

Stein, Andreas, 1214<br />

Stein, Daniel S., 448<br />

Stein, Gary E., 89<br />

Steingrube, Vincent A., 1850<br />

Stephens, L. Clifton, 729<br />

Stevens, David A., 1177,<br />

1334, 2224<br />

Stevens, Robert C., 448<br />

St. John, Lisa, 2285<br />

Stoeckel, Klaus, 2706<br />

Stotka, Jennifer, 2139<br />

St-Pierre, Claude, 1373<br />

Strauss, H. William, 1270,<br />

2144<br />

Strle, Franc, 1444<br />

Strosberg, A. Donny, 26<br />

Stuber, Dietrich, 1400<br />

Sugar, Alan M., 39<br />

Sugiyama, Takashi, 2042<br />

Sullivan, John L., 178<br />

Sullivan, Maureen C., 234<br />

Sullivan, Veronica, 19<br />

Sum, Phaik-Eng, 2270<br />

Sumita, Yoshihiro, 2743<br />

Summanen, P., 2638<br />

Summers, Anne O., 825

viii AUTHORINDEX<br />

Sun, He, 1132<br />

Sundstrom, Lars, 761, 1297<br />

Suomalainen, Kimmo, 592<br />

Supp, Andrew P., 1890<br />

Supparatpinyo, Khuanchai,<br />

2407<br />

Sutton, David, 642<br />

Sutton, Lorraine, 2760<br />

Suzuki, Eiko, 1219<br />

Suzuki, Yasuyuki, 229<br />

Svensson, Ulla, 240<br />

Swan, S. K., 347<br />

Swaney, Steven M., 1127<br />

Swanson, Keith A., 778<br />

Swedberg, Gote, 761<br />

Swenson, Christine E., 1869<br />

Swenson, Jana M., 2311<br />

Taburet, Anne-Marie, 1777<br />

Tagliabue, G., 2545<br />

Taira, Kazushige, 1877<br />

Takada, Kanji, 810<br />

Takahata, Masahiro, 384<br />

Takashima, Ikuo, 901<br />

Takatsuki, Akira, 980<br />

Takayama, Satoshi, 1764<br />

Takeda, Katsuo, 287<br />

Tal, Ruth, 1037<br />

Talan, D. A., 1580<br />

Talarico, Christine, 19<br />

Talbot, George H., 474<br />

Tallan, B. M., 554<br />

Tally, Francis P., 2270<br />

Tamura, Toshihide, 769<br />

Tan, J. S., 1580<br />

Tan, Tina Q., 2401<br />

Tanaka, Koji, 1945<br />

Tanaka, Kouichi, 2217<br />

Tanaka, Makoto, 2173<br />

Tanaka, Mayumi, 2112<br />

Tanaka, Nobuo, 2756<br />

Tanaka, Yasunori, 957<br />

Tanimura, M., 1043<br />

Taniyama, Yumi, 1547<br />

Tankovic, Jacques, 789<br />

Tarasi, Agapito, 1190<br />

Tardif, Carole, 2571<br />

Tardif, Manon, 2727<br />

Tarpley, W. Gary, 1127<br />

Tarr<strong>and</strong>, Jeffrey J., 2584<br />

Tateda, Kazuhiro, 675<br />

Taylor, David, 1552<br />

Taylor, Diane E., 457, 2645<br />

Taylor, Lester C., 2285<br />

Teggi, Antonella, 1679<br />

Teitz, Yael, 2483<br />

Teixeira, M., 1232<br />

Telenti, Amalio, 2054<br />

Tenorio, Carmen, 2427<br />

Tenover, Fred C., 2311<br />

Tenovuo, Jorma, 1158<br />

ter Kuile, F. O., 1977<br />

ter Laak, E. A., 317<br />

Terpenning, Margaret S., 2003<br />

Testa, Raymond T., 2270<br />

Thadepalli, Haragopal, 1711<br />

Thadepalli, Harini D., 1711<br />

Thal, Lee Ann, 134, 1187,<br />

2474<br />

Thaller, M. C., 2618<br />

Thanassi, David G., 1393<br />

Thauvin-Eliopoulos, C., 1604<br />

Thauvin-Eliopoulos, Claudie,<br />

507<br />

Thayer, Walter R., 1645<br />

The<strong>and</strong>er, Thor G., 2550<br />

Then, Rudolf L., 1400<br />

Thom, Edna, 2144<br />

Thomas, Richard C., 1127<br />

Thompson, R. C. A., 328<br />

Thomson, Kenneth S., 1375<br />

Thormar, Halldor, 2540<br />

Thornsberry, Clyde, 1122<br />

Ticehurst, Julia, 1473<br />

Tidwell, Richard R., 2668<br />

Tidwell, R. R., 1713<br />

Tijnagel, Jol<strong>and</strong>a, 1525<br />

Tilles, Jeremiah G., 1593<br />

Tilling, Janet, 1473<br />

Ting, Windsor, 2106<br />

Titus, Donna L., 1576<br />

Tiwari, M., 2418<br />

Tod, M., 737, 2674<br />

Todo, Yozo, 384<br />

Tokuda, Yoshiko, 2228<br />

Tolkoff-Rubin, Nina E., 619<br />

Toltzis, Philip, 1610<br />

Tomasz, Alex<strong>and</strong>er, 342<br />

Tomazic, J., 1786<br />

Tomioka, H., 67, 1259<br />

Tomioka, Haruaki, 722<br />

Tomonaga, Fumiya, 2042<br />

Tomono, Kazunori, 2762<br />

Tong, William, 398<br />

Torres, Carmen, 2427<br />

Torres, H., 491<br />

Tournay, C., 142<br />

Towle, Michelle, 2193<br />

Toyosawa, Toshio, 60<br />

Trautmann, Matthias, 2153<br />

Trias, Joaquim, 322<br />

Trieu-Cuot, Patrick, 2593<br />

Trifillis, A. L., 2496<br />

Troke, P. F., 1962<br />

Truffot-Pernot, Chantal, 407<br />

Trujillano, I., 911<br />

Tselentis, Yannis, 51<br />

Tseng, Cheng-Chuang, 1826<br />

Ts'o, Paul 0. P., 429<br />

Tsuda, Toshihiko, 2412<br />

Tsuda, Yasuyuki, 2327<br />

Tsui, S. Y. T., 1001<br />

Tsuji, Akiyoshi, 60<br />

Tsuji, Miho, 2228<br />

Tudela, Encarna, 868<br />

Turgeon, Fern<strong>and</strong>, 1174<br />

Turik, Michael, 2193<br />

Turner, Ronald B., 297<br />

Tzeng, Jausheng, 1909<br />

Uckun, Fatih M., 835<br />

Ueda, Yasushi, 2217<br />

Ueno, Kazue, 957<br />

Unal, S., 1604<br />

Unal, Serhat, 1831<br />

Urbina, Julio A., 580, 1353<br />

Ussery, Michael A., 71<br />

Utsui, Yukio, 2278<br />

Uzun, Omrum, 1831<br />

Vaara, Martti, 354, 2255<br />

Valdivia, Eva, 148<br />

Valero-Guillen, Pedro, 1536<br />

Valette, M., 2239<br />

Vallee, E., 633<br />

Vallois, J. M., 633<br />

Vance-Bryan, Kyle, 436, 2454<br />

V<strong>and</strong>en Bossche, Hugo, 2101<br />

van den Broek, P. J., 2318<br />

Van Den Ende, Jan, 2733<br />

Van der Auwera, P., 1015,<br />

1860<br />

V<strong>and</strong>erkolk, Julie, 2364<br />

van der Meer, Jos W. M.,<br />

276, 2527<br />

Van De Velde, Vera, 778<br />

van Leeuwen, Remko, 1525<br />

Vantha, Wanta Sok, 1977<br />

van Winkelhoff, A. J., 1184<br />

van Woensel, J. B. M., 1977<br />

Vapiwala, Manisha, 419<br />

Varela, Manuel F., 1253<br />

Vaudaux, Pierre, 625<br />

Vazquez, Jose A., 2474<br />

Venditti, Mario, 1190<br />

Venitz, Jurgen, 2139<br />

Venuti, Elaine, 2736<br />

Verboom, T., 1184<br />

Verdier, Francoise, 970<br />

Vergara, Yol<strong>and</strong>a, 138<br />

Verhoef, Jan, 885<br />

Verschure, M. H., 317<br />

Videler, Joseph, 1480<br />

Vieler, Elke, 846<br />

Vila, Jordi, 138<br />

Vilde, Jean-Louis, 692, 1690<br />

Villareal, Kara, 39<br />

Vimy, Murray J., 825<br />

Vince, Robert, 1004<br />

Vincent, S., 2432<br />

Viola, Renato, 2693<br />

Visbal, Gonzalo, 580<br />

Visconti, M., 2545<br />

Vishvanathan, N., 183<br />

Visser, Maarten R., 885<br />

Voeller, Donna, 1227<br />

Vogels, Maria T. E., 276,<br />

2527<br />

Von B<strong>and</strong>el, Marc, 1873<br />

Vorachit, M., 2000<br />

Vrenzos, George, 51<br />

Wacharotayankun,<br />

Rochaporn, 984<br />

Wainberg, Mark A., 130,<br />

1305, 1390, 2231<br />

Walcott, Sarah M., 1473<br />

Waldvogel, Francis A., 625<br />

Walker, Clay B., 2037<br />

Walker, Karla J., 1377, 2454<br />

Walker, Maja, 2087<br />

Walker, Sheila, 1558<br />

Wallace, Richard J., Jr., 1850<br />

Walsh, Thomas J., 1334<br />

Walter, Eike, 1539<br />

Walzer, Peter D., 1436<br />

Wang, Julie, 2139<br />

Wang, Li, 1781<br />

Wang, Shaomeng, 1799, 1807<br />

Wang, Ying, 457<br />

Ward, S. A., 2337<br />

Ward, Stephen A., 1318<br />

Warden, Glenn D., 1890<br />

Warnock, D. W., 1962<br />

Warren, John R., 2470<br />

Warren, Reed P., 2716<br />

Wasan, Kishor M., 246<br />

Washington, J. A., 1696<br />

Washington, John A., II, 1375<br />

ANTIMICROB. AGENTS CHEMOTHER.<br />

Waskin, Hetty A., 2449<br />

Wassmundt, Frederick W.,<br />

754<br />

Watanabe, Junko, 2656<br />

Watanabe, Kiwao, 164<br />

Watanabe, Kunitomo, 957<br />

Watanabe, Taiji, 2412<br />

Waterbury, Julie A., 1576<br />

Watson, Durward A., 1869<br />

Watts, J. L., 1122<br />

Waysbort, A., 1232<br />

Wear, Douglas J., 2500<br />

Webb, Douglas, 1270, 1383<br />

Webb, Vera, 2379<br />

Weickmann, Joachim, 1614<br />

Weidekamm, E., 293, 2132<br />

Weidner, Wolfgang, 846<br />

Weinstein, Melvin P., 106<br />

Weinstein, Robert A., 1989<br />

Weislow, Owen S., 754<br />

Wennersten, C. B., 1604<br />

Wennersten, Christine, 2009<br />

Wennersten, Christine B.,<br />

598, 1364<br />

Were, Joab B. O., 1193<br />

Westphal, J. F., 1488<br />

Wexler, Hannah M., 2509<br />

Wexler, H. M., 2638<br />

Weyer, Claudia, 1367<br />

Whiley, R. A., 2493<br />

Whitby, M., 1924<br />

White, E. Lucile, 754<br />

White, John, 1137<br />

White, Michael, 1436<br />

Whitman, M. S., 2069<br />

Wiedemann, B., 224<br />

Wiener, Janis, 1989<br />

Wilairat, Prapon, 403<br />

Wilber, R. B., 1180<br />

Wilcox, Gary, 1614<br />

Williams, Denise S., 1447<br />

Williams, G., 1924<br />

Willmott, Christopher J. R.,<br />

126<br />

Wilson, Jeanne E., 1720<br />

Wilson, W. R., 554<br />

Wingard, John R., 1847<br />

Winkler, Irvin, 1659<br />

Winslow, Dean L., 2606<br />

Wireman, Joy, 825<br />

Wise, Richard, 637<br />

Wise, W. Curtis, 393<br />

Wishnow, R. M., 1580<br />

Witt, Mallory D., 2030<br />

Witzig, Richard S., 1997<br />

Woestenborghs, Robert, 2224<br />

Wojcik, Stan, 991<br />

Wolanski, Bohdan S., 1576<br />

Wolfgang, Jill A., 1576<br />

Wolfson, John S., 2588<br />

Wong, Edward S., 1447<br />

Woodcook, Jocelyn, 637<br />

Woodford, Neil, 681<br />

Woods, Jacqueline M., 1473<br />

Woods-Cook, Kathie, 2087<br />

Wraber, B., 1786<br />

Wright, Esther L., 652<br />

Wright, Susan C., 2534<br />

Wrighton, Steven A., 265<br />

Wudl, Fred, 1707<br />

Xiao, Xinfa, 84<br />

Xicota, M. Angels, 868

VOL. 37, 1993 AUTHOR INDEX ix<br />

Yamada, Hidehiko, 2412<br />

Yamada, Hideo, 2327<br />

Yamaguchi, Hideyo, 785, 2228<br />

Yamaguchi, Keizo, 60, 675<br />

Yamaguchi, Totaro, 287<br />

Yamaguchi, Yoshiyuki, 26<br />

Yamamoto, Naoki, 2486<br />

Yamamoto, S., 1043<br />

Yamashiro, Yoshiko, 384<br />

Yamazaki, Masatoshi, 2228<br />

Yamazaki, Toshiyuki, 100<br />

Yancey, R. J., Jr., 1122<br />

Yang, Ying-Zi, 1108<br />

Yang, Youjun, 851<br />

Yano, Takafumi, 287<br />

Yao, Gang-qing, 1420<br />

Yasuda, Hiroshi, 322, 1749<br />

Yazawa, Katsukiyo, 1313<br />

Yeaman, Michael R., 546<br />

Yew, W. W., 1001<br />

Yoder, Steven L., 2563<br />

Yokoo, Mamoru, 363<br />

Yokota, Takeshi, 1749, 2217<br />

Yoneyama, Hiroshi, 2385<br />

Yoshida, Hiroaki, 839<br />

Yoshida, Masao, 2534<br />

Yoshida, Takuji, 793<br />

Yoshihara, Fumie, 2662<br />

Yoshiyama, Yuji, 2042<br />

Young, Glenda, 1850<br />

Young, Robert D., 1102<br />

Yuthavong, Yongyuth, 1108<br />

Zabinski, Richard A., 1377,<br />

2454<br />

Zaccardi, Joe, 1624<br />

Zakut, H., 293<br />

Zannier, Arnold, 1214<br />

Zappala, M., 1497<br />

Zarins, Lidija T., 2003<br />

Zausner, A., 2069<br />

Zenilman, Jonathan M., 2244<br />

Zervos, Marcus J., 134, 1187,<br />

2474<br />

Zeytinoglu, Aysin, 218<br />

Zhanel, George G., 1154<br />

Zhang, Ruiwen, 1771<br />

Zhang, Yansheng, 1850<br />

Zheng, Hui, 2534<br />

Zhong, Jian, 2534<br />

Zhou, Xiang Yang, 1387<br />

Zhou, Zhu, 1816<br />

Zienicke, Helga, 2064<br />

Zieroth, Shelley R., 1154<br />

Zimmerli, Werner, 2622<br />

Zimmerman, Stephen W.,<br />

2650<br />

Zinner, Stephen H., 1756<br />

Zon, Gerald, 171<br />

Zscheck, Karen K., 1966

A77003<br />

human immunodeficiency virus type 1<br />

preclinical evaluation, 115<br />

toxicity<br />

preclinical evaluation, 115<br />

aac(6')-Ii<br />

characterization, 1896<br />

E. faecium<br />

specificity for, 1896<br />

aac(3)-VIa<br />

E. cloacae<br />

biochemical analysis, 2074<br />

Abelson murine leukemia virus<br />

thiosemicarbazones<br />

v-abl protein, suppression of, 2483<br />

Abscesses<br />

ampicillin-sulbactam<br />

comparative evaluation, 610<br />

cefoxitin<br />

comparative evaluation, 610<br />

E. coli<br />

ampicillin-sulbactam, comparative<br />

evaluation, 610<br />

cefoxitin, comparative evaluation, 610<br />

2-Acetylpyridine 5-[(dimethylamino)thiocarbonyl]-thiocarbonohydrazone<br />

cytomegalovirus<br />

potent inhibition of replication, 602<br />

ganciclovir<br />

potentiation of antiviral effects, 602<br />

3-N-Acetyltransferase<br />

E. cloacae<br />

aac(3)-VIa gene, biochemical analysis<br />

of, 2074<br />

Acetyltransferases<br />

P. aeruginosa<br />

aac(6')-Ib, characterization of, 1456<br />

Acinetobacter baumannii<br />

aminoglycoside-modifying enzymes<br />

production of, 138<br />

P-lactamase production, 138<br />

chloramphenicol acetyltransferase<br />

production of, 138<br />

in vitro susceptibilities, 138<br />

Acinetobacter haemolyticus<br />

aac(6')-Ig gene<br />

6'-N-acetyltransferase, 2093<br />

Acinetobacter spp.<br />

antimicrobial susceptibility, 750<br />

Actinobacillus actinomycetemcomitans<br />

HPQYNQR<br />

in vitro activity, 2710<br />

IIGGR<br />

in vitro activity, 2710<br />

Acyclic nucleoside phosphonates<br />

bis(pivaloyloxymethyl) prodrugs<br />

metabolism <strong>and</strong> in vitro antiretroviral<br />

activities, 2247<br />

herpesviruses<br />

(S) <strong>and</strong> (R) enantiomers, 332<br />

(S) <strong>and</strong> (R) enantiomers<br />

herpesviruses, 332<br />

retroviruses, 332<br />

retroviruses<br />

(S) <strong>and</strong> (R) enantiomers, 332<br />

visna virus<br />

inhibition of replication, 2540<br />

Acyclovir<br />

combinations<br />

348-U87, 975<br />

herpes simplex virus, acyclovir resis-<br />

SUBJECT INDEX<br />

VOLUME 37<br />

tant, 975<br />

ribonucleotide reductase inhibitor, 975<br />

herpes simplex virus resistance<br />

pencyclovir, 2241<br />

herpes simplex virus susceptibility<br />

strains from organ transplant recipients<br />

after acyclovir or ganciclovir<br />

prophylaxis, 357<br />

herpes simplex virus type 1<br />

comparative evaluation, 642<br />

salmonellae<br />

in vitro activities, 106<br />

Aeromonas hydrophila<br />

1-lactamase<br />

P-lactam resistance, contribution to,<br />

1324<br />

carbapenems, high specificity for, 1324<br />

Aeromonas spp.<br />

in vitro susceptibilities<br />

tropical isolates from Queensl<strong>and</strong>,<br />

Australia, 905<br />

Afipia felis<br />

antibiotic susceptibilities<br />

axenic medium <strong>and</strong> cells, 1410<br />

AG-2000<br />

H. pylori<br />

urease activity, inhibition of, 769<br />

Agar dilution<br />

G. vaginalis<br />

susceptibilities to 25 antimicrobial<br />

agents, 2733<br />

Albendazole<br />

hydatid disease<br />

treatment of, 1679<br />

N-n-Alkyl-3,4-dihydroxybenzamide<br />

T. brucei brucei<br />

in vitro <strong>and</strong> in vivo activities, 1082<br />

Allopurinol riboside<br />

pharmacokinetics<br />

probenecid, effects of, 1193<br />

Alpha-1-antitrypsin<br />

doxycycline<br />

protection from human neutrophil collagenase<br />

<strong>and</strong> gelatinase, 592<br />

Alpha interferon<br />

pharmacokinetics<br />

transplacental passage, two assay<br />

techniques, 1232<br />

Aluminum hydroxide<br />

levofloxacin<br />

inhibition of absorption of, 2173<br />

AM-1155<br />

Mycobacterium spp.<br />

in vitro activity, comparative evaluation,<br />

1259<br />

Ames Salmonella TA102 assay<br />

quinolones<br />

bacterial mutagenicity, 213<br />

Amikacin<br />

A. haemolyticus resistance<br />

aac(6')-Ig gene, characterization of,<br />

2093<br />

combinations<br />

aztreonam, 308<br />

ceftazidime, 308<br />

endocarditis, 308<br />

imipenem, 1931<br />

P. aeruginosa, 308, 1931<br />

E. coli resistance<br />

bleomycin, increase of, 1982<br />

M. fortuitum<br />

x<br />

postantibiotic effect, 1001<br />

M. haemophilum<br />

in vitro activities, 2323<br />

pharmacokinetics<br />

attachment to collagen for local delivery<br />

in wounds, 1890<br />

patients with septic multiple-organ<br />

failure during intermittent hemofiltration,<br />

464<br />

postantibiotic effect<br />

M. fortuitum, 1001<br />

synergy<br />

ethambutol, 1285<br />

M. malmoense, 1285<br />

Aminoglycosides<br />

6'-N-acetyltransferase<br />

aac(6')-Ig gene, characterization of,<br />

2093<br />

combinations<br />

inhibitors of glycosylation <strong>and</strong> fatty<br />

acid <strong>and</strong> peptide biosynthesis, 652<br />

M. avium, 652<br />

F. oryzihabitans<br />

in vitro activities against clinical isolates<br />

from patients with cancer,<br />

2504<br />

P. aeruginosa resistance<br />

ant(4')-IIa, nucleotide sequence analysis<br />

<strong>and</strong> DNA hybridization studies,<br />

708<br />

population pharmacokinetics<br />

oncology patients, 1025<br />

resistance gene nomenclature<br />

letter to the editor, 927<br />

T. brucei brucei resistance phenotype<br />

in vivo system to select for bloodstream-form<br />

transfectants, 1167<br />

8-Aminoquinolones<br />

P. cannii<br />

in vivo <strong>and</strong> in vitro studies, 2166<br />

Amopyroquin<br />

malaria<br />

P. falciparum, 970<br />

P. falciparum<br />

malaria treatment, 970<br />

Amorolfine<br />

C<strong>and</strong>ida spp.<br />

temperature, effect on activity, 685<br />

Amoxicillin<br />

B. burgdorferi<br />

in vitro susceptibility, 1444<br />

combinations<br />

clavulanic acid, 14<br />

H. influenzae, 1-lactamase producing<br />

<strong>and</strong> nonproducing, ampicillin resistant,<br />

14<br />

comparative evaluation<br />

chronic bronchitis, 2298<br />

rufloxacin, 2298<br />

otitis media<br />

S. pneumoniae, penicillin resistant,<br />

1599<br />

pharmacokinetics<br />

local gastric <strong>and</strong> serum concentrations<br />

after different oral applications,<br />

1506<br />

S. mutans<br />

in vitro susceptibility, 1158<br />

synergy<br />

H. pylon, 1184<br />

metronidazole, 1184

VOL. 37, 1993<br />

metronidazole, hydroxymetabolite of,<br />

1184<br />

ampD<br />

C. freundii<br />

sequences of wild-type <strong>and</strong> mutant<br />

genes, comparison with those in<br />

E. coli, 224<br />

E. coli<br />

sequences of wild-type <strong>and</strong> mutant<br />

genes, comparison with those in<br />

C. freundii, 224<br />

Amphotericin B<br />

aspergillosis, 2307<br />

invasive pulmonary, prophylactic inhalations,<br />

1367<br />

C. albicans<br />

comparative evaluation, 729<br />

disseminated infection in normal <strong>and</strong><br />

granulocytopenic mice, 729<br />

interleukin-6, reduction in release,<br />

1958<br />

tumor necrosis factor alpha, reduction<br />

in release, 1958<br />

C. neoformans<br />

in vitro susceptibility, 1383<br />

recurrent meningitis, isolates from patients<br />

with, 1383<br />

C<strong>and</strong>ida spp.<br />

temperature, effect on activity, 685<br />

comparative evaluation<br />

fluconazole, 2030<br />

itraconazole, 2307<br />

endocarditis<br />

C. parapsilosis, 2030<br />

C. tropicalis, 2030<br />

immunological effects on splenocytes<br />

from immune-normal <strong>and</strong> immunecompromised<br />

mice, 2716<br />

in vitro <strong>and</strong> in vivo studies, 2228<br />

L. donovani<br />

T-cell-deficient mice, 1504<br />

leishmaniasis, visceral<br />

T-cell-deficient mice, 1504<br />

liposomal<br />

immunological effects on splenocytes<br />

from immune-normal <strong>and</strong> immune-compromised<br />

mice, 2716<br />

liposome composition<br />

role in distribution of drug in serum<br />

lipoproteins, 246<br />

mono-methyl ester derivative<br />

neurotoxicity, comparative evaluation,<br />

419<br />

murine tumor necrosis factor<br />

augmentation of production, 2228<br />

neurotoxicity<br />

mono-methyl ester derivative, comparative<br />

evaluation, 419<br />

rats, comparative evaluation, 419<br />

P. marneffei<br />

response of human immunodeficiency<br />

virus-infected patients, 2407<br />

temperature<br />

role in distribution of drug in serum<br />

lipoproteins, 246<br />

Ampicillin<br />

combinations<br />

ciprofloxacin, 1904<br />

comparative evaluation, 610<br />

E. coli intra-abdominal abscess model,<br />

610<br />

E. faecalis, j-lactamase producing,<br />

highly gentamicin resistant, 1447<br />

E. faecium, 1904<br />

endocarditis, 507, 1447<br />

S. aureus, P-lactamase hyperproducing,<br />

507<br />

sulbactam, 251, 507, 610, 1447<br />

susceptibility testing with a predictor<br />

panel, 251<br />

E. faecium resistance, 1904<br />

endocarditis, 2069<br />

H. influenzae<br />

distribution in patients with lower respiratory<br />

tract infections, effect on,<br />

804<br />

H. parainfluenzae<br />

distribution in patients with lower respiratory<br />

tract infections, effect on,<br />

804<br />

oxidant-scavenging activities<br />

neutrophil functions, effect on, 950<br />

Amsacrine<br />

P. carinii<br />

activity in vitro <strong>and</strong> in a mouse model,<br />

1543<br />

Anaerobic organisms<br />

Bay Y3118<br />

in vitro activity, 2509<br />

FK037<br />

in vitro activity, 957<br />

MDL 62,879, 746<br />

9-Anilinoacridines<br />

Leishmania spp.<br />

in vitro activity, 991<br />

structure-activity relationships, 991<br />

P. falciparum<br />

chloroquine resistant, 403<br />

mode of action, 403<br />

structure-activity relationship, 403<br />

Antibiotic carryover<br />

quinolones<br />

antibiotic-removal beads, elimination<br />

with, 1377<br />

Antibodies<br />

AS-48<br />

immunocytological studies, 148<br />

neutralizing<br />

simian immunodeficiency virus-infected<br />

macrophages, 360<br />

P. aeruginosa flagella<br />

therapeutic effects in a murine model,<br />

164<br />

Antifungal agents<br />

susceptibility testing<br />

broth macrodilution, 39<br />

yeasts, pathogenic, 39<br />

triazino[5,6-b]indoles<br />

GR99060, 1243<br />

GR99062, 1243<br />

ant(4')-IIa<br />

P. aeruginosa<br />

nucleotide sequence analysis <strong>and</strong><br />

DNA hybridization studies, 708<br />

Antipneumocystis agents<br />

screening assay<br />

development <strong>and</strong> characterization,<br />

1674<br />

Antiviral agents<br />

combinations<br />

strategic design <strong>and</strong> three-dimensional<br />

analysis, 540<br />

hepatitis B virus<br />

selectivity, high-capacity in vitro assessment,<br />

441<br />

selectivity<br />

SUBJECT INDEX xi<br />

high-capacity in vitro assessment, 441<br />

Artemisinin<br />

iron-dependent free radical generation,<br />

1108<br />

mechanism of action<br />

iron dependence, 1108<br />

AS-48<br />

antibodies, neutralizing<br />

immunocytological studies, 148<br />

Aspergillosis<br />

amphotericin B<br />

aerosol, prophylaxis, 1367<br />

comparative evaluation<br />

itraconazole-cyclodextrin versus amphotericin<br />

B in a rabbit model,<br />

2307<br />

pulmonary, invasive<br />

amphotericin B, aerosol, for prophylaxis,<br />

1367<br />

Aspergillus fumigatus<br />

aspergillosis<br />

itraconazole-cyclodextrin versus amphotericin<br />

B in a rabbit model,<br />

comparative evaluation, 2307<br />

D0870<br />

in vivo <strong>and</strong> in vitro activities, 2412<br />

itraconazole<br />

efficacy in a rat model, 2762<br />

Atovaquone<br />

combinations<br />

clarithromycin, 2371<br />

minocycline, 2371<br />

pyrimethamine, 2371<br />

sulfadiazine, 2371<br />

T. gondii<br />

in vitro <strong>and</strong> in vivo activities, 2371<br />

Avermectins<br />

S. erythraea<br />

glycosylation, microbial conversion<br />

by, 1737<br />

3'-Azido-2',3'-deoxythymidine<br />

synergy<br />

carbovir, 144<br />

human immunodeficiency virus type 1,<br />

144<br />

3'-Azido-3'-deoxythymidine<br />

toxicity<br />

thymidine kinase activity, correlation<br />

with circadian variation in, 1771<br />

time of administration, effect on, 1771<br />

3'-Azido-3'-deoxythymidine<br />

human immunodeficiency virus type 1<br />

replication in human fetal brain macrophages,<br />

effect on, 1305<br />

3'-Azido-3'-deoxythymidine monophosphate<br />

exonucleolytic repair of AZT-terminated<br />

DNA<br />

inhibition of, 918<br />

3'-Azidothymidine<br />

simian immunodeficiency virus<br />

macrophages, comparative evaluation,<br />

360<br />

Azithromycin<br />

B. burgdorferi<br />

in vitro activity, comparative evaluation,<br />

1704<br />

Brucella spp.<br />

in vitro activity, comparative evaluation,<br />

911<br />

C. pneumoniae<br />

in vitro activity, 1746<br />

C. trachomatis

xii SUBJECT INDEX<br />

in vitro activity, 1746<br />

combinations<br />

pyrimethamine, 1993<br />

T. gondii, 1993<br />

cross-resistance<br />

frequency distribution curves, scattergrams,<br />

<strong>and</strong> regression analyses,<br />

2080<br />

enteric bacterial pathogens<br />

in vitro activity, 1203<br />

gram-negative organisms<br />

outer membrane permeability barrier,<br />

354<br />

in vitro activities<br />

frequency distribution curves, scattergrams,<br />

<strong>and</strong> regression analyses,<br />

2080<br />

L. micdadei<br />

inhibition of intracellular strains, 2261<br />

lymphocyte response<br />

in vivo activities, 1786<br />

M. avium<br />

cross-resistance, 2364<br />

M. avium complex<br />

rats treated with cyclosporine, 398<br />

M. haemophilum<br />

in vitro activities, 2323<br />

M. kansasii<br />

susceptibility testing, 1997<br />

pharmacokinetics<br />

pediatric patients, multiple oral doses<br />

of suspension, 314<br />

S. aureus<br />

uptake by human monocytes, 2318<br />

T. gondii<br />

protein synthesis, inhibition of, 1701<br />

Aztreonam<br />

C. albicans<br />

colonization of the human gastrointestinal<br />

tract, effect on, 51<br />

combinations<br />

amikacin, 308<br />

endocarditis, 308<br />

P. aeruginosa, 308<br />

endocarditis<br />

P. aeruginosa, 308<br />

P. aeruginosa<br />

endocarditis, 308<br />

yeast colonization of the human gastrointestinal<br />

tract, effect on, 51<br />

Bacteroides fragilis<br />

Bay Y3118<br />

in vitro activity, 2509<br />

cepA<br />

cloning <strong>and</strong> characterization reveal a<br />

new subgroup of P-lactamases,<br />

2391<br />

ciprofloxacin<br />

T-cell subsets <strong>and</strong> tumor necrosis factor<br />

production in infected mice,<br />

effect on, 1711<br />

clindamycin<br />

in vivo efficacy, correlation with in<br />

vitro susceptibility, 997<br />

mice, 997<br />

E. coli, polymicrobial infection<br />

mice, 1531<br />

quinolones<br />

in vivo efficacy, correlation with in<br />

vitro susceptibility, 997<br />

mice, 997<br />

rufloxacin<br />

T-cell subsets <strong>and</strong> tumor necrosis factor<br />

production in infected mice,<br />

effect on, 1711<br />

S. aureus, polymicrobial infection<br />

mice, 1531<br />

temafloxacin<br />

evaluation of activity by an in vitro<br />

pharmacodynamic system, 2454<br />

tet(Q)<br />

nucleotide <strong>and</strong> deduced amino acid<br />

sequences, 2037<br />

Bacteroides gracilis<br />

Bay Y3118<br />

in vitro activity, 2509<br />

Bacteroides spp.<br />

Bay Y3118<br />

in vitro activity, 2509<br />

,-lactamase<br />

cefoxitin resistance, 1028<br />

novel Ambler class A, 1028<br />

cefoxitin resistance<br />

J-lactamase, 1028<br />

Bacteroides thetaiotaomicron<br />

E. coli, polymicrobial infection<br />

mice, 1531<br />

S. aureus, polymicrobial infection<br />

mice, 1531<br />

Bay y 3118<br />

broth macrodilution assays<br />

in vitro activity <strong>and</strong> comparative evaluation,<br />

2348<br />

Bay y3118<br />

gram-negative organisms<br />

anaerobic, 1649<br />

comparative susceptibilities, 1649<br />

gram-positive organisms<br />

anaerobic, 1649<br />

comparative susceptibilities, 1649<br />

in vitro activities<br />

gram-negative organisms, 2017<br />

gram-positive organisms, 2017<br />

Benzimidazoles<br />

Giardia spp.<br />

in vitro activity, 328<br />

Bis-benzimidazoles<br />

P. carindi<br />

pneumonia, treatment of, 1713<br />

Benzoxazinorifamycin<br />

M. avium complex<br />

radiometric method, determination by,<br />

67<br />

Benzoxazinorifamycins<br />

KRM-1648<br />

M. avium, 722<br />

Benzylpenicillin<br />

Pneumococcus spp.<br />

postantibiotic effect, 2200<br />

Streptococcus spp.<br />

postantibiotic effect, 2200<br />

,B-Lactamase inhibitors<br />

combinations<br />

P-lactams, 702<br />

S. aureus, borderline methicillin susceptible,<br />

702<br />

S. aureus, methicillin resistant, 702<br />

13-Lactamases<br />

A. baumannii<br />

production by, 138<br />

A. hydrophila<br />

,B-lactam resistance, contribution to,<br />

1324<br />

carbapenems, high specificity for, 1324<br />

ANTIMICROB. AGENTS CHEMOTHER.<br />

B. fragilis<br />

cloning <strong>and</strong> characterization of cepA<br />

reveal new subgroup, 2391<br />

Bacteroides spp.<br />

cefoxitin resistance, 1028<br />

novel Ambler class A, 1028<br />

C. coli<br />

P-lactam susceptibilities, 1174<br />

carbapenem hydrolyzing<br />

E. cloacae, biochemical properties,<br />

939<br />

CP-70,429<br />

stability to, 1547<br />

E. cloacae<br />

biochemical properties, 939<br />

cloning of gene into E. coli, 939<br />

E. coli<br />

clavulanate, 2059<br />

sulbactam, 2059<br />

tazobactam, 2059<br />

E. faecalis<br />

mobilization of gene, 1187<br />

production by, 1966<br />

fecal activity<br />

healthy volunteers after cefixime treatment,<br />

1432<br />

FK-037<br />

stability to, 566<br />

H. alvei<br />

ceftazidime resistant, 1375<br />

K pneumoniae<br />

P-lactams, broad spectrum, resistance<br />

to, 984<br />

,-lactams, extended spectrum, resistance<br />

to, 2020<br />

MGH-1, 2760<br />

plasmid encoded, TEM derived, 2020<br />

plasmid mediated, AmpC type, transferable,<br />

984<br />

YOU-1, 2760<br />

YOU-2, 2760<br />

MGH-1<br />

gene sequences for, 2760<br />

minireview<br />

induction of, molecular basis for, 153<br />

N. farcinica<br />

characterization, 1850<br />

P. aeruginosa<br />

carbapenem resistance, role in, 1387<br />

extended spectrum, characterization<br />

of, 962<br />

OXA-1 1, extended-spectrum variant of<br />

OXA-10, 1637<br />

P. cepacia, 249<br />

chromosomal penicillinase, member of<br />

AmpC family, 667<br />

plasmid mediated<br />

P-lactams, broad spectrum, resistance<br />

to, 984<br />

E. coli, 1989<br />

K pneumoniae, 984, 1989<br />

S. aureus<br />

blaI <strong>and</strong> blaRI, regulation by, 1144<br />

cefazolin, inactivation <strong>and</strong> efficacy of,<br />

203<br />

cefmetazole, inactivation <strong>and</strong> efficacy<br />

of, 203<br />

production by, 1966<br />

Streptococcus spp., group A beta-hemolytic<br />

production of, role in infection management,<br />

1452<br />

susceptibility testing

VOL. 37, 1993<br />

predictor panel for evaluating methods,<br />

2578<br />

tazobactam<br />

kinetic interactions, 851<br />

TEM-1<br />

hydrogen bonding by serine 235 for<br />

cephalosporinase activity, 2438<br />

YOU-1<br />

gene sequences for, 2760<br />

YOU-2<br />

gene sequences for, 2760<br />

P-Lactams<br />

A. hydrophila resistance<br />

metallo-p-lactamase, cphA encoded,<br />

1324<br />

C. coli susceptibility<br />

j-lactamase-positive <strong>and</strong> -negative<br />

strains, 1174<br />

combinations<br />

1-lactamase inhibitors, 702<br />

S. aureus, borderline methicillin susceptible,<br />

702<br />

S. aureus, methicillin resistant, 702<br />

E. faecium resistance<br />

synergistic combinations, resistance<br />

to, 1238<br />

minireviews<br />

penicillin-binding protein resistance,<br />

2045<br />

penicillin-binding protein resistance<br />

minireview, 2045<br />

synergy<br />

E. faecium resistance, 1238<br />

Biapenem<br />

comparative evaluation<br />

imipenem, 2009<br />

gram-negative bacteria, 2009<br />

gram-positive bacteria, 2009<br />

P. aeruginosa<br />

phenotypic resistance induced by salicylate,<br />

2743<br />

Bilobalide<br />

P. carinji<br />

in vitro <strong>and</strong> in vivo activities, 1492<br />

Bilophila wadsworthia<br />

Bay Y3118<br />

in vitro activity, 2509<br />

imipenem<br />

morphological response, 2638<br />

penicillin-binding protein patterns,<br />

2638<br />

Bioavailability<br />

cefetamet pivoxil<br />

syrup <strong>and</strong> tablet formulations to<br />

healthy male volunteers, 2706<br />

(-)-cis-5-fluoro-1-[2-(hydroxymethyl)-<br />

1,3-oxathiolan-5-yl] cytosine<br />

studies with rats, 2285<br />

clindamycin<br />

healthy volunteers <strong>and</strong> AIDS patients,<br />

1137<br />

fluconazole<br />

patients with AIDS, 2187<br />

Biofilms<br />

S. epidermidis<br />

diffusion of rifampin, 2522<br />

diffusion of vancomycin, 2522<br />

Bioscreen C<br />

benzylpenicillin<br />

postantibiotic effect, 2200<br />

Bis(pivaloyloxymethyl) prodrugs<br />

metabolism <strong>and</strong> in vitro antiretroviral<br />

activities, 2247<br />

Bis-benzimidazoles<br />

G. lamblia<br />

correlation of antigiardial activity,<br />

DNA binding affinity, <strong>and</strong> giardial<br />

topoisomerase II inhibition, 2668<br />

structure-activity studies, 2668<br />

Blastomyces dermatitidis<br />

D0870<br />

murine blastomycosis, 1177<br />

Blastomycosis<br />

D0870<br />

murine, 1177<br />

Bleomycin<br />

E. coli<br />

amikacin <strong>and</strong> streptomycin resistance,<br />

1982<br />

S. cerevisiae<br />

cell wall anchorage of mannoproteins,<br />

disruption of, 1264<br />

Boric acid<br />

C<strong>and</strong>ida spp.<br />

temperature, effect on activity, 685<br />

Borrelia burgdorferi<br />

azithromycin<br />

in vitro activity, comparative evaluation,<br />

1704<br />

clarithromycin<br />

hamsters, 1329<br />

in vitro activity, comparative evaluation,<br />

1704<br />

coumermycin Al<br />

growth inhibition <strong>and</strong> induction of relaxation<br />

of supercoiled plasmids,<br />

46<br />

erythromycin<br />

in vitro activity, comparative evaluation,<br />

1704<br />

in vitro susceptibilities, 1444<br />

vancomycin<br />

in vitro activity, 1115<br />

Bronchitis<br />

chronic<br />

rufloxacin <strong>and</strong> amoxicillin, comparative<br />

evaluation, 2298<br />

Broth macrodilution assay<br />

Bay y 3118<br />

in vitro activity <strong>and</strong> comparative evaluation,<br />

2348<br />

yeasts<br />

susceptibility testing, 39<br />

Brucella melitensis<br />

experimental murine brucellosis<br />

streptomycin alone <strong>and</strong> in combination<br />

with ciprofloxacin, doxycycline,<br />

<strong>and</strong> rifampin, 2333<br />

Brucella spp.<br />

azithromycin<br />

in vitro activity, comparative evaluation,<br />

911<br />

clarithromycin<br />

in vitro activity, comparative evaluation,<br />

911<br />

dirithromycin<br />

in vitro activity, comparative evaluation,<br />

911<br />

doxycycline-rifampin<br />

comparative evaluation, 1831<br />

ofloxacin-rifampin<br />

comparative evaluation, 1831<br />

rifapentine<br />

in vitro activity, comparative evaluation,<br />

911<br />

roxithromycin<br />

SUBJECT INDEX xiii<br />

in vitro activity, comparative evaluation,<br />

911<br />

Butenafine<br />

C. albicans<br />

mechanisms of action, 785<br />

percutaneous permeation, 363<br />

T. mentagrophytes<br />

guinea pigs, 363<br />

Camptothecin<br />

P. carinii<br />

activity in vitro <strong>and</strong> in a mouse model,<br />

1543<br />

Campylobacter coli<br />

3-lactamase-positive <strong>and</strong> -negative<br />

strains<br />

P-lactam susceptibilities, 1174<br />

Campylobacterjejuni<br />

cytokines<br />

effect of oral recombinant interleukin<br />

on mucosal immunity in mice,<br />

2688<br />

DNA gyrase<br />

gyrA, cloning <strong>and</strong> nucleotide sequence,<br />

457<br />

gyrA<br />

cloning <strong>and</strong> nucleotide sequence, 457<br />

quinolone resistance<br />

DNA gyrase mutations, characterization<br />

of, 457<br />

Tet(O)<br />

effect of mutational alteration of Asn-<br />

128, 2645<br />

tetracycline resistance<br />

effect of mutational alteration of Asn-<br />

128, 2645<br />

Campylobacter spp.<br />

azithromycin<br />

in vitro activity, 1203<br />

C<strong>and</strong>ida albicans<br />

amphotericin B<br />

comparative evaluation, 729<br />

disseminated infection in normal <strong>and</strong><br />

granulocytopenic mice, 729<br />

tumor necrosis factor alpha, reduction<br />

in release, 1958<br />

aztreonam<br />

colonization of the human gastrointestinal<br />

tract, effect on, 51<br />

butenafine<br />

mechanisms of action, 785<br />

ceftazidime<br />

colonization of the human gastrointestinal<br />

tract, effect on, 51<br />

ceftriaxone<br />

colonization of the human gastrointestinal<br />

tract, effect on, 51<br />

cilofungin<br />

comparative evaluation, 729<br />

disseminated infection in normal <strong>and</strong><br />

granulocytopenic mice, 729<br />

D0870<br />

in vitro activities, 2126<br />

in vivo <strong>and</strong> in vitro activities, 2412<br />

fluconazole resistance<br />

patients infected with human immunodeficiency<br />

virus type 1, correlation<br />

to therapy <strong>and</strong> symptoms,<br />

2449<br />

fluconazole susceptibility<br />

emergence of resistance of Norwegian<br />

strains, 2443

xiv SUBJECT INDEX<br />

imipenem-cilastatin<br />

colonization of the human gastrointestinal<br />

tract, effect on, 51<br />

itraconazole<br />

placebo-controlled trial, 89<br />

myeloperoxidase, human recombinant<br />

c<strong>and</strong>idicidal activity, 142<br />

picolinic acid<br />

protective effect on mice, 2422<br />

Ro 09-1470<br />

inhibition of P-450 lanosterol C-14<br />

demethylase, 2662<br />

ticarcillin-clavulanic acid<br />

colonization of the human gastrointestinal<br />

tract, effect on, 51<br />

C<strong>and</strong>ida glabrata<br />

fluconazole resistance, 1962<br />

C<strong>and</strong>ida parapsilosis<br />

amphotericin B, 2030<br />

endocarditis, 2030<br />

fluconazole, 2030<br />

C<strong>and</strong>ida spp.<br />

amorolfine<br />

temperature, effect on activity, 685<br />

amphotericin B<br />

temperature, effect on activity, 685<br />

boric acid<br />

temperature, effect on activity, 685<br />

flucytosine<br />

temperature, effect on activity, 685<br />

platelet microbicidal protein<br />

fungicidal activity, 546<br />

susceptibility testing<br />

current status of the st<strong>and</strong>ardization<br />

process, minireview, 2517<br />

terbinafine<br />

temperature, effect on activity, 685<br />

terconazole<br />

temperature, effect on activity, 685<br />

C<strong>and</strong>ida tropicalis<br />

amphotericin B, 2030<br />

endocarditis, 2030<br />

fluconazole, 2030<br />

C<strong>and</strong>idiasis<br />

itraconazole<br />

placebo-controlled trial, 89<br />

CAP18<br />

gram-negative organisms<br />

in vitro activity, 2534<br />

gram-positive organisms<br />

in vitro activity, 2534<br />

Capnocytophaga spp.<br />

antimicrobial susceptibilities<br />

letter to the editor, 1206<br />

Capnocytophaga sputigena<br />

HPQYNQR<br />

in vitro activity, 2710<br />

IIGGR<br />

in vitro activity, 2710<br />

Carbapenems<br />

P-lactamase hydrolysis<br />

E. cloacae, 939<br />

biapenem<br />

P. aeruginosa resistance induced by<br />

salicylate, 2743<br />

BO-2727<br />

in vitro activity, 2756<br />

F. oryzihabitans<br />

in vitro activities against clinical isolates<br />

from patients with cancer,<br />

2504<br />

imipenem<br />

P. aeruginosa resistance induced by<br />

salicylate, 2743<br />

LJC 10,627<br />

neurotoxicity in rats, low levels of,<br />

199<br />

P. aeruginosa resistance<br />

cephalosporinase, role in, 1387<br />

panipenem<br />

P. aeruginosa resistance induced by<br />

salicylate, 2743<br />

Carbenicillin<br />

epimers<br />

stereoselective renal tubular secretion<br />

in human volunteers, 2327<br />

Carbovir<br />

cellular metabolism<br />

effects on, 1004<br />

metabolism, 1004<br />

synergy<br />

3'-azido-2',3'-deoxythymidine, 144<br />

human immunodeficiency virus type 1,<br />

144<br />

Carboxyquinolones<br />

Q-35<br />

L. interrogans, 901<br />

Cecropin<br />

C terminus, modification of<br />

broad-spectrum antimicrobial activity,<br />

essential for, 1614<br />

Cefaclor<br />

H. influenzae<br />

P-lactamase producing <strong>and</strong> nonproducing,<br />

ampicillin resistant, 14<br />

Cefazolin<br />

abscesses<br />

P-lactamase-mediated inactivation <strong>and</strong><br />

efficacy, 203<br />

pharmacokinetics<br />

protein binding in rats, 1781<br />

proconvulsant effects<br />

DBA/2 <strong>and</strong> Swiss mice, 1497<br />

S. aureus<br />

13-lactamase-mediated inactivation <strong>and</strong><br />

efficacy, 203<br />

seizures<br />

DBA/2 <strong>and</strong> Swiss mice, 1497<br />

Cefepime<br />

in vitro activity<br />

multicenter comparison, 1696<br />

pharmacokinetics<br />

cystic fibrosis patients, 1414<br />

Cefetamet pivoxil<br />

bioavailability<br />

syrup <strong>and</strong> tablet formulations to<br />

healthy male volunteers, 2706<br />

Cefixime<br />

1-lactamase activity, fecal<br />

healthy volunteers after drug treatment,<br />

1432<br />

C. difficile shedding<br />

healthy volunteers after drug treatment,<br />

1432<br />

gastrointestinal symptoms<br />

effect on in healthy volunteers after<br />

drug treatment, 1432<br />

H. influenzae<br />

1-lactamase producing <strong>and</strong> nonproducing,<br />

ampicillin resistant, 14<br />

pharmacokinetics<br />

biliary excretion in patients with<br />

T-tube drainage, 1488<br />

Cefmetazole<br />

abscesses<br />

1-lactamase-mediated inactivation <strong>and</strong><br />

ANTiMICROB. AGENTS CHEMOTHER.<br />

efficacy, 203<br />

S. aureus<br />

P-lactamase-mediated inactivation <strong>and</strong><br />

efficacy, 203<br />

Cefonicid<br />

peritonitis, spontaneous bacterial<br />

comparative evaluation, 1587<br />

pharmacokinetics<br />

protein binding in adult <strong>and</strong> neonatal<br />

sera, 1343<br />

protein binding<br />

adult <strong>and</strong> neonatal sera, 1343<br />

Cefoperazone<br />

combinations<br />

E. coli, 1927<br />

K pneumoniae resistance, 1061<br />

P. aeruginosa, 1927<br />

sulbactam, 1061, 1927<br />

Cefotaxime<br />

B. burgdorfen<br />

in vitro susceptibility, 1444<br />

E. coli<br />

comparative evaluation, 846<br />

epididymitis, 846<br />

postantibiotic effect in pooled cerebrospinal<br />

fluid <strong>and</strong> Mueller-Hinton<br />

broth, 1154<br />

epididymitis<br />

comparative evaluation, 846<br />

E. coli, 846<br />

H. influenzae<br />

P-lactamase producing <strong>and</strong> nonproducing,<br />

ampicillin resistant, 14<br />

pharmacokinetics<br />

cerebrospinal fluid of patients with<br />

uninflamed meninges, passage<br />

into, 1518<br />

postantibiotic effect<br />

E. coli, in pooled cerebrospinal fluid<br />

<strong>and</strong> Mueller-Hinton broth, 1154<br />

S. pneumoniae breakpoint<br />

letter to the editor, 616<br />

Cefoxitin<br />

abscesses, intra-abdominal<br />

comparative evaluation, 610<br />

Bacteroides resistance<br />

P-lactamase, 1028<br />

E. coli<br />

comparative evaluation, 610<br />

Cefozopran<br />

K pneumoniae<br />

respiratory tract infection, 100<br />

P. aeruginosa<br />

urinary tract infection, 100<br />

S. aureus<br />

thigh muscle infection, 100<br />

Cefpodoxime proxetil<br />

ex vivo susceptibility<br />

studies with patients receiving continuous<br />

ambulatory peritoneal dialysis,<br />

2650<br />

pharmacokinetics<br />

studies with patients receiving continuous<br />

ambulatory peritoneal dialysis,<br />

2650<br />

Cefprozil<br />

pharmacokinetics<br />

tonsillar <strong>and</strong> adenoidal tissues, penetration<br />

into, 1180<br />

tonsillopharyngitis, streptococcal<br />

comparative evaluation, 1620

VOL. 37, 1993<br />

Ceftazidime<br />

C. albicans<br />

colonization of the human gastrointestinal<br />

tract, effect on, 51<br />

combinations<br />

amikacin, 308<br />

endocarditis, 308<br />

P. aeruginosa, 308<br />

E. coli resistance<br />

,-lactamase, 1989<br />

endocarditis<br />

P. aeruginosa, 308<br />

H. alvei resistance<br />

f3-lactamase producing, 1375<br />

in vitro activity<br />

multicenter comparison, 1696<br />

K. pneumoniae resistance<br />

,-lactamase, 1989<br />

P. aeruginosa<br />

endocarditis, 308<br />

P. cepacia<br />

comparative evaluation, 123<br />

P. pseudomallei resistance<br />

biofilm cells, 2000<br />

pharmacokinetics<br />

healthy volunteers, 1835<br />

patients with septic multiple-organ<br />

failure during intermittent hemofiltration,<br />

464<br />

serum bactericidal activities, 1835<br />

side effects, 1835<br />

yeast colonization of the human gastrointestinal<br />

tract, effect on, 51<br />

Ceftibuten<br />

H. influenzae<br />

,-lactamase producing <strong>and</strong> nonproducing,<br />

ampicillin resistant, 14<br />

Ceftizoxime<br />

B. burgdorferi<br />

in vitro susceptibility, 1444<br />

Ceftriaxone<br />

C. albicans<br />

colonization of the human gastrointestinal<br />

tract, effect on, 51<br />

C. bumetii<br />

shell vial assay, 491<br />

combinations<br />

endocarditis, 1971<br />

netilmicin, 1971<br />

concentrations in plasma during liver<br />

transplantation, 1873<br />

gonorrhea, uncomplicated<br />

single-dose therapy, comparative evaluation,<br />

1670<br />

in vitro activity<br />

multicenter comparison, 1696<br />

peritonitis, spontaneous bacterial<br />

comparative evaluation, 1587<br />

pharmacokinetics<br />

cerebrospinal fluid of patients with<br />

uninflamed meninges, passage<br />

into, 1518<br />

elimination, effect of plasmapheresis,<br />

1171<br />

pregnant women, 54<br />

protein binding during pregnancy, 54<br />

S. typhi<br />

5 days, comparative evaluation, 1572<br />

synergy<br />

netilmicin, 207<br />

streptococcal endocarditis, 207<br />

tissue penetration during liver transplantation,<br />

1873<br />

typhoid fever<br />

5 days, comparative evaluation, 1572<br />

yeast colonization of the human gastrointestinal<br />

tract, effect on, 51<br />

Cefuroxime<br />

H. influenzae<br />

,-lactamase producing <strong>and</strong> nonproducing,<br />

ampicillin resistant, 14<br />

in vitro activity<br />

multicenter comparison, 1696<br />

pharmacokinetics<br />

protein binding in adult <strong>and</strong> neonatal<br />

sera, 1343<br />

protein binding<br />

adult <strong>and</strong> neonatal sera, 1343<br />

S. mutans<br />

in vitro susceptibility, 1158<br />

Cefuroxime axetil<br />

pharyngitis<br />

comparative evaluation, 159<br />

Streptococcus spp.<br />

comparative evaluation, 159<br />

group A, 159<br />

pharyngitis, 159<br />

suspension<br />

comparative evaluation, 159<br />

group A streptococcal pharyngitis, 159<br />

Cephalosporin 7a-hydroxylase<br />

S. clavuligerus<br />

cloning <strong>and</strong> expression in S. lividans,<br />

84<br />

Cephalosporinases<br />

P. aeruginosa<br />

carbapenem resistance, role in, 1387<br />

Cephalosporins<br />

B. fragilis <strong>and</strong> E. coli infection<br />

mice, 1531<br />

B. fragilis <strong>and</strong> S. aureus infection<br />

mice, 1531<br />

B. thetaiotaomicron <strong>and</strong> E. coli infection<br />

mice, 1531<br />

B. thetaiotaomicron <strong>and</strong> S. aureus infection<br />

mice, 1531<br />

cefozopran<br />

K pneumoniae, 100<br />

P. aeruginosa, 100<br />

respiratory tract infections, 100<br />

S. aureus, 100<br />

urinary tract infections, 100<br />

cefpodoxime proxetil<br />

ex vivo susceptibility, 2650<br />

pharmacokinetics, 2650<br />

E1077<br />

in vitro <strong>and</strong> in vivo activities, 60<br />

F. oryzihabitans<br />

in vitro activities against clinical isolates<br />

from patients with cancer,<br />

2504<br />

FK037<br />

anaerobic organisms, 957<br />

P-lactamase stability, 566<br />

in vitro activity, 566<br />

in vitro <strong>and</strong> in vivo activities, 301<br />

polymicrobial infection<br />

mice, 1531<br />

3'-quinolone carbamates<br />

E. coli, mechanism of action, 559<br />

3'-quinolone esters<br />

E. coli, mechanism of action, 559<br />

3'-quinolone tertiary amines<br />

E. coli, mechanism of action, 559<br />

Ro 40-6890<br />

SUBJECT INDEX xv<br />

antibiotic activity <strong>and</strong> host defense<br />

mechanisms, 2622<br />

pharmacodynamic activity in human<br />

skin blister fluid, 2622<br />

S. aureus<br />

endocarditis, 554<br />

methicillin susceptible, 554<br />

Cephems<br />

S-1108<br />

pharmacokinetics, 1043<br />

safety of <strong>and</strong> carnitine status of patients,<br />

1043<br />

CGI 17341<br />

M. tuberculosis<br />

in vitro <strong>and</strong> in vivo activities, 183<br />

CGP 53437<br />

antiviral activity<br />

human immunodeficiency virus type 1<br />

protease, 2087<br />

Chagas' disease<br />

ICI 195,739-terbinafine<br />

murine model, 1353<br />

ketoconazole-terbinafine<br />

murine model, 1353<br />

Chancroid<br />

agents for treatment of, currently recommended<br />

<strong>and</strong> newer<br />

H. ducreyi from the United States <strong>and</strong><br />

Thail<strong>and</strong>, 1552<br />

in vitro susceptibilities, 1552<br />

Chlamydia pneumoniae<br />

azithromycin<br />

in vitro activity, 1746<br />

OPC-17116<br />

in vitro <strong>and</strong> in vivo activities, 801<br />

sparfloxacin<br />

in vitro <strong>and</strong> in vivo activities, 801<br />

tosufloxacin<br />

in vitro <strong>and</strong> in vivo activities, 801<br />

Chlamydia psittaci<br />

OPC-17116<br />

in vitro <strong>and</strong> in vivo activities, 801<br />

sparfloxacin<br />

in vitro <strong>and</strong> in vivo activities, 801<br />

tosufloxacin<br />

in vitro <strong>and</strong> in vivo activities, 801<br />

Chlamydia spp.<br />

OPC-17116<br />

in vitro <strong>and</strong> in vivo activities, 801<br />

sparfloxacin<br />

in vitro <strong>and</strong> in vivo activities, 801<br />

tosufloxacin<br />

in vitro <strong>and</strong> in vivo activities, 801<br />

Chlamydia trachomatis<br />

azithromycin<br />

in vitro activity, 1746<br />

CI-960<br />

salpingitis, 8<br />

doxycycline<br />

comparative evaluation, 1373<br />

genital infections, treatment of, 1373<br />

genital infections<br />

doxycycline, comparative evaluation,<br />

1373<br />

spiramycin, comparative evaluation,<br />

1373<br />

OPC-17116<br />

in vitro <strong>and</strong> in vivo activities, 801<br />

sparfloxacin<br />

in vitro <strong>and</strong> in vivo activities, 801<br />

spiramycin<br />

comparative evaluation, 1373<br />

genital infections, treatment of, 1373

xvi SUBJECT INDEX<br />

tosufloxacin<br />

in vitro <strong>and</strong> in vivo activities, 801<br />

Chloramphenicol<br />

P. cepacia<br />

comparative evaluation, 123<br />

S. typhi<br />

14 days, comparative evaluation, 1572<br />

typhoid fever<br />

14 days, comparative evaluation, 1572<br />

Chloramphenicol acetyltransferases<br />

A. baumannii<br />

production by, 138<br />

Chlorhexidine<br />

S. mutans<br />

in vitro susceptibility, 1158<br />

Chloroquine<br />

P. falciparum<br />

clonal viability measurements to assess<br />

in vitro activity, 1102<br />

CI-960<br />

C. trachomatis<br />

salpingitis, monkey model, 8<br />

Cilastatin<br />

combinations<br />

imipenem, 51<br />

yeast colonization of the human gastrointestinal<br />

tract, effect on, 51<br />

Cilofungin<br />

C. albicans<br />

comparative evaluation, 729<br />

disseminated infection in normal <strong>and</strong><br />

granulocytopenic mice, 729<br />

Ciprofloxacin<br />

adverse effects<br />

convulsions in mice, 1764<br />

B. burgdorferi<br />

in vitro susceptibility, 1444<br />

combinations<br />

ampicillin, 1904<br />

E. faecium, 1904<br />

novobiocin, 1904<br />

comparative evaluation<br />

DU-6859a, 2747<br />

ofloxacin, 2193<br />

disk elution<br />

M. avium complex susceptibility testing,<br />

1556<br />

M. tuberculosis susceptibility testing,<br />

1556<br />

E. coli<br />

postantibiotic effect in pooled cerebrospinal<br />

fluid <strong>and</strong> Mueller-Hinton<br />

broth, 1154<br />

gonorrhea, uncomplicated<br />

single-dose therapy, comparative evaluation,<br />

1670<br />

H. influenzae<br />

adherence changes induced by subinhibitory<br />

concentrations, 885<br />

in vitro activities<br />

gram-negative organisms, 2017<br />

gram-positive organisms, 2017<br />

K pneumoniae<br />

adherence changes induced by subinhibitory<br />

concentrations, 885<br />

keratitis<br />

age <strong>and</strong> therapeutic outcome, 1856<br />

liposome incorporated<br />

treatment of murine salmonellosis,<br />

2293<br />

M. catarrhalis<br />

adherence changes induced by subinhibitory<br />

concentrations, 885<br />

M. haemophilum<br />

in vitro activities, 2323<br />

M. pneumoniae<br />

hamsters, 287<br />

N. gonorrhoeae<br />

antibacterial activities, 2244<br />

P. aeruginosa<br />

age <strong>and</strong> therapeutic outcome, 1856<br />

dose-ranging <strong>and</strong> fractionation, 1756<br />

in vitro model of infection, 1756<br />

increased susceptibility in the presence<br />

of vancomycin, 2506<br />

resistance to unrelated antibiotics, effects<br />

on, 1289<br />

P. cepacia<br />

comparative evaluation, 123<br />

pharmacokinetics<br />

effects of cardiopulmonary bypass surgery<br />

on disposition, 2106<br />

multiple oral doses to healthy volunteers,<br />

2193<br />

seriously ill patients, 1073<br />

population pharmacokinetics<br />

optimal sampling strategies, 1065<br />

postantibiotic effect<br />

E. coli, in pooled cerebrospinal fluid<br />

<strong>and</strong> Mueller-Hinton broth, 1154<br />

S. aureus<br />

dose-ranging <strong>and</strong> fractionation, 1756<br />

in vitro model of infection, 1756<br />

resistance to unrelated antibiotics, effects<br />

on, 1289<br />

S. pneumoniae<br />

mouse protection model, 234<br />

S. typhimurium resistance<br />

isolates from two patients, 662<br />

serum bactericidal titers<br />

multiple oral doses to healthy volunteers,<br />

2193<br />

synergy<br />

ethambutol, 1285<br />

M. malmoense, 1285<br />

T-cell subsets <strong>and</strong> tumor necrosis factor<br />

production<br />

mice infected with B. fragilis, effect<br />

on, 1711<br />

typhoid fever<br />

severe, in children, 1197<br />

vancomycin<br />

increased susceptibility of P. aeruginosa,<br />

2506<br />

Citrobacter freundii<br />

ampD<br />

sequences of wild-type <strong>and</strong> mutant<br />

genes, comparison with those of<br />

E. coli, 224<br />

Clarithromycin<br />

B. burgdorferi<br />

hamsters, 1329<br />

in vitro activity, comparative evaluation,<br />

1704<br />

in vitro susceptibility, 1444<br />

bite wound isolates<br />

aerobic <strong>and</strong> anaerobic, 1150<br />

Brucella spp.<br />

in vitro activity, comparative evaluation,<br />

911<br />

C. bumetii<br />

in vitro susceptibilities, 2633<br />

combinations<br />

granulocyte colony-stimulating factor,<br />

692<br />

M. avium complex, 692<br />

ANTIMICROB. AGENTS CHEMOTHER.<br />

M. avium, prophylaxis in mice, 1690<br />

minocycline, 1690<br />

RU-4055, 692<br />

cross-resistance<br />

frequency distribution curves, scattergrams,<br />

<strong>and</strong> regression analyses,<br />

2080<br />

gram-negative organisms<br />

outer membrane permeability barrier,<br />

354<br />

in vitro activities<br />

frequency distribution curves, scattergrams,<br />

<strong>and</strong> regression analyses,<br />

2080<br />

Lyme disease<br />

hamsters, 1329<br />

M. avium<br />

cross-resistance, 2364<br />

erratum, 2515<br />

human macrophages, 111<br />

macrophages, inhibition of intracellular<br />

growth, 1380<br />

prophylaxis in C57BL/6 mice, 1690<br />

M. avium complex, 692<br />

M. haemophilum<br />

in vitro activities, 2323<br />

M. kansasii<br />

susceptibility testing, 1997<br />

metabolite<br />

B. burgdorferi, susceptibility in vitro,<br />

1444<br />

P. aeruginosa<br />

biofilms, interaction with, 1749<br />

S. pneumoniae resistance<br />

cultures from Providence, R.I., 1742<br />

T. pallidum<br />

hamsters, 864<br />

Clavulanate<br />

combinations<br />

E. coli, 2059<br />

sulbactam, 2059<br />

tazobactam, 2059<br />

E. coli<br />

P-lactamase, TEM type, resistant,<br />

2059<br />

Clavulanic acid<br />

combinations<br />

amoxicillin, 14<br />

H. influenzae, P-lactamase producing<br />

<strong>and</strong> nonproducing, ampicillin resistant,<br />

14<br />

ticarcillin, 51<br />

yeast colonization of the human gastrointestinal<br />

tract, effect on, 51<br />

Clindamycin<br />

B. fragilis<br />

in vivo efficacy, correlation with in<br />

vitro susceptibility, 997<br />

mice, 997<br />

bioavailability<br />

healthy volunteers <strong>and</strong> AIDS patients,<br />

1137<br />

E. coli<br />

in vivo efficacy, correlation with in<br />

vitro susceptibility, 997<br />

mice, 997<br />

peptidyl-RNA<br />

dissociation from ribosomes, 2027<br />

pharmacokinetics<br />

bioavailability, 1137<br />

healthy volunteers <strong>and</strong> AIDS patients,<br />

1137<br />

T. gondii

VOL. 37, 1993<br />

infectivity, 2571<br />

intracellular replication, 2571<br />

protein synthesis, 2571<br />

Clofazamine<br />

M. haemophilum<br />

in vitro activities, 2323<br />

Clofazimine<br />

M. avium-M. intracellulare complex<br />

in vitro activities, 2584<br />

M. tuberculosis<br />

in vitro activities, 2584<br />

Clonal viability measurements<br />

P. falciparum<br />

leupeptin, chloroquine, <strong>and</strong> 5-fluoroorotate,<br />

in vitro activity, 1102<br />

Clostridium difficile<br />

cefixime<br />

effect on shedding in healthy volunteers,<br />

1432<br />

Clostridium spp.<br />

Bay Y3118<br />

in vitro activity, 2509<br />

Co-trimoxazole<br />

P. cepacia<br />

comparative evaluation, 123<br />

P. pseudomallei resistance<br />

biofilm cells, 2000<br />

Coumermycin Al<br />

B. burgdorferi<br />

growth inhibition <strong>and</strong> induction of relaxation<br />

of supercoiled plasmids,<br />

46<br />

Coxiella bumetii<br />

ceftriaxone<br />

shell vial assay, 491<br />

clarithromycin<br />

in vitro susceptibilities, 2633<br />

Q fever<br />

minireview, 1733<br />

treatment of, 1733<br />

Coxsackievirus<br />

WIN 54954<br />

group B diabetogenic strain in mice,<br />

1593<br />

CP-70,429<br />

in vitro antibacterial activity, 1547<br />

P-lactamase stability, 1547<br />

CP-99,219<br />

gram-positive organisms<br />

in vitro activity, 366<br />

in vitro activity, 349<br />

Cryptococcus neofornans<br />

amphotericin B<br />

in vitro susceptibility, 1383<br />

recurrent meningitis, isolates from patients<br />

with, 1383<br />

D0870<br />

in vitro activities, 2126<br />

in vivo <strong>and</strong> in vitro activities, 2412<br />

fluconazole<br />

in vitro susceptibility, 1383<br />

recurrent meningitis, isolates from patients<br />

with, 1383<br />

itraconazole<br />

effects on cytochrome P-450-dependent<br />

sterol 14a-demethylation <strong>and</strong><br />

reduction of 3-ketosteroids, 2101<br />

NP-1<br />

in vitro activity, 2628<br />

platelet microbicidal protein<br />

fungicidal activity, 546<br />

susceptibility testing<br />

current status of the st<strong>and</strong>ardization<br />

process, minireview, 2517<br />

Cryptosporidium parvum<br />

sinefungin<br />

curative <strong>and</strong> preventive activities, 889<br />

immunosuppressed rat model, 889<br />

Cycloguanil<br />

P. falciparum<br />

African isolates, 924<br />

Cyclothialidine<br />

Eubactenum spp.<br />

inhibition, 2656<br />

Cytochrome P-450<br />

dirithromycin<br />

type I binding spectrum, 265<br />

macrolides<br />

type I binding spectrum, 265<br />

Cytokines<br />

C. jejuni<br />

effect of oral recombinant interleukin<br />

on mucosal immunity in mice,<br />

2688<br />

interleukin-8<br />

nonspecific resistance to infection in<br />

neutropenic <strong>and</strong> normal mice, 276<br />

Cytomegalovirus<br />

1110U81<br />

ganciclovir, potentiation of antiviral<br />

effects, 602<br />

potent inhibition of replication, 602<br />

ganciclovir<br />

decrease in frequency <strong>and</strong> severity of<br />

disease in liver transplant recipients<br />

treated with OKT3 monoclonal<br />

antibodies, 2490<br />

sensitivity at diagnosis <strong>and</strong> during<br />

treatment, 1360<br />

ganciclovir resistance<br />

point mutation in DNA polymerase<br />

gene, 19<br />

(S)-1-(3-hydroxy-2-phosphonyl-methoxypropyl)cytosine<br />

interstitial pneumonitis after bone<br />

marrow transplantation, 218<br />

phosphonylmethoxyalkyl derivatives,<br />

resistance to<br />

point mutation in DNA polymerase<br />

gene, 19<br />

phosphorothioate oligonucleotides<br />

ISIS 2922, in vitro activity of, 1945<br />

D0870<br />

A. fumigatus<br />

in vivo <strong>and</strong> in vitro activities, 2412<br />

B. dermatitidis<br />

murine blastomycosis, 1177<br />

blastomycosis<br />

murine, 1177<br />

C. albicans<br />

in vitro activities, 2126<br />

in vivo <strong>and</strong> in vitro activities, 2412<br />

C. neoformans<br />

in vitro activities, 2126<br />

in vivo <strong>and</strong> in vitro activities, 2412<br />

comparative evaluation<br />

fluconazole, 2412<br />

pathogenic yeasts<br />

in vitro activities, 2126<br />

Dapsone<br />

synergy<br />

dihydrofolate reductase inhibitors,<br />

1436<br />

P. carinii, 1436<br />

SUBJECT INDEX xvii<br />

Ro 11-8958, 1436<br />

Daptomycin<br />

bactericidal activity<br />

albumin or serum, presence of, controlled<br />

pH <strong>and</strong> calcium, 605<br />

Decimal assay for additivity<br />

synergy <strong>and</strong> antagonism<br />

delineation of, 260<br />

Deglucoteicoplanin amides<br />

E. coli<br />

uptake, mechanism of, 453<br />

P. aeruginosa<br />

uptake, mechanism of, 453<br />

Dental amalgam<br />

mercury<br />

bacterial resistance, 825<br />

bacterial resistance, letter to the editor,<br />

1730<br />

3'-Deoxy-2',3'-didehydrothymidine<br />

pharmacokinetics<br />

disposition <strong>and</strong> metabolism in hepatocytes<br />

<strong>and</strong> nonhuman primates,<br />

1816<br />

2'-Deoxy-3'-thiacytidine<br />

human immunodeficiency virus type 1<br />

resistance<br />

due to amino acid substitution at catalytic<br />

site of reverse transcriptase,<br />

2231<br />

Diarylsulfones<br />

human immunodeficiency virus type 1<br />

mechanism of action, 754<br />

reverse transcriptase inhibitor, 754<br />

Didanosine<br />

human immunodeficiency virus resistance<br />

pol mutations, multiple resistance,<br />

1480<br />

salmonellae<br />

in vitro activities, 106<br />

2',3-Dideoxy-3-thiacytidine<br />

(-) enantiomer<br />

human immunodeficiency virus, resistance,<br />

characterization of, 875<br />

human immunodeficiency virus resistance<br />

characterization of, 875<br />

conferred by the same mutation that<br />

confers resistance to ddl <strong>and</strong><br />

ddC, 1390<br />

generation of variants, 130<br />

2',3'-Dideoxy-5-fluoro-3'-thiacytidine<br />

(-) enantiomer<br />

human immunodeficiency virus, resistance,<br />

characterization of, 875<br />

human immunodeficiency virus resistance<br />

characterization of, 875<br />

2',3'-Dideoxycytidine<br />

human immunodeficiency virus resistance<br />

generation of variants, 130<br />

salmonellae<br />

in vitro activities, 106<br />

2',3'-Dideoxyinosine<br />

salmonellae<br />

in vitro activities, 106<br />

2',3'-Dideoxynucleosides<br />

visna virus<br />

inhibition of replication, 2540<br />

Dihydrofolate reductase<br />

T. gondii<br />

inhibitors, identification of, 1914

xviii SUBJECT INDEX<br />

trimethoprim resistance<br />

integron on a Tn2l-like element, 1297<br />

Dihydrofolate reductase inhibitors<br />

synergy<br />

dapsone, 1436<br />

P. carinii, 1436<br />

sulfamethoxazole, 1436<br />

Dihydrofolate reductases<br />

S. aureus<br />

characterization of gene for, 1400<br />

trimethoprim sensitive<br />

S. aureus, characterization of gene<br />

for, 1400<br />

Diltiazem<br />

netilmicin<br />

nephrotoxicity in rabbits, induction<br />

by, 1790<br />

Diminazine<br />

pharmacokinetics<br />

Boran cattle, noninfected <strong>and</strong> infected<br />

with T. congolense, 1050<br />

Dinitroanilines<br />

L. mexicana<br />

structure-function analysis, 1909<br />

trifluralin, 1909<br />

Dirithromycin<br />

B. burgdorferi<br />

in vitro susceptibility, 1444<br />

Brucella spp.<br />

in vitro activity, comparative evaluation,<br />

911<br />

cytochrome P-450 complex formation<br />

rat <strong>and</strong> human livers, 265<br />

polymorphonuclear leukocytes<br />

interactions may promote killing of<br />

infecting organisms, 2557<br />

Disk elution<br />

ciprofloxacin susceptibility testing<br />

M. avium complex, 1556<br />

M. tuberculosis, 1556<br />

DNA gyrases<br />

E. coli<br />

quinolones, mechanism of action, 839<br />

quinolones<br />

E. coli, mechanism of action, 839<br />

DNA gyrases<br />

C. jejuni<br />

gyrA, cloning <strong>and</strong> nucleotide sequence,<br />

457<br />

Eubacterium spp.<br />

cyclothialidine, characterization of,<br />

2656<br />

fluoroquinolones<br />

single point mutation in E. coli A protein<br />

reduces binding, 126<br />

Doxycycline<br />

alpha-1-antitrypsin<br />

protection from human neutrophil collagenase<br />

<strong>and</strong> gelatinase, 592<br />

B. burgdorferi<br />

in vitro susceptibility, 1444<br />

C. trachomatis<br />

comparative evaluation, 1373<br />

genital infections, treatment of, 1373<br />

combinations<br />

Brucella spp., 1831<br />

rifampin, 1831<br />

E. coli<br />

comparative evaluation, 846<br />

epididymitis, 846<br />

epididymitis<br />

comparative evaluation, 846<br />

E. coli, 846<br />

DR-3354<br />

comparative evaluation<br />

accumulation by human polymorphonuclear<br />

leukocytes, 1882<br />

Drosophila melanogaster<br />

pyrimido[1,6-a]benzimidazoles<br />

effects on topoisomerase II <strong>and</strong> Kc<br />

cells, 2599<br />

Ro 46-7864<br />

effects on topoisomerase II <strong>and</strong> Kc<br />

cells, 2599<br />

Ro 47-3359<br />

effects on topoisomerase II <strong>and</strong> Kc<br />

cells, 2599<br />

Drug combination testing<br />

fractional maximal effect method, 523<br />

DU-6859a<br />

comparative evaluation<br />

ciprofloxacin, 2747<br />

fleroxacin, 2747<br />

levofloxacin, 2747<br />

lomefloxacin, 2747<br />

ofloxacin, 2747<br />

Duck hepatitis B virus<br />

suramin<br />

prevention of infection in vivo, 1539<br />

DV-7751a<br />

fluoroquinolones<br />

in vitro antibacterial activity, 2112<br />

E1077<br />

in vitro <strong>and</strong> in vivo activities, 60<br />

E-4868<br />

in vitro <strong>and</strong> in vivo activities, 868<br />

Efflux pump inhibitors<br />

screening assay, 1624<br />

Encephalitis<br />

foscarnet<br />

blood-brain barrier, penetration of,<br />

1010<br />

Endocarditis<br />

amphotericin B, 2030<br />

ampicillin-sulbactam<br />

S. aureus, P-lactamase hyperproducing,<br />

507<br />

aztreonam, 308<br />

aztreonam-amikacin, 308<br />

C. parapsilosis, 2030<br />

C. tropicalis, 2030<br />

ceftazidime, 308<br />

ceftazidime-amikacin, 308<br />

ceftriaxone-netilmicin<br />

Streptococcus spp., 1971<br />

synergy, 207<br />

cephalosporins<br />

broad spectrum, 554<br />

E. faecalis, ,3-lactamase producing,<br />

highly gentamicin resistant<br />

ampicillin-sulbactam, comparative<br />

evaluation, 1447<br />

vancomycin, comparative evaluation,<br />

1447<br />

fluconazole, 2030<br />

oxacillin<br />

S. aureus, 1-lactamase hyperproducing,<br />

507<br />

S. aureus, methicillin susceptible<br />

cephalosporins, broad spectrum, 554<br />

Streptococcus spp.<br />

ceftriaxone-netilmicin synergy, 207<br />

ANTIMICROB. AGENTS CHEMOTHER.<br />

Endotoxic shock<br />

magainins<br />

eicosanoid release by rat peritoneal<br />

macrophages, effect on, 393<br />

Enoxacin<br />

infection prevention<br />

adults with acute nonlymphocytic leukemia,<br />

474<br />

pharmacokinetics<br />

oral antacids, effect on disposition,<br />

775<br />

urinary tract infections, recurrent<br />

cefuroxime axetil, more rapid than,<br />

1558<br />

rapid symptom alleviation, 1558<br />

Enterobacter cloacae<br />

3-N-acetyltransferase<br />

aac(3)-VIa gene, biochemical analysis<br />

of, 2074<br />

1-lactamase<br />

carbapenem hydrolyzing, biochemical<br />

properties, 939<br />

Enterococcus faecalis<br />

3-lactamase<br />

mobilization of gene, 1187<br />

production, genes involved in regulation,<br />

1966<br />

,-lactamase producing, highly gentamicin<br />

resistant<br />

ampicillin-sulbactam, comparative<br />

evaluation, 1447<br />

vancomycin, comparative evaluation,<br />

1447<br />

endocarditis<br />

ampicillin-sulbactam, comparative<br />

evaluation, 1447<br />

vancomycin, comparative evaluation,<br />

1447<br />

virulence in a rabbit model conferred<br />

by plasmid-associated hemolysin<br />

<strong>and</strong> aggregation substance production,<br />

2474<br />

highly gentamicin resistant<br />

molecular characterization of isolates<br />

lacking high-level streptomycin<br />

resistance, 134<br />

penicillinase gene<br />

mobilization of, 1187<br />

polymerase chain reaction<br />

heterogeneity of chloramphenicol acetyltransferase<br />

genes, 2593<br />

vancomycin resistance gene<br />

homology with vanB, vanA, <strong>and</strong><br />

vanC, 1604<br />

WIN 57273<br />

activity against high-level gentamicinresistant<br />

strains, 2470<br />

Enterococcus faecium<br />

aac(6')-Ii<br />

specificity for, 1896<br />

ampicillin resistance, 1904<br />

ampicillin resistant, 2069<br />

endocarditis, 2069<br />

gentamicin resistance, 1904<br />

gentamicin resistant, high level<br />

isolates from different continents,<br />

comparison of, 681<br />

novobiocin<br />

in vitro activity against multiresistant<br />

strains, 2736<br />

penicillin resistance<br />

time-kill studies, 2427<br />

polymerase chain reaction

VOL. 37, 1993<br />

heterogeneity of chloramphenicol acetyltransferase<br />

genes, 2593<br />

streptogramin A acetyltransferase<br />

identification of satA, 2119<br />

synergy<br />

penicillin-gentamicin, 2427<br />

vancomycin resistance, 1904<br />

vancomycin resistance gene<br />

homology with vanB, vanA, <strong>and</strong><br />

vanC, 1604<br />

vancomycin resistant, 2069<br />

resistance to synergistic P-lactam<br />

combinations, 1238<br />

Enterococcus spp.<br />

antimicrobial susceptibilities<br />

isolates from hospitalized patients,<br />

1190<br />

glycopeptide resistance<br />

genetics <strong>and</strong> mechanisms of, minireview,<br />

1563<br />

glycopeptide resistant<br />

characterization of isolates from U.S.<br />

hospitals, 2311<br />

pulsed-field gel electrophoresis, 2311<br />

Epididymitis<br />

cefotaxime<br />

comparative evaluation, 846<br />

doxycycline<br />

comparative evaluation, 846<br />

E. coli<br />

cefotaxime, comparative evaluation,<br />

846<br />

doxycycline, comparative evaluation,<br />

846<br />

ofloxacin, comparative evaluation, 846<br />

ofloxacin<br />

comparative evaluation, 846<br />

Epipodophyllotoxins<br />

P. carinji<br />

activity in vitro <strong>and</strong> in a mouse model,<br />

1543<br />

Epstein-Barr virus<br />

phosphorothioate oligodeoxynucleotides<br />

inhibition of replication, 1420<br />

Equine herpesvirus 1<br />

phosphonylmethoxyalkyl derivatives<br />

murine model for abortion, 2478<br />

Errata<br />

M. avium<br />

activities of quinolones, 2766<br />

clarithromycin, minocycline, <strong>and</strong> rifabutin<br />

treatments of C57BL/6<br />

mice, 2515<br />

quinolones<br />

anti-M. avium activities, 2766<br />

Erythromycin<br />

B. burgdorferi<br />

in vitro activity, comparative evaluation,<br />

1704<br />

in vitro susceptibility, 1444<br />

cross-resistance<br />

frequency distribution curves, scattergrams,<br />

<strong>and</strong> regression analyses,<br />

2080<br />

H. influenzae<br />

distribution in patients with lower respiratory<br />

tract infections, effect on,<br />

804<br />

H. parainfluenzae<br />

distribution in patients with lower respiratory<br />

tract infections, effect on,<br />

804<br />

in vitro activities<br />

frequency distribution curves, scattergrams,<br />

<strong>and</strong> regression analyses,<br />

2080<br />

M. haemophilum<br />

in vitro activities, 2323<br />

P. aeruginosa<br />

serum sensitivity, effect of sub-MICs<br />

on, 675<br />

peptidyl-RNA<br />

accumulation, 2027<br />

S. mutans<br />

in vitro susceptibility, 1158<br />

S. pneumoniae resistance<br />

cultures from Providence, R.I., 1742<br />

Escherichia coli<br />

amikacin resistance<br />

bleomycin, increase of, 1982<br />

ampD<br />

sequences of wild-type <strong>and</strong> mutant<br />

genes, comparison with those of<br />

C. freundii, 224<br />

ampicillin-sulbactam<br />

comparative evaluation, 610<br />

azithromycin<br />

in vitro activity, 1203<br />

B. fragilis, polymicrobial infection<br />

mice, 1531<br />

B. thetaiotaomicron, polymicrobial infection<br />

mice, 1531<br />

1-lactamase<br />

ceftazidime resistance, 1989<br />

,-lactamase, TEM type, resistant<br />

clavulanate, 2059<br />

sulbactam, 2059<br />

tazobactam, 2059<br />

,-lactamases<br />

TEM-1, cephalosporinase activity of,<br />

2438<br />

cefoperazone-sulbactam<br />

granulocytopenic mice, disseminated<br />

infections in, 1927<br />

cefotaxime<br />

comparative evaluation, 846<br />

postantibiotic effect in cerebrospinal<br />

fluid <strong>and</strong> Mueller-Hinton broth,<br />

1154<br />

cefoxitin<br />

comparative evaluation, 610<br />

ceftazidime resistance<br />

P-lactamase, 1989<br />

cephalosporins<br />

3'-quinolone esters, carbamates, <strong>and</strong><br />

tertiary amines, mechanism of<br />

action, 559<br />

ciprofloxacin<br />

postantibiotic effect in cerebrospinal<br />

fluid <strong>and</strong> Mueller-Hinton broth,<br />

1154<br />

clindamycin<br />

in vivo efficacy, correlation with in<br />

vitro susceptibility, 997<br />

mice, 997<br />

deglucoteicoplanin amide derivatives<br />

uptake, mechanism of, 453<br />

DNA gyrase<br />

quinolones, mechanism of action, 839<br />

DNA gyrase A protein<br />

fluoroquinolones, single point mutation<br />

reduces binding, 126<br />

doxycycline<br />

comparative evaluation, 846<br />

epididymitis<br />

SUBJECT INDEX xix<br />

cefotaxime, comparative evaluation,<br />

846<br />

doxycycline, comparative evaluation,<br />

846<br />

ofloxacin, comparative evaluation, 846<br />

fluoroquinolone resistant<br />

gyrA, mutations in, 696<br />

fluoroquinolone resistant, nalidixic acid<br />

susceptible<br />

gyrA point mutation, novel, 1247<br />

gentamicin<br />

kill kinetics <strong>and</strong> regrowth patterns after<br />

exposure, 914<br />

postantibiotic effect in cerebrospinal<br />

fluid <strong>and</strong> Mueller-Hinton broth,<br />

1154<br />

isoniazid<br />

susceptibilities of oxyR regulon mutants,<br />

2251<br />

lactoferrin-porin interaction<br />

antibacterial activity, effect on, 240<br />

mutants<br />

supersusceptibility to antibiotics, 2255<br />

ofloxacin<br />

comparative evaluation, 846<br />

pefloxacin<br />

one 800-mg versus two 400-mg doses,<br />

737<br />

plasmid complementation test<br />

quinolone resistance, 2588<br />

postantibiotic effect<br />

correlation of tobramycin-induced inhibition<br />

of protein synthesis, 2678<br />

quinolone resistance<br />

plasmid complementation test, 2588<br />

quinolones<br />

DNA gyrase, mechanism of action,<br />

839<br />

in vivo efficacy, correlation with in<br />

vitro susceptibility, 997<br />

mice, 997<br />

S. aureus tetK<br />

expression in, 191<br />

streptomycin resistance<br />

bleomycin, increase of, 1982<br />

tobramycin resistance<br />

3'-aminoglycoside phosphotransferase<br />

type I, overproduction of, 78<br />

Ethambutol<br />

Mycobacterium spp.<br />

glucose metabolism, inhibition of,<br />

1536<br />

synergy<br />

amikacin, 1285<br />

ciprofloxacin, 1285<br />

M. malmoense, 1285<br />

rifampin, 1285<br />

Eubacterium spp.<br />

DNA gyrases<br />

cyclothialidine, characterization of,<br />

2656<br />

FDA approvals<br />

anti-infective agents, biologics, <strong>and</strong> vaccines<br />

approved in 1992, 926<br />

FK037<br />

anaerobic organisms<br />

in vitro activity, 957<br />

B. burgdorfeni<br />

in vitro susceptibility, 1444<br />

P-lactamase stability, 566<br />

in vitro activity, 566

xx SUBJECT INDEX<br />

multicenter comparison, 1696<br />

in vitro <strong>and</strong> in vivo activities<br />

comparative evaluation, 301<br />

Flavimonas oryzihabitans<br />

aminoglycosides<br />

in vitro activities against clinical isolates<br />

from patients with cancer,<br />

2504<br />

carbapenems<br />

in vitro activities against clinical isolates<br />

from patients with cancer,<br />

2504<br />

extended-spectrum cephalosporins<br />

in vitro activities against clinical isolates<br />

from patients with cancer,<br />

2504<br />

monobactams<br />

in vitro activities against clinical isolates<br />

from patients with cancer,<br />

2504<br />

ureidopenicillins<br />

in vitro activities against clinical isolates<br />

from patients with cancer,<br />

2504<br />

Fleroxacin<br />

breast milk<br />

penetration into, 293<br />

combinations<br />

rifampin, 2132<br />

comparative evaluation<br />

DU-6859a, 2747<br />

in vitro activities<br />

gram-negative organisms, 2017<br />

gram-positive organisms, 2017<br />

pharmacokinetics<br />

breast milk, penetration into, 293<br />

effects in healthy volunteers by<br />

positron emission tomography,<br />

8F labeled, 2144<br />

lactating women, 293<br />

rifampin, influence of, 2132<br />

S. aureus, 2132<br />

Fluconazole<br />

bioavailability<br />

patients with AIDS, 2187<br />

C. albicans<br />

emergence of resistance of Norwegian<br />

strains, 2443<br />

patients infected with human immunodeficiency<br />

virus type 1, correlation<br />

to therapy <strong>and</strong> symptoms,<br />

2449<br />

C. glabrata resistance, 1962<br />

C. neoformans<br />

in vitro susceptibility, 1383<br />

recurrent meningitis, isolates from patients<br />

with, 1383<br />

comparative evaluation<br />

amphotericin B, 2030<br />

endocarditis<br />

C. parapsilosis, 2030<br />

C. tropicalis, 2030<br />

intracellular activity<br />

human polymorphonuclear leukocytes,<br />

187<br />

P. marneffei<br />

response of human immunodeficiency<br />

virus-infected patients, 2407<br />

pharmacokinetics<br />

healthy human subjects, 1270<br />

influence of radiotherapy on penetration<br />

into human saliva, 2674<br />

patients with AIDS, 2187<br />

positron emission tomography, 18F<br />

labeled, 1270<br />

uptake in human polymorphonuclear<br />

leukocytes, 187<br />

T. glabrata<br />

prophylaxis in neutropenic bone marrow<br />

transplant patients, 1847<br />

Flucytosine<br />

C<strong>and</strong>ida spp.<br />

temperature, effect on activity, 685<br />

cis-5-Fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolane-5-yl]cytosine<br />

(-) <strong>and</strong> (+) enantiomers, 5'-triphosphates<br />

human immunodeficiency virus, 1720<br />

human immunodeficiency virus<br />

(-) <strong>and</strong> (+) enantiomers, 5' triphosphates,<br />

1720<br />

5-Fluorocytosine<br />

P. mameffei<br />

response of human immunodeficiency<br />

virus-infected patients, 2407<br />

5-Fluoroorotate<br />

P. falciparum<br />

clonal viability measurements to assess<br />

in vitro activity, 1102<br />

Fluoroquinolones<br />

ciprofloxacin<br />

reduced susceptibilities of S. sonnei<br />

strains, 2486<br />

combinations<br />

inhibitors of glycosylation <strong>and</strong> fatty<br />

acid <strong>and</strong> peptide biosynthesis, 652<br />

M. avium, 652<br />

CP-99,219<br />

gram-positive organisms, in vitro activity,<br />

366<br />

in vitro activity, 349<br />

DNA gyrase<br />

E. coli A protein, single point mutation<br />

reduces binding, 126<br />

DV-7751a<br />

in vitro antibacterial activity, 2112<br />

E-4868<br />

in vitro <strong>and</strong> in vivo activities, 868<br />

E. coli DNA gyrase A protein<br />

single point mutation reduces binding,<br />

126<br />

E. coli resistance<br />

gyrA, mutations in, 696<br />

E. coli resistance, nalidixic acid susceptible<br />

gyrA, novel point mutation, 1247<br />

gram-positive cocci<br />

bloodstream isolates, 896<br />

in vitro activity, 896<br />

M. pneumoniae, 1826<br />

ofloxacin<br />

reduced susceptibilities of S. sonnei<br />

strains, 2486<br />

OPC-17116<br />

accumulation by human polymorphonuclear<br />

leukocytes, 1882<br />

penetration into bacterial cells<br />

minireview, 1393<br />

Q-35<br />

in vitro <strong>and</strong> in vivo activities, 1826<br />

reduced phototoxicity in mice irradiated<br />

with long-wavelength UV,<br />

2217<br />

S. aureus resistance<br />

efflux mediated, 1086<br />

NorA, multidrug efflux transporter,<br />

ANTIMICROB. AGENTS CHEMOTHER.<br />

128<br />

sparfloxacin<br />

reduced susceptibilities of S. sonnei<br />

strains, 2486<br />

WIN 57273<br />

E. faecalis, 2470<br />

Flurbiprofen<br />

keratitis<br />

age <strong>and</strong> therapeutic outcome, 1856<br />

P. aeruginosa<br />

age <strong>and</strong> therapeutic outcome, 1856<br />

Foscarnet<br />

human immunodeficiency virus<br />

cerebrospinal fluid of patients with<br />

AIDS, penetration of, 1777<br />

human renal proximal tubule cells<br />

nephrotoxicity, 2496<br />

nephrotoxicity<br />

human renal proximal tubule cells,<br />

2496<br />

pharmacokinetics<br />

blood-brain barrier, penetration of,<br />

1010<br />

cerebrospinal fluid of patients with<br />

AIDS, penetration of, 1777<br />

Fosfomycin<br />

B-lymphocyte function<br />

immunomodulatory effect, 270<br />

T cells<br />

immunosuppressive effect, 2684<br />

Fractional maximal effect method<br />

antibiotic combinations<br />

effect, characterization of, 523<br />

nonlinear pharmacodynamics<br />

characterization of, 523<br />

Fullerenes<br />

human immunodeficiency virus<br />

activity against, 1707<br />

Fusidic acid<br />

combinations<br />

S. aureus, 2466<br />

vancomycin, 2466<br />

M. kansasii<br />

susceptibility testing, 1997<br />

pharmacokinetics<br />

intravenous, cholestatic patients, 501<br />

Fusobacterium spp.<br />

Bay Y3118<br />

in vitro activity, 2509<br />

G418<br />

T. brucei brucei resistance phenotype<br />

in vivo system to select for bloodstream-form<br />

transfectants, 1167<br />

Gamma interferon<br />

receptors<br />

relation to therapy of typhoid fever,<br />

2418<br />

Ganciclovir<br />

cytomegalovirus<br />

1110U81, potentiation of antiviral effects,<br />

602<br />

prophylaxis decreases frequency <strong>and</strong><br />

severity in liver transplant recipients<br />

treated with OKT3 monoclonal<br />

antibodies, 2490<br />

sensitivity at diagnosis <strong>and</strong> during<br />

treatment, 1360<br />

cytomegalovirus resistance<br />

point mutation in DNA polymerase<br />

gene, 19

VOL. 37, 1993<br />

Gardnerella vaginalis<br />

agar dilution<br />

susceptibilities to 25 antimicrobial<br />

agents, 2733<br />

Gentamicin<br />

E. coli<br />

kill kinetics <strong>and</strong> regrowth patterns after<br />

exposure, 914<br />

postantibiotic effect in pooled cerebrospinal<br />

fluid <strong>and</strong> Mueller-Hinton<br />

broth, 1154<br />

E. faecalis resistance, high level<br />

molecular characterization of isolates<br />

lacking high-level streptomycin<br />

resistance, 134<br />

E. faecium resistance, 1904<br />

E. faecium resistance, high level<br />

isolates from different continents,<br />

comparison of, 681<br />

glomerular basement membrane<br />

alteration of development after administration<br />

during gestation, 1510<br />

M. avium complex<br />

AIDS patients with bacteremia, 1869<br />

nephrotoxicity<br />

neonates, drug-treated pregnant<br />

Wistar rats, 1510<br />

polyaspartic acid, protective effects,<br />

pharmacologic limits of, 347<br />

P. aeruginosa<br />

A b<strong>and</strong> <strong>and</strong> B b<strong>and</strong> lipopolysaccharides,<br />

interaction with, 715<br />

pharmacokinetics<br />

increased renal uptake in endotoxemic<br />

rats receiving thromboxane A2<br />

therapy, 2727<br />

population pharmacokinetic models,<br />

comparison of, 93<br />

postantibiotic effect<br />

E. coli, in pooled cerebrospinal fluid<br />

<strong>and</strong> Mueller-Hinton broth, 1154<br />

S. mitis<br />

chromosomally mediated high-level<br />

resistance, 2740<br />

TLC G-65, 1869<br />

Giardia lamblia<br />

bis-benzimidazoles<br />

correlation of antigiardial activity,<br />

DNA binding affinity, <strong>and</strong> giardial<br />

topoisomerase II inhibition, 2668<br />

structure-activity studies, 2668<br />

Giardia spp.<br />

benzimidazoles<br />

in vitro activity, 328<br />

tubulin inhibitors<br />

in vitro activity, 328<br />

Glucan<br />

irradiated mice, therapy for after adverse<br />

effects from pefloxacin, 1877<br />

Glucose oxidase<br />

human immunodeficiency virus type 1<br />

virucidal effects, 26<br />

Glucose peroxidase<br />

human immunodeficiency virus type 1<br />

virucidal effects, 26<br />

Glycopeptides<br />

Enterococcus resistance<br />

genetics <strong>and</strong> mechanisms of, minireview,<br />

1563<br />

gram-positive cocci<br />

bloodstream isolates, 896<br />

in vitro activity, 896<br />

Glycylcyclines<br />

comparative evaluation<br />

in vitro <strong>and</strong> in vivo activities, 2270<br />

minocycline <strong>and</strong> tetracycline, 2270<br />

Gonorrhea<br />

ceftriaxone<br />

single-dose therapy for women, comparative<br />

evaluation, 1670<br />

ciprofloxacin<br />

single-dose therapy for women, comparative<br />

evaluation, 1670<br />

GR99060<br />

antifungal activity, 1243<br />

GR99062<br />

antifungal activity, 1243<br />

Gram-negative organisms<br />

anaerobic<br />

Bay y3118, comparative susceptibilities,<br />

1649<br />

azithromycin<br />

outer membrane permeability barrier,<br />

354<br />

Bay y3118<br />

comparative susceptibilities, 1649<br />

biapenem<br />

in vitro activity, 2009<br />

CAP18<br />

in vitro activity, 2534<br />

clarithromycin<br />

outer membrane permeability barrier,<br />

354<br />

CP-70,429<br />

in vitro activity, 1547<br />

imipenem<br />

in vitro activity, 2009<br />

outer membrane permeability barrier<br />

azithromycin, clarithromycin, <strong>and</strong><br />

roxithromycin, 354<br />

roxithromycin<br />

outer membrane permeability barrier,<br />

354<br />

Gram-positive organisms<br />

aerobic<br />

MDL 62,879, 746<br />

anaerobic<br />

Bay y3118, comparative susceptibilities,<br />

1649<br />

Bay y3118<br />

comparative susceptibilities, 1649<br />

biapenem<br />

in vitro activity, 2009<br />

bloodstream isolates<br />

fluoroquinolones, 896<br />

glycopeptides, 896<br />

ramoplanin, 896<br />

CAP18<br />

in vitro activity, 2534<br />

CP-70,429<br />

in vitro activity, 1547<br />

CP-99,219<br />

in vitro activity, 366<br />

fluoroquinolones<br />

in vitro activity, 896<br />

glycopeptides<br />

in vitro activity, 896<br />

imipenem<br />

in vitro activity, 2009<br />

MDL 62,879<br />

aerobic, 746<br />

PD 138312<br />

in vitro activities, 2563<br />

PD 140248<br />

in vitro activities, 2563<br />

SUBJECT INDEX<br />

ramoplanin<br />

in vitro activity, 896<br />

RP59500<br />

in vitro activity, 598<br />

vancomycin resistant<br />

ramoplanin, 1364<br />

RP59500, 598<br />

Granulocyte colony-stimulating factor<br />

combinations<br />

clarithromycin, 692<br />

M. avium complex, 692<br />

M. avium complex, 692<br />

Granulocyte-macrophage colony-stimulating<br />

factor<br />

pharmacokinetics<br />

zidovudine, administration with, 512<br />

Griseofulvin<br />

comparative evaluation<br />

itraconazole, 2064<br />

tinea unguium, 2064<br />

4-Guanidino-2,4-dideoxy-2,3-dehydro-Nacetylneuraminic<br />

acid<br />

influenza viruses<br />

growth inhibition, 1473<br />

sialidase, inhibition of, 1473<br />

gyrA<br />

E. coli<br />

fluoroquinolone resistance, 696<br />

mutations in, 696<br />

E. coli, fluoroquinolone resistant, nalidixic<br />

acid susceptible<br />

point mutation, novel, 1247<br />

Haemophilus ducreyi<br />

chancroid, currently recommended <strong>and</strong><br />

newer agents for<br />

in vitro susceptibilities, 1552<br />

isolates from the United States <strong>and</strong><br />

Thail<strong>and</strong>, 1552<br />

parenteral <strong>and</strong> oral antimicrobial agents<br />

in vitro activities, 1986<br />

Haemophilus influenzae<br />

ampicillin<br />

distribution in patients with lower respiratory<br />

tract infections, effect on,<br />

804<br />

,-lactamase producing <strong>and</strong> nonproducing,<br />

ampicillin resistant<br />

amoxicillin-clavulanic acid, susceptibility<br />

to, 14<br />

cefaclor, susceptibility to, 14<br />

cefixime, susceptibility to, 14<br />

cefotaxime, susceptibility to, 14<br />

ceftibuten, susceptibility to, 14<br />

cefuroxime, susceptibility to, 14<br />

ciprofloxacin<br />

adherence changes induced by subinhibitory<br />

concentrations, 885<br />

ecblogy in sputum <strong>and</strong> saliva, 804<br />

erythromycin<br />

distribution in patients with lower respiratory<br />

tract infections, effect on,<br />

804<br />

macrolides<br />

subinhibitory concentrations, influence<br />

on human neutrophil chemiluminescence,<br />

1015<br />

sparfloxacin<br />

adherence changes induced by subinhibitory<br />

concentrations, 885<br />

trimethoprim<br />

adherence changes induced by subin-

xxii SUBJECT INDEX<br />

hibitory concentrations, 885<br />

Haemophilus parainfluenzae<br />

ampicillin<br />

distribution in patients with lower respiratory<br />

tract infections, effect on,<br />

804<br />

ecology in sputum <strong>and</strong> saliva, 804<br />

erythromycin<br />

distribution in patients with lower respiratory<br />

tract infections, effect on,<br />

804<br />

Hafnia alvei<br />

ceftazidime resistant<br />

,B-lactamase producing, 1375<br />

Halofantrine<br />

P. falciparum, 1955<br />

efficacy in semi-immune patients in<br />

Cameroon, 1955<br />

P. falciparum resistance, 2337<br />

Helicobacterpylori<br />

AG-2000<br />

urease activity, inhibition of, 769<br />

lansoprazole<br />

urease activity, inhibition of, 769<br />

metronidazole <strong>and</strong> its hydroxymetabolite<br />

synergy, 1184<br />

metronidazole's hydroxymetabolite-tetracycline-HCl<br />

synergy, 1184<br />

metronidazole's hydroxymetaboliteamoxicillin<br />

synergy, 1184<br />

metronidazole-tetracycline-HCI<br />

synergy, 1184<br />

metronidazole-amoxicillin<br />

synergy, 1184<br />

omeprazole<br />

urease activity, inhibition of, 769<br />

Hepatitis B virus<br />

antiviral agents<br />

assessment in vitro, high capacity, 441<br />

duck<br />

suramin, prevention of infection in<br />

vivo, 1539<br />

Hepatitis C virus<br />

alpha interferon treatment<br />

HCV RNA levels in patients with<br />

chronic infections, 595<br />

RNA levels<br />

patients with chronic infections receiving<br />

interferon treatment, 595<br />

Herpes simplex virus<br />

acyclovir <strong>and</strong> foscarnet resistant<br />

pencyclovir, 2241<br />

acyclovir resistant<br />

348-U87-acyclovir, 975<br />

ribonucleotide reductase inhibitor-acyclovir,<br />

975<br />

acyclovir susceptibility<br />

strains from organ transplant recipients<br />

after acyclovir or ganciclovir<br />

prophylaxis, 357<br />

acyclovir-5-fluorodeoxyuridine-2acetylpyridine<br />

thiosemicarbazone<br />

three-dimensional analysis of, 540<br />

pencyclovir<br />

in vitro activities, 2241<br />

Herpes simplex virus type 1<br />

acyclovir<br />

comparative evaluation, 642<br />

penciclovir<br />

comparative evaluation, 642<br />

Herpesviruses<br />

acyclic nucleoside phosphonates<br />

(S) <strong>and</strong> (R) enantiomers, 332<br />

(R)-9-(2-phosphonomethoxypropyl)-2,6diaminopurine,<br />

332<br />

High-performance liquid chromatography<br />

carbenicillin epimers<br />

analysis in biological fluids, 2327<br />

Human immunodeficiency virus<br />

antiretroviral agents<br />

resistance to, minireview, 1207<br />

(-)-2',3'-dideoxy-5-fluoro-3'-thiacytidine<br />

characterization of, 875<br />

(-)-2',3'-dideoxy-3'-thiacytidine<br />

characterization of, 875<br />

foscarnet<br />

cerebrospinal fluid of patients with<br />

AIDS, penetration of, 1777<br />

fullerene, derivatized C60<br />

activity of, 1707<br />

protease inhibitors<br />

allophenylnorstatine containing, in<br />

vitro activities, 810<br />

XM323<br />

in vitro activity, 2606<br />

Human immunodeficiency virus type 1<br />

3TC resistance<br />

conferred by same mutation that confers<br />

resistance to ddI <strong>and</strong> ddC,<br />

1390<br />

A77003<br />

preclinical evaluation, 115<br />

protease inhibitor, 115<br />

anti-CD4-pokeweed antiviral protein immunoconjugate<br />

in vitro activity, 835<br />

3'-azido-3'-deoxythymidine<br />

replication in human fetal brain macrophages,<br />

effect on, 1305<br />

C. albicans<br />

fluconazole resistance, 2449<br />

carbovir<br />

cellular metabolism, effects on, 1004<br />

metabolism, 1004<br />

carbovir-3'-azido-2',3'-deoxythymidine<br />

synergy, 144<br />

CGP 53437<br />

protease, inhibition of, 2087<br />

chimeric enzymes, inhibition of<br />

nonnucleoside inhibitors, 1037<br />

2'-deoxy-3'-thiacytidine resistance<br />

due to amino acid substitution at catalytic<br />

site of reverse transcriptase,<br />

2231<br />

diarylsulfones<br />

mechanism of action, 754<br />

reverse transcriptase inhibitor, 754<br />

2',3'-dideoxy-3'-thiacytidine resistance<br />

generation of variants, 130<br />

2',3'-dideoxycytidine resistance<br />

generation of variants, 130<br />

drug susceptibility<br />

peripheral blood mononuclear cell culture<br />

assay, 1095<br />

fluconazole<br />

C. albicans resistance, 2449<br />

FTC<br />

5'-triphosphates of (-) <strong>and</strong> (+) enantiomers,<br />

1720<br />

glucose oxidase <strong>and</strong> peroxidase<br />

virucidal effects, 26<br />

peripheral blood mononuclear cell culture<br />

assay<br />

ANTIMICROB. AGENTS CHEMOTHER.<br />

drug susceptibility, determination of,<br />

1095<br />

protease inhibitors<br />

A77003, 115<br />

reverse transcriptase inhibition<br />

nonnucleoside inhibitors, 1037<br />

reverse transcriptase inhibitor<br />

isolates resistant to related inhibitors,<br />

activity against, 947<br />

reverse transcriptase inhibitor resistance<br />

mutant enzyme <strong>and</strong> viral variant assessment,<br />

1576<br />

reverse transcriptase inhibitors<br />

FTC, 5'-triphosphates of (-) <strong>and</strong> (+)<br />

enantiomers, 1720<br />

infectious amplification from lymphocytes<br />

<strong>and</strong> modulation, 2206<br />

S-2720, activity of, 1659<br />

S-2720<br />

inhibition of reverse transcriptase <strong>and</strong><br />

viral replication, 1659<br />

thiazolo-iso-indolinones<br />

resistance, 2612<br />

U-90152<br />

replication, inhibition of, 1127<br />

zidovudine <strong>and</strong> didanosine resistant<br />

pol mutations, 1480<br />

zidovudine sensitivity<br />

discontinuation of zidovudine treatment,<br />

effects on, 1525<br />

Human immunodeficiency virus type 2<br />

chimeric enzymes, inhibition of<br />

nonnucleoside inhibitors, 1037<br />

Human renal proximal tubule cells<br />

nephrotoxicity<br />

in vitro studies, 2496<br />

Hydatid disease<br />

albendazole<br />

treatment of, 1679<br />

mebendazole<br />

treatment of, 1679<br />

(-)-9-[4-Hydroxy-2-(hydroxymethyl)<br />

butyl]guanine<br />

simian varicella virus<br />

African green monkeys, 1370<br />

(S)-1-(3-Hydroxy-2-phosphonyl-methoxypropyl)cytosine<br />

cytomegalovirus<br />

interstitial pneumonitis after bone<br />

marrow transplantation, 218<br />

Hydroxyitraconazole<br />

bioassay <strong>and</strong> chromatography, effect on,<br />

2224<br />

itraconazole, metabolism of, 2224<br />

ICI 195,739<br />

combinations<br />

Chagas' disease, murine, 1353<br />

T. cruzi, 1353<br />

terbinafine, 1353<br />

Imipenem<br />

B. wadsworthia<br />

morphological response, 2638<br />

penicillin-binding protein patterns,<br />

2638<br />

combinations<br />

amikacin, 1931<br />

cilastatin, 51<br />

P. aeruginosa, 1931<br />

yeast colonization of the human gastrointestinal<br />

tract, effect on, 51<br />

P. aeruginosa

VOL. 37, 1993<br />

phenotypic resistance induced by salicylate,<br />

2743<br />

pharmacodynamics<br />

P. aeruginosa, 1931<br />

postantibiotic effect<br />

repeated exposures, 1723<br />

R. equi resistance<br />

penicillin-binding proteins, potential<br />

role in, 1406<br />

Imipenem resistance<br />

P. aeruginosa<br />

mechanism of efficient elimination of<br />

protein D2, 2385<br />

Immune globulin<br />

respiratory syncytial virus<br />

prophylaxis for high-risk infants, evaluation<br />

of, 1655<br />

Influenza virus<br />

rimantadine<br />

susceptibilities of subtypes A/HlN1<br />

<strong>and</strong> A/H3N2, 2239<br />

Influenza viruses<br />

4-guanidino-2,4-dideoxy-2,3-dehydro-Nacetylneuraminic<br />

acid<br />

growth inhibition, 1473<br />

sialidase, inhibition of, 1473<br />

Intercellular adhesion molecule 1<br />

E. coli, expression in<br />

functional studies, 1278<br />

soluble<br />

function studies of, 1278<br />

Interleukin-6<br />

amphotericin B, 1958<br />

C. albicans, 1958<br />

receptors<br />

relation to therapy of typhoid fever,<br />

2418<br />

Interleukin-8<br />

nonspecific resistance to infection<br />

neutropenic <strong>and</strong> normal mice, 276<br />

Intestinal microflora<br />

anaerobic<br />

resistance patterns, 1665<br />

Isepamicin<br />

pharmacokinetics<br />

nephrotoxicity, influence on in rats,<br />

2042<br />

ISIS 2922<br />

cytomegalovirus<br />

in vitro activity, 1945<br />

Isoniazid<br />

E. coli<br />

susceptibilities of oxyR regulon mutants,<br />

2251<br />

S. typhimurium<br />

susceptibilities of oxyR regulon mutants,<br />

2251<br />

Isoprinosine<br />

P. carinii<br />

dihydropteroate synthetase inhibition,<br />

1227<br />

Itraconazole<br />

A. fumigatus<br />

efficacy in a rat model, 2762<br />

alveolar macrophages, uptake by, 903<br />

aspergillosis, 2307<br />

bioassay <strong>and</strong> chromatography, discrepancies<br />

in<br />

hydroxyitraconazole, metabolism to,<br />

2224<br />

C. albicans<br />

placebo-controlled trial, 89<br />

C. neoformans<br />

effects on cytochrome P-450-dependent<br />

sterol 14a-demethylation <strong>and</strong><br />

reduction of 3-ketosteroids, 2101<br />

c<strong>and</strong>idiasis, acute vaginal<br />

placebo-controlled trial, 89<br />

comparative evaluation<br />

amphotericin B, 2307<br />

griseofulvin, 2064<br />

interpatient variations in concentration,<br />

2224<br />

P. marneffei<br />

response of human immunodeficiency<br />

virus-infected patients, 2407<br />

pharmacokinetics<br />

food interaction, 778<br />

steady state, 778<br />

tinea unguium, 2064<br />

Ivermectins<br />

S. erythraea<br />

glycosylation, microbial conversion<br />

by, 1737<br />

Keratitis<br />

ciprofloxacin<br />

age <strong>and</strong> therapeutic outcome, 1856<br />

flurbiprofen<br />

age <strong>and</strong> therapeutic outcome, 1856<br />

P. aeruginosa<br />

age <strong>and</strong> therapeutic outcome, 1856<br />

prednisolone<br />

age <strong>and</strong> therapeutic outcome, 1856<br />

Ketoconazole<br />

combinations<br />

Chagas' disease, murine, 1353<br />

T. cruzi, 1353<br />

terbinafine, 1353<br />

mevinolin<br />

T. cruzi, potentiation of antiproliferative<br />

effects, 580<br />

P. marneffei<br />

response of human immunodeficiency<br />

virus-infected patients, 2407<br />

Klebsiella pneumoniae<br />

P-lactamase<br />

P-lactams, broad spectrum, resistance<br />

to, 984<br />

j-lactams, extended spectrum, resistance<br />

to, 2020<br />

ceftazidime resistance, 1989<br />

plasmid encoded, TEM derived, 2020<br />

plasmid mediated, AmpC type, transferable,<br />

984<br />

cefoperazone-sulbactam resistance<br />

coexistence of two different resistance<br />

mechanisms, 1061<br />

cefozopran<br />

respiratory tract infection, 100<br />

ceftazidime resistance<br />

P-lactamase, 1989<br />

ciprofloxacin<br />

adherence changes induced by subinhibitory<br />

concentrations, 885<br />

interleukin-1-induced nonspecific resistance<br />

role of acute-phase proteins in studies<br />

with mice, 2527<br />

sparfloxacin<br />

adherence changes induced by subinhibitory<br />

concentrations, 885<br />

trimethoprim<br />

adherence changes induced by subinhibitory<br />

concentrations, 885<br />

SUBJECT INDEX xxiii<br />

KNI-227<br />

human immunodeficiency virus<br />

protease inhibitor, allophenylnorstatine<br />

containing, 810<br />

KNI-272<br />

human immunodeficiency virus<br />

protease inhibitor, allophenylnorstatine<br />

containing, 810<br />

KRM-1648<br />

M. avium, 722<br />

L-696,229<br />

analogs<br />

human immunodeficiency virus isolates<br />

resistant to related inhibitors,<br />

947<br />

human immunodeficiency virus<br />

isolates resistant to related inhibitors,<br />

activity against, 947<br />

Lactoferrin<br />

porin binding<br />

E. coli antibacterial activity, relationship<br />

with, 240<br />

S. typhimurium antibacterial activity,<br />

relationship with, 240<br />

Lansoprazole<br />

H. pyloni<br />

urease activity, inhibition of, 769<br />

Legionella micdadei<br />

azithromycin<br />

inhibition of intracellular strains, 2261<br />

intracellular<br />

azithromycin inhibition, 2261<br />

Legionella spp.<br />

RP 74501-RP 74502<br />

in vitro activity, 908<br />

Leishmania amazonensis<br />

quinoline alkaloids<br />

2 substituted, 859<br />

Leishmania donovani<br />

amphotericin B<br />

T-cell-deficient mice, 1504<br />

leishmaniasis<br />

trans-aconitic acid in combined chemotherapy,<br />

2459<br />

licochalcone A<br />

inhibition of growth, 2550<br />

pentamidine<br />

T-cell-deficient mice, 1504<br />

trans-aconitic acid<br />

role in combined chemotherapy for<br />

experimentally infected hamsters,<br />

2459<br />

Leishmania major<br />

licochalcone A<br />

inhibition of growth, 2550<br />

Leishmania mexicana<br />

dinitroanilines<br />

structure-function analysis, 1909<br />

trifluralin, 1909<br />

Leishmania panamensis<br />

sodium stibogluconate<br />

in vitro activities of fractions, 1842<br />

Leishmania spp.<br />

9-anilinoacridines<br />

in vitro activity, 991<br />

structure-activity relationships, 991<br />

quinoline alkaloids<br />

2 substituted, 859<br />

Leishmania venezuelensis<br />

quinoline alkaloids<br />

2 substituted, 859

xy-jv SUBJECT INDEX<br />

Leishmaniasis<br />

cutaneous<br />

quinolone alkaloids, 2 substituted, 859<br />

quinoline alkaloids<br />

2 substituted, 859<br />

visceral<br />

amphotericin B, T-cell-deficient mice,<br />

1504<br />

pentamidine, T-cell-deficient mice,<br />

1504<br />

Leptospira interrogans<br />

Q-35<br />

five serogroups, 901<br />

Letters to the editor<br />

aminoglycoside resistance genes<br />

nomenclature, 927<br />

Capnocytophaga spp.<br />

antimicrobial susceptibilities, 1206<br />

cefotaxime<br />

S. pneumoniae breakpoint, 616<br />

dental amalgam<br />

multiple antibiotic resistance, 1730<br />

Nocardia spp.<br />

susceptibility testing, 2514<br />

S. pneumoniae<br />

cefotaxime breakpoint, 616<br />

susceptibility data<br />

multidimensional analysis, 929<br />

Leukemia<br />

enoxacin<br />

infection prevention in adults with<br />

nonlymphocytic leukemia, 474<br />

Leupeptin<br />

P. falciparum<br />

clonal viability measurements to assess<br />

in vitro activity, 1102<br />

Levofloxacin<br />

adverse effects<br />

convulsions in mice, 1764<br />

aluminum hydroxide<br />

inhibition of absorption by, 2173<br />

comparative evaluation<br />

accumulation by human polymorphonuclear<br />

leukocytes, 1882<br />

DU-6859a, 2747<br />

synergy<br />

oxacillin, 339<br />

S. aureus, quinolone resistant, 339<br />

Licochalcone A<br />

L. donovani<br />

inhibition of growth, 2550<br />

L. major<br />

inhibition of growth, 2550<br />

Lincomycin<br />

peptidyl-RNA<br />

accumulation, 2027<br />

dissociation from ribosomes, 2027<br />

Lipophilic agents<br />

penetration into bacterial cells<br />

minireview, 1393<br />

Liposomes<br />

ciprofloxacin, liposome incorporated<br />

treatment of murine salmonellosis,<br />

2293<br />

LJC 10,627<br />

toxicity<br />

central nervous systems of rats, low<br />

levels of, 199<br />

Lomefloxacin<br />

comparative evaluation<br />

DU-6859a, 2747<br />

pharmacodynamics<br />

concentration in plasma-time profile,<br />

relation to survival, 483<br />

neutropenic rat model of Pseudomonas<br />

sepsis, 483<br />

urinary tract infections<br />

3-day treatment, 574<br />

acute uncomplicated, 574<br />

comparative evaluation, 574<br />

Luciferase<br />

M. tuberculosis<br />

antimicrobial activity against, method<br />

for screening for, 1348<br />

Lyme disease<br />

clarithromycin<br />

hamsters, 1329<br />

Macrolides<br />

combinations<br />

inhibitors of glycosylation <strong>and</strong> fatty<br />

acid <strong>and</strong> peptide biosynthesis, 652<br />

M. avium, 652<br />

cytochrome P-450 complex formation<br />

rat <strong>and</strong> human livers, 265<br />

dirithromycin<br />

interactions with polymorphonuclear<br />

leukocytes, 2557<br />

H. infuenzae<br />

subinhibitory concentrations, influence<br />

on human neutrophil chemiluminescence,<br />

1015<br />

P. acidilactici resistance<br />

genetic basis for, 789<br />

P. aeruginosa<br />

serum sensitivity, effect of sub-MICs<br />

on, 675<br />

Magainins<br />

eicosanoid release<br />

rat peritoneal macrophages, effect on,<br />

393<br />

Magnesium-aluminum hydroxide<br />

rufloxacin<br />

effects on absorption, 2212<br />

Malaria<br />

amopyroquin<br />

intramuscular, 970<br />

halofantrine<br />

efficacy in semi-immune patients in<br />

Cameroon, 1955<br />

mefloquine<br />

P. falcipanum, 1977<br />

P. falciparum, 1955<br />

amopyroquin, 970<br />

mefloquine, 1977<br />

Mastitis<br />

bovine<br />

pirlimycin, activity <strong>and</strong> disk diffusion<br />

breakpoints, 1122<br />

pirlimycin<br />

activity against bovine pathogens,<br />

1122<br />

disk diffusion breakpoints, 1122<br />

MDL 62,879<br />

anaerobic bacteria, 746<br />

gram-positive organisms<br />

aerobic, 746<br />

in vitro activity, 741<br />

Mebendazole<br />

hydatid disease<br />

treatment of, 1679<br />

mec<br />

Staphylococcus spp., methicillin resistant<br />

distribution of regulator genes in, 1219<br />

ANTIMICROB. AGENTS CHEMOTHER.<br />

Mefloquine<br />

malaria<br />

comparison of two regimens, 1977<br />

P. falciparum<br />

comparative evaluation of two regimens,<br />

1977<br />

Meningitis<br />

pneumococcal, penicillin <strong>and</strong> cephalosporin<br />

resistant<br />

treatment regimens, evaluation of,<br />

1630<br />

recurrent cryptococcal<br />

susceptibility of C. neoformans isolates<br />

to amphotericin B <strong>and</strong> fluconazole,<br />

1383<br />

Mercury<br />

bacterial resistance<br />

letter to the editor, 1730<br />

mercury from dental fillings provokes<br />

increased occurrence, 825<br />

Meropenem<br />

P. cepacia<br />

comparative evaluation, 123<br />

pharmacokinetics<br />

patients with various degrees of renal<br />

function, 229<br />

Metabolic disposition<br />

(-)-cis-5-fluoro-1-[2-(hydroxymethyl)-<br />

1,3-oxathiolan-5-yl] cytosine<br />

studies with rats, 2285<br />

Methicillin<br />

S. aureus resistance<br />

abnormal peptidoglycan, 342<br />

j-lactam-I-lactamase inhibitor combinations,<br />

702<br />

1-lactams, 702<br />

penicillin-binding protein 2A, role in<br />

cell wall synthesis, 342<br />

S. aureus resistance <strong>and</strong> susceptibility<br />

sequential acquisition of norfloxacin<br />

<strong>and</strong> ofloxacin resistance in isolates,<br />

2278<br />

Staphylococcus resistance<br />

mec regulator genes, distribution of,<br />

1219<br />

Metronidazole<br />

synergy<br />

amoxicillin, 1184<br />

H. pylon, 1184<br />

hydroxymetabolite of metronidazole,<br />

1184<br />

tetracycline-HCl, 1184<br />

Mevinolin<br />

T. cruzi<br />

ketoconazole <strong>and</strong> terbinafine, potentiation<br />

of antiproliferative effects,<br />

580<br />

Miconazole<br />

P. mameffei<br />

response of human immunodeficiency<br />

virus-infected patients, 2407<br />

Microdilution checkerboard method<br />

synergy measurement<br />

reproducibility, 613<br />

Minireviews<br />

3-lactamases<br />

induction of, molecular basis for, 153<br />

P-lactams<br />

penicillin-binding protein resistance,<br />

2045<br />

C. neoformans<br />

susceptibility testing, status of the<br />

st<strong>and</strong>ardization process, 2517

VOL. 37, 1993<br />

C<strong>and</strong>ida spp.<br />

susceptibility testing, status of the<br />

st<strong>and</strong>ardization process, 2517<br />

Enterococcus spp.<br />

glycopeptide resistance, genetics <strong>and</strong><br />

mechanisms of, 1563<br />

glycopeptides<br />

Enterococcus resistance, genetics <strong>and</strong><br />

mechanisms of, 1563<br />

human immunodeficiency virus<br />

antiretroviral agents, resistance to,<br />

1207<br />

lipophilic agents with multiple protonation<br />

sites<br />

penetration into bacterial cells, 1393<br />

new antibiotics<br />

discovery <strong>and</strong> development, problem<br />

of resistance, 377<br />

nosocomial pneumonia<br />

critically ill patients, prevention of,<br />

931<br />

organ transplant recipients<br />

antimicrobial strategies, 619<br />

penicillin-binding proteins<br />

1-lactam resistance, 2045<br />

Q fever<br />

treatment of, 1733<br />

rifampin<br />

nonstaphylococcal, nonmycobacterial<br />

disease, 1<br />

Minocycline<br />

combinations<br />

clarithromycin, 1690<br />

M. avium, prophylaxis in mice, 1690<br />

rifabutin, 1690<br />

M. avium<br />

erratum, 2515<br />

Monobactams<br />

F. oryzihabitans<br />

in vitro activities against clinical isolates<br />

from patients with cancer,<br />

2504<br />

Moraxella catarrhalis<br />

ciprofloxacin<br />

adherence changes induced by subinhibitory<br />

concentrations, 885<br />

sparfloxacin<br />

adherence changes induced by subinhibitory<br />

concentrations, 885<br />

trimethoprim<br />

adherence changes induced by subinhibitory<br />

concentrations, 885<br />

Mupirocin<br />

S. aureus resistance, high level<br />

isoleucyl-tRNA synthetases, evidence<br />

for two distinct, 32<br />

Mupirocin resistance<br />

S. aureus<br />

detection <strong>and</strong> characterization, 2003<br />

Mureidomycins<br />

bacterial translocase reaction in peptidoglycan<br />

synthesis, inhibition of,<br />

980<br />

Murine leukemia virus<br />

protease inhibitors<br />

antiretroviral activity, 71<br />

Mutagenicity<br />

quinolones<br />

Ames Salmonella TA102 assay, 213<br />

Mycobactenum avium<br />

activities of quinolones<br />

erratum, 2766<br />

aminoglycosides<br />

combination with inhibitors of glycosylation<br />

<strong>and</strong> fatty acid <strong>and</strong> peptide<br />

biosynthesis, 652<br />

azithromycin resistance<br />

clarithromycin, 2364<br />

cross-resistance, 2364<br />

clarithromycin<br />

erratum, 2515<br />

human macrophages, 111<br />

macrophages, inhibition of intracellular<br />

growth, 1380<br />

prophylaxis in C57BL/6 mice, 1690<br />

clarithromycin resistance<br />

azithromycin, 2364<br />

cross-resistance, 2364<br />

clarithromycin-minocycline<br />

prophylaxis in C57BL/6 mice, 1690<br />

fluoroquinolones<br />

combination with inhibitors of glycosylation<br />

<strong>and</strong> fatty acid <strong>and</strong> peptide<br />

biosynthesis, 652<br />

KRM-1648, 722<br />

macrolides<br />

combination with inhibitors of glycosylation<br />

<strong>and</strong> fatty acid <strong>and</strong> peptide<br />

biosynthesis, 652<br />

minocycline<br />

erratum, 2515<br />

quinolones<br />

in vitro activities, 1799<br />

structure-activity relationship studies,<br />

1807<br />

rifabutin<br />

erratum, 2515<br />

prophylaxis in C57BL/6 mice, 1690<br />

rifabutin-minocycline<br />

prophylaxis in C57BL/6 mice, 1690<br />

Mycobacterium avium complex<br />

azithromycin<br />

rats treated with cyclosporine, 398<br />

benzoxazinorifamycin<br />

radiometric method, determination by,<br />

67<br />

clarithromycin, 692<br />

gentamicin<br />

AIDS patients with bacteremia, 1869<br />

TLC G-65, 1869<br />

granulocyte colony-stimulating factor,<br />

692<br />

granulocyte colony-stimulating factorclarithromycin,<br />

692<br />

rifabutin<br />

rats treated with cyclosporine, 398<br />

rifapentine<br />

rats treated with cyclosporine, 398<br />

RU-40555, 692<br />

RU-40555-clarithromycin, 692<br />

Mycobacterium avium-M. intracellulare<br />

complex<br />

clofazimine<br />

in vitro activities, 2584<br />

resorcinomycin<br />

in vitro activities, 2584<br />

Mycobacterium fortuitum<br />

amikacin<br />

postantibiotic effect, 1001<br />

ofloxacin<br />

postantibiotic effect, 1001<br />

Mycobactenum haemophilum<br />

amikacin<br />

in vitro activities, 2323<br />

azithromycin<br />

in vitro activities, 2323<br />

SUBJECT INDEX xxv<br />

ciprofloxacin<br />

in vitro activities, 2323<br />

clarithromycin<br />

in vitro activities, 2323<br />

clofazamine<br />

in vitro activities, 2323<br />

erythromycin<br />

in vitro activities, 2323<br />

ofloxacin<br />

in vitro activities, 2323<br />

rifabutin<br />

in vitro activities, 2323<br />

rifampin<br />

in vitro activities, 2323<br />

sparfloxacin<br />

in vitro activities, 2323<br />

Mycobacterium kansasii<br />

susceptibility testing<br />

azithromycin, 1997<br />

clarithromycin, 1997<br />

fusidic acid, 1997<br />

ofloxacin, 1997<br />

sparfloxacin, 1997<br />

Mycobacterium leprae<br />

rifampin resistance<br />

molecular basis, 414<br />

Mycobacterium malmoense<br />

ethambutol<br />

ciprofloxacin, amikacin, rifampin, synergy<br />

with, 1285<br />

susceptibility to antibacterial drugs <strong>and</strong><br />

drug combinations, 1285<br />

Mycobacterium paratuberculosis<br />

rifabutin<br />

systemic infection in mice, 1645<br />

Mycobacterium spp.<br />

AM-1155<br />

in vitro activity, comparative evaluation,<br />

1259<br />

ethambutol<br />

glucose metabolism, inhibition of,<br />

1536<br />

roxithromycin<br />

in vitro activity, 1560<br />

pH, effect on radiometric MICs, 1560<br />

Mycobacterium tuberculosis<br />

antimicrobial activity<br />

method for screening for, 1348<br />

CGI 17341<br />

in vitro <strong>and</strong> in vivo activities, 183<br />

clofazimine<br />

in vitro activities, 2584<br />

luciferase expressing<br />

antimicrobial activity against, method<br />

for screening for, 1348<br />

multidrug resistant<br />

studies with mice, 2344<br />

polymerase chain reaction<br />

detection, 2054<br />

resorcinomycin<br />

in vitro activities, 2584<br />

rifampin resistant<br />

detection, 2054<br />

single-str<strong>and</strong> conformation polymorphism<br />

analysis<br />

detection, 2054<br />

sparfloxacin, 407<br />

Mycoplasma bovis<br />

antimicrobial susceptibilities, 317<br />

Mycoplasma dispar<br />

antimicrobial susceptibilities, 317

xxvi SUBJECT INDEX<br />

Mycoplasma fermentans<br />

susceptibility testing<br />

in vitro strains from AIDS patients,<br />

2500<br />

in vitro strains from non-AIDS patients<br />

with acute respiratory disease,<br />

2500<br />

tissue culture, 2500<br />

Mycoplasma hominis<br />

OPC 17116<br />

susceptibility in vitro, 1726<br />

Mycoplasma pneumoniae<br />

ciprofloxacin<br />

hamsters, 287<br />

ofloxacin<br />

hamsters, 287<br />

OPC 17116<br />

susceptibility in vitro, 1726<br />

Q-35<br />

in vitro <strong>and</strong> in vivo activities, 1826<br />

temafloxacin<br />

hamsters, 287<br />

Myeloperoxidase<br />

C. albicans<br />

human recombinant, c<strong>and</strong>idicidal activity,<br />

142<br />

human recombinant<br />

C. albicans, c<strong>and</strong>idicidal activity, 142<br />

Neissena gonorrhoeae<br />

ciprofloxacin<br />

antibacterial activities, 2244<br />

ofloxacin<br />

antibacterial activities, 2244<br />

in vitro susceptibilities, 2007<br />

OPC-17116<br />

antibacterial activities, 2244<br />

Neisseria meningitidis<br />

ofloxacin<br />

single doses to eradicate tonsillopharyngeal<br />

carriage in Norway, 2024<br />

penicillin susceptible, moderately<br />

isolation in Argentina, 1728<br />

Nephrotoxicity<br />

gentamicin<br />

neonates, drug-treated pregnant<br />

Wistar rats, 1510<br />

Netilmicin<br />

combinations<br />

ceftriaxone, 1971<br />

endocarditis, 1971<br />

diltiazem<br />

nephrotoxicity in rabbits, effects on,<br />

1790<br />

synergy<br />

ceftriaxone, 207<br />

streptococcal endocarditis, 207<br />

Nevirapine<br />

pharmacokinetics<br />

single-rising-dose study in humans,<br />

178<br />

Nitrofurazone<br />

urinary tract infections<br />

catheter associated, 2033<br />

Nitroimidazoles<br />

CGI 17341<br />

M. tuberculosis, 183<br />

M. tuberculosis<br />

CGI 17341, 183<br />

NM394<br />

antibacterial activity, 793<br />

Nocardia brasiliensis<br />

rifampin<br />

inactivation of, 1313<br />

Nocardia farcinica<br />

13-lactamases<br />

characterization, 1850<br />

Nocardia spp.<br />

antimicrobial susceptibilities<br />

in vitro, 882<br />

susceptibility testing<br />

letter to the editor, 2514<br />

Norfloxacin<br />

urinary tract infections<br />

3-day treatment, 574<br />

acute uncomplicated, 574<br />

comparative evaluation, 574<br />

Northern (RNA) blot analysis<br />

C. albicans<br />

picolinic acid, protective effect on<br />

mice, 2422<br />

Novobiocin<br />

combinations<br />

ciprofloxacin, 1904<br />

E. faecium, 1904<br />

rifampin, 1334<br />

S. aureus, methicillin resistant, eradication<br />

of, 1334<br />

E. faecium<br />

in vitro activity against multiresistant<br />

strains, 2736<br />

NP-1<br />

C. neofortnans<br />

fungicidal properties, 2628<br />

in vitro activity, 2628<br />

Ofloxacin<br />

B. burgdorferi<br />

in vitro susceptibility, 1444<br />

combinations<br />

Brucella spp., 1831<br />

rifampin, 1214, 1831<br />

Staphylococcus-infected orthopedic<br />

implants, 1214<br />

comparative evaluation<br />

accumulation by human polymorphonuclear<br />

leukocytes, 1882<br />

ciprofloxacin, 2193<br />

DU-6859a, 2747<br />

E. coli<br />

comparative evaluation, 846<br />

epididymitis, 846<br />

epididymitis<br />

comparative evaluation, 846<br />

E. coli, 846<br />

in vitro activities<br />

gram-negative organisms, 2017<br />

gram-positive organisms, 2017<br />

M. fortuitum<br />

postantibiotic effect, 1001<br />

M. haemophilum<br />

in vitro activities, 2323<br />

M. kansasii<br />

susceptibility testing, 1997<br />

M. pneumoniae<br />

hamsters, 287<br />

N. gonorrhoeae<br />

antibacterial activities, 2244<br />

in vitro susceptibilities, 2007<br />

N. meningitidis<br />

single doses to eradicate tonsillopharyngeal<br />

carriage in Norway, 2024<br />

pharmacokinetics<br />

ANTIMICROB. AGENTS CHEMOTHER.<br />

bioequivalence after multiple doses to<br />

healthy volunteers, 1468<br />

multiple oral doses to healthy volunteers,<br />

2193<br />

postantibiotic effect<br />

M. fortuitum, 1001<br />

serum bactericidal titers<br />

multiple oral doses to healthy volunteers,<br />

2193<br />

Omeprazole<br />

H. pylon<br />

urease activity, inhibition of, 769<br />

OPC 17116<br />

M. hominis<br />

susceptibility in vitro, 1726<br />

M. pneumoniae<br />

susceptibility in vitro, 1726<br />

U. urealyticum<br />

susceptibility in vitro, 1726<br />

OPC-17116<br />

C. pneumoniae<br />

in vitro <strong>and</strong> in vivo activities, 801<br />

C. psittaci<br />

in vitro <strong>and</strong> in vivo activities; 801<br />

C. trachomatis<br />

in vitro <strong>and</strong> in vivo activities, 801<br />

comparative evaluation<br />

accumulation by human polymorphonuclear<br />

leukocytes, 1882<br />

N. gonorrhoeae<br />

antibacterial activities, 2244<br />

Ophthalmitis<br />

sparfloxacin<br />

rabbit model, efficacy in, 633<br />

Oral flora<br />

mercury resistant<br />

mercury from dental fillings provokes<br />

increased occurrence, 825<br />

Oral microflora<br />

anaerobic<br />

resistance patterns, 1665<br />

Organ transplant patients<br />

antimicrobial strategies<br />

minireview, 619<br />

Ornidazole<br />

concentrations in plasma during liver<br />

transplantation, 1873<br />

tissue penetration during liver transplantation,<br />

1873<br />

Orthopedic implants<br />

Staphylococcus infections<br />

rifampin-ofloxacin, 1214<br />

Otitis media<br />

S. pneumoniae, penicillin resistant<br />

amoxicillin, increased dosages of, 1599<br />

Oxacillin<br />

endocarditis<br />

S. aureus, 1-lactamase hyperproducing,<br />

507<br />

S. aureus<br />

P-lactamase hyperproducing, 507<br />

synergy<br />

levofloxacin, 339<br />

S. aureus, quinolone resistant, 339<br />

Oxidase inhibitors<br />

P. berghei<br />

drug susceptibility, enhancement of,<br />

1318<br />

P. falciparum<br />

drug susceptibility, enhancement of,<br />

1318

VOL. 37, 1993<br />

Panipenem<br />

P. aeruginosa, 322<br />

diffusion through outer membrane,<br />

role of OprD protein, 322<br />

phenotypic resistance induced by salicylate,<br />

2743<br />

Papillomavirus<br />

E2 mRNA<br />

phosphorothioate oligonucleotides,<br />

potential treatment for genital<br />

warts, 171<br />

phosphorothioate oligonucleotides<br />

E2 mRNA, potential treatment for<br />

genital warts, 171<br />

Pasteurella multocida<br />

Tet H<br />

active efflux of tetracycline, 2699<br />

PBP 2a<br />

S. aureus<br />

blaI <strong>and</strong> blaRI, regulation by, 1144<br />

PD 127391<br />

P. cepacia<br />

comparative evaluation, 123<br />

PD 131628<br />

P. cepacia<br />

comparative evaluation, 123<br />

PD 138312<br />

gram-positive organisms<br />

in vitro activities, 2563<br />

PD 140248<br />

gram-positive organisms<br />

in vitro activities, 2563<br />

Pediococcus acidilactici<br />

macrolide resistance<br />

genetic basis for, 789<br />

Pediococcus spp.<br />

antimicrobial susceptibilities, 789<br />

Pefloxacin<br />

bactericidal activities<br />

one 800-mg versus two 400-mg doses,<br />

737<br />

irradiated mice, adverse effects on <strong>and</strong><br />

glucan therapy for, 1877<br />

pharmacokinetics<br />

one 800-mg versus two 400-mg doses,<br />

737<br />

Penciclovir<br />

herpes simplex virus type 1<br />

comparative evaluation, 642<br />

Pencyclovir<br />

herpes simplex virus<br />

acyclovir <strong>and</strong> foscarnet resistant, 2241<br />

in vitro activities, 2241<br />

herpes simplex virus resistance<br />

pencyclovir, 2241<br />

Penems<br />

CP-70,429<br />

,-lactamase stability <strong>and</strong> in vitro activity,<br />

1547<br />

Penicillin<br />

E. faecium resistance<br />

time-kill studies, 2427<br />

haptenation<br />

serum proteins, facilitation of, 1463<br />

N. meningitidis, moderately susceptible<br />

isolation in Argentina, 1728<br />

S. mutans<br />

in vitro susceptibility, 1158<br />

synergy<br />

gentamicin, 2427<br />

Penicillin V<br />

tonsillopharyngitis, streptococcal<br />

comparative evaluation, 1620<br />

Penicillin-binding proteins<br />

B. wadsworthia<br />

inhibition by imipenem, 2638<br />

,-lactam resistance<br />

minireview, 2045<br />

expression of a novel membrane protein<br />

<strong>and</strong> increased expression of<br />

penicillin-binding protein 2 complex,<br />

2432<br />

minireviews<br />

P-lactam resistance, 2045<br />

R. equi<br />

imipenem resistance, potential role in,<br />

1406<br />

S. aureus<br />

blaI <strong>and</strong> blaRl, regulation by, 1144<br />

cell wall synthesis, role in, 342<br />

S. pneumoniae<br />

2B <strong>and</strong> 2X, genetic diversity of, 1938<br />

Penicillium marneffei<br />

human immunodeficiency virus<br />

response of patients to antifungal therapy,<br />

2407<br />

Pentamidine<br />

L. donovani<br />

T-cell-deficient mice, 1504<br />

leishmaniasis, visceral<br />

T-cell-deficient mice, 1504<br />

Peptide antibiotics<br />

AS-48<br />

neutralizing antibodies, immunocytological<br />

studies, 148<br />

MDL 62,879<br />

in vitro activity, 741<br />

Peptidoglycan synthesis inhibitors<br />

mureidomycins<br />

bacterial translocase reaction, inhibition<br />

of, 980<br />

Peptostreptococcus spp.<br />

Bay Y3118<br />

in vitro activity, 2509<br />

Peripheral blood mononuclear cell culture<br />

assay<br />

human immunodeficiency virus<br />

drug susceptibility, determination of,<br />

1095<br />

Peritonitis<br />

bacterial, spontaneous<br />

ceftriaxone versus cefonicid, 1587<br />

cefonicid<br />

comparative evaluation, 1587<br />

ceftriaxone<br />

comparative evaluation, 1587<br />

Pharmacokinetics<br />

3'-deoxy-2',3'-didehydrothymidine<br />

disposition <strong>and</strong> metabolism in hepatocytes<br />

<strong>and</strong> nonhuman primates,<br />

1816<br />

allopurinol riboside<br />

probenecid, effects of, 1193<br />

alpha interferon<br />

transplacental passage, two assay<br />

techniques, 1232<br />

amikacin<br />

attachment to collagen for local delivery<br />

in wounds, 1890<br />

patients with septic multiple-organ<br />

failure during intermittent hemofiltration,<br />

464<br />

amoxicillin<br />

local gastric <strong>and</strong> serum concentrations<br />

after different oral applications,<br />

1506<br />

SUBJECT INDEX xxvii<br />

azithromycin<br />

pediatric patients, multiple oral doses<br />

of suspension, 314<br />

carbenicillin epimers<br />

stereoselective renal tubular secretion,<br />

2327<br />

cefazolin<br />

protein binding in rats, 1781<br />

cefepime<br />

cystic fibrosis patients, 1414<br />

cefixime<br />

biliary excretion in patients with<br />

T-tube drainage, 1488<br />

cefonicid<br />

protein binding in adult <strong>and</strong> neonatal<br />

sera, 1343<br />

cefotaxime<br />

cerebrospinal fluid of patients with<br />

uninflamed meninges, passage<br />

into, 1518<br />

cefpodoxime proxetil<br />

studies with patients receiving continuous<br />

ambulatory peritoneal dialysis,<br />

2650<br />

cefprozil<br />

tonsillar <strong>and</strong> adenoidal tissues, penetration<br />

into, 1180<br />

ceftazidime<br />

patients with septic multiple-organ<br />

failure during intermittent hemofiltration,<br />

464<br />

serum bactericidal activities, 1835<br />

side effects, 1835<br />

ceftriaxone<br />

cerebrospinal fluid of patients with<br />

uninflamed meninges, passage<br />

into, 1518<br />

elimination, effect of plasmapheresis,<br />

1171<br />

liver transplantation, 1873<br />

pregnant women, 54<br />

protein binding during pregnancy, 54<br />

cefuroxime<br />

protein binding in adult <strong>and</strong> neonatal<br />

sera, 1343<br />

ciprofloxacin<br />

effects of cardiopulmonary bypass surgery<br />

on disposition, 2106<br />

healthy volunteers, multiple oral<br />

doses, 2193<br />

seriously ill patients, 1073<br />

(-)-cis-5-fluoro-1-[2-(hydroxymethyl)-<br />

1,3-oxathiolan-5-yl] cytosine<br />

studies with rats, 2285<br />

clindamycin<br />

bioavailability, 1137<br />

healthy volunteers <strong>and</strong> AIDS patients,<br />

1137<br />

diminazine<br />

Boran cattle, noninfected <strong>and</strong> infected<br />

with T. congolense, 1050<br />

enoxacin<br />

oral antacids, effect on disposition,<br />

775<br />

fleroxacin<br />

breast milk, penetration into, 293<br />

effects in healthy volunteers by<br />

positron emission tomography,<br />

8F labeled, 2144<br />

lactating women, 293<br />

rifampin, influence of, 2132<br />

fluconazole<br />

healthy human subjects, 1270

xxviii SUBJECT INDEX<br />

influence of radiotherapy on penetration<br />

into human saliva, 2674<br />

patients with AIDS, 2187<br />

positron emission tomography, 18F<br />

labeled, 1270<br />

uptake in human polymorphonuclear<br />

leukocytes, 187<br />

foscarnet<br />

blood-brain barrier, penetration of,<br />

1010<br />

fusidic acid<br />

intravenous, cholestatic patients, 501<br />

gentamicin<br />

increased renal uptake in endotoxemic<br />

rats receiving thromboxane A2<br />

therapy, 2727<br />

population pharmacokinetic models,<br />

comparison of, 93<br />

patients with AIDS <strong>and</strong> severe AIDSrelated<br />

complex, 512<br />

isepamicin<br />

nephrotoxicity, influence on in rats,<br />

2042<br />

itraconazole<br />

alveolar macrophages, uptake by, 903<br />

food interaction, 778<br />

steady state, 778<br />

lomefloxacin<br />

concentration in plasma-time profile,<br />

relation to survival, 483<br />

neutropenic rat model of Pseudomonas<br />

sepsis, 483<br />

meropenem<br />

patients with various degrees of renal<br />

function, 229<br />

nevirapine<br />

single-rising-dose study in humans,<br />

178<br />

nonparametric expectation maximization<br />

oncology patients receiving aminoglycoside<br />

therapy, 1025<br />

ofloxacin<br />

bioequivalence after multiple doses to<br />

healthy volunteers, 1468<br />

healthy volunteers, multiple oral<br />

doses, 2193<br />

ornidazole<br />

liver transplantation, 1873<br />

pefloxacin<br />

one 800-mg versus two 400-mg doses,<br />

737<br />

piperacillin<br />

healthy volunteers, 1860<br />

piperacillin-tazobactam<br />

healthy volunteers, 1860<br />

population<br />

ciprofloxacin, optimal sampling strategies,<br />

1065<br />

nonparametric approach, 1025<br />

ribavirin<br />

children with human immunodeficiency<br />

virus infection, 532<br />

rifampin<br />

fleroxacin, influence on, 2132<br />

zidovudine, interaction with, 1426<br />

rufloxacin<br />

biliary excretion in humans, 2545<br />

patients with impaired renal function,<br />

637<br />

S-1108<br />

safety of <strong>and</strong> carnitine status of patients,<br />

1043<br />

S. aureus<br />

fleroxacin-rifampin, 2132<br />

SCE-2787<br />

serum bactericidal activities, 1835<br />

side effects, 1835<br />

sparfloxacin<br />

ocular penetration in rabbits with ophthalmitis,<br />

633<br />

stavudine<br />

cynomolgus monkeys, 1160<br />

teicoplanin<br />

evaluation of a fluorescence polarization<br />

immunoassay, 1924<br />

prophylaxis in monolateral <strong>and</strong> bilateral<br />

total knee replacement procedures,<br />

2693<br />

ticarcillin-clavulanic acid<br />

healthy volunteers, 1860<br />

trimethoprim-sulfamethoxazole<br />

12/60 mg/kg/day, multiple dose, 448<br />

healthy volunteers, 448<br />

vancomycin<br />

obesity, effect on, 436<br />

pulmonary lining fluid, penetration<br />

into, 281<br />

serum protein-binding characteristics,<br />

1132<br />

zidovudine<br />

effects of st<strong>and</strong>ard breakfast in patients<br />

with AIDS, 2153<br />

prodrugs, enhanced levels in brain tissue,<br />

818<br />

rifampin, interaction with, 1426<br />

zidovudine-granulocyte-macrophage colony-stimulating<br />

factor<br />

patients with AIDS <strong>and</strong> severe AIDSrelated<br />

complex, 512<br />

Pharyngitis<br />

cefuroxime axetil suspension<br />

comparative evaluation, 159<br />

Streptococcus spp., group A<br />

cefuroxime axetil suspension, comparative<br />

evaluation, 159<br />

(R)-9-(2-Phosphonomethoxypropyl)-2,6diaminopurine<br />

herpesviruses, 332<br />

retroviruses, 332<br />

Phosphonylmethoxyalkyl derivatives<br />

cytomegalovirus resistance<br />

point mutation in DNA polymerase<br />

gene, 19<br />

Phosphorothioate oligodeoxynucleotides<br />

Epstein-Barr virus<br />

inhibition of replication, 1420<br />

Picolinic acid<br />

C. albicans<br />

protective effect on mice, 2422<br />

Picornavirus<br />

capsid binders<br />

detection with soluble intercellular<br />

adhesion molecule 1, 1693<br />

Piperacillin<br />

combinations<br />

comparative evaluation, 1580<br />

skin <strong>and</strong> skin structure infections,<br />

1580<br />

tazobactam, 1580, 2578<br />

pharmacokinetics<br />

healthy volunteers, 1860<br />

Piperacillin-tazobactam<br />

pharmacokinetics<br />

healthy volunteers, 1860<br />

ANTIMICROB. AGENTS CHEMOTHER.<br />

Pirlimycin<br />

bovine mastitis, isolates from<br />

activity of, 1122<br />

disk diffusion breakpoints, 1122<br />

Plasmids<br />

R751<br />

multidrug resistance to antiseptics <strong>and</strong><br />

disinfectants, 761<br />

resistance<br />

S. aureus, 2003<br />

Plasmodium berghei<br />

oxidase inhibitors<br />

drug susceptibility, enhancement of,<br />

1318<br />

Plasmodium falciparum<br />

5-fluoroorotate<br />

clonal viability measurements to assess<br />

in vitro activity, 1102<br />

amopyroquin<br />

malaria treatment, 970<br />

chloroquine<br />

clonal viability measurements to assess<br />

in vitro activity, 1102<br />

chloroquine resistant<br />

9-anilinoacridines, 403<br />

clonal viability measurements<br />

leupeptin, chloroquine, <strong>and</strong> 5-fluoroorotate,<br />

in vitro activity, 1102<br />

cross-resistance patterns, 2337<br />

cycloguanil<br />

African isolates, 924<br />

halofantrine resistance, 2337<br />

leupeptin<br />

clonal viability measurements to assess<br />

in vitro activity, 1102<br />

malaria<br />

amopyroquin, 970<br />

halofantrine, 1955<br />

mefloquine, 1977<br />

mefloquine<br />

malaria treatment, 1977<br />

oxidase inhibitors<br />

drug susceptibility, enhancement of,<br />

1318<br />

Platelet microbicidal protein<br />

C. neoforinans<br />

fungicidal activity, 546<br />

C<strong>and</strong>ida spp.<br />

fungicidal activity, 546<br />

Pneumocystis carinji<br />

8-aminoquinolones<br />

in vivo <strong>and</strong> in vitro studies, 2166<br />

amsacrine<br />

activity in vitro <strong>and</strong> in a mouse model,<br />

1543<br />

bis-benzimidazoles<br />

pneumonia, treatment of, 1713<br />

biguanide folate antagonist<br />

PS-15, immunosuppressed rat model,<br />

1417<br />

bilobalide<br />

in vitro <strong>and</strong> in vivo activities, 1492<br />

camptothecin<br />

activity in vitro <strong>and</strong> in a mouse model,<br />

1543<br />

dihydrofolate reductase inhibitors <strong>and</strong><br />

dapsone<br />

synergy, 1436<br />

dihydrofolate reductase inhibitors <strong>and</strong><br />

sulfamethoxazole<br />

synergy, 1436<br />

epipodophyllotoxins<br />

activity in vitro <strong>and</strong> in a mouse model,

VOL. 37, 1993<br />

1543<br />

isoprinosine<br />

dihydropteroate synthetase inhibition,<br />

1227<br />

pneumonia<br />

bis-benzimidazoles, cationically substituted,<br />

activity of, 1713<br />

PS-15<br />

folate antagonism, 1417<br />

immunosuppressed rat model, 1417<br />

quinolones<br />

activity in vitro <strong>and</strong> in a mouse model,<br />

1543<br />

Ro 11-8958-dapsone<br />

synergy, 1436<br />

Ro 11-8958-sulfamethoxazole<br />

synergy, 1436<br />

topoisomerase inhibitors<br />

activity in vitro <strong>and</strong> in a mouse model,<br />

1543<br />

Pneumonia<br />

cytomegalovirus<br />

ganciclovir sensitivity at diagnosis <strong>and</strong><br />

during treatment, 1360<br />

nosocomial<br />

critically ill patients, prevention of,<br />

931<br />

minireview, 931<br />

Pneumonitis<br />

cytomegalovirus<br />

(S)-1-(3-hydroxy-2-phosphonyl-methoxypropyl)cytosine,<br />

218<br />

Poloxamers<br />

T. gondii, 2265<br />

toxoplasmosis, 2265<br />

Poly(I):poly(Cl2U)<br />

biologic effects<br />

healthy volunteers, 429<br />

Polyaspartic acid<br />

gentamicin<br />

nephrotoxicity, protective effects,<br />

pharmacologic limits of, 347<br />

nephrotoxicity<br />

gentamicin, protective effects, pharmacologic<br />

limits of, 347<br />

Polymerase chain reaction<br />

E. faecalis<br />

heterogeneity of chloramphenicol acetyltransferase<br />

genes, 2593<br />

E. faecium<br />

heterogeneity of chloramphenicol acetyltransferase<br />

genes, 2593<br />

M. tuberculosis<br />

rifampin resistant, 2054<br />

S. pneumoniae<br />

heterogeneity of chloramphenicol acetyltransferase<br />

genes, 2593<br />

Polymorphonuclear leukocytes<br />

dirithromycin<br />

interactions may promote killing of<br />

infecting organisms, 2557<br />

suramin<br />

suppression of bactericidal activity,<br />

495<br />

Porphyromonas spp.<br />

Bay Y3118<br />

in vitro activity, 2509<br />

Positron emission tomography<br />

fleroxacin<br />

pharmacokinetics, 18F labeled, 2144<br />

pharmacokinetics<br />

fleroxacin, "8F labeled, 2144<br />

fluconazole, "8F labeled, 1270<br />

Postantibiotic effect<br />

benzylpenicillin<br />

Bioscreen C, 2200<br />

Streptococcus <strong>and</strong> Pneumococcus<br />

spp., 2200<br />

E. coli<br />

correlation of tobramycin-induced inhibition<br />

of protein synthesis, 2678<br />

imipenem<br />

repeated exposure to, 1723<br />

temafloxacin<br />

repeated exposure to, 1723<br />

tobramycin<br />

hyperoxia, prolongation by, role of<br />

reactive oxygen species, 120<br />

P. aeruginosa, 120<br />

repeated exposure to, 1723<br />

Prednisolone<br />

keratitis<br />

age <strong>and</strong> therapeutic outcome, 1856<br />

P. aeruginosa<br />

age <strong>and</strong> therapeutic outcome, 1856<br />

Prevotella spp.<br />

Bay Y3118<br />

in vitro activity, 2509<br />

Pristinamycin resistance<br />

S. aureus<br />

isolates responsible for outbreak in<br />

Parisian hospital, 2159<br />

Probenecid<br />

allopurinol riboside<br />

pharmacokinetics, effects on, 1193<br />

Protease inhibitors<br />

human immunodeficiency virus<br />

in vitro activity of XM323, 2606<br />

murine leukemia virus<br />

antiretroviral activity, 71<br />

simian immunodeficiency virus<br />

antiretroviral activity, 71<br />

PS-15<br />

P. carinii<br />

folate antagonism, 1417<br />

immunosuppressed rat model, 1417<br />

Pseudomonas aeruginosa<br />

6'-N-acetyltransferase<br />

aac(6')-Ib, characterization of, 1456<br />

antiflagella monoclonal antibodies<br />

therapeutic effects in a murine model,<br />

164<br />

ant(4')-IIa<br />

nucleotide sequence analysis <strong>and</strong><br />

DNA hybridization studies, 708<br />

aztreonam, 308<br />

aztreonam-amikacin, 308<br />

,3-lactamase<br />

extended spectrum, characterization<br />

of, 962<br />

OXA-11, extended-spectrum variant of<br />

OXA-10, 1637<br />

biapenem<br />

phenotypic resistance induced by salicylate,<br />

2743<br />

biofilms<br />

clarithromycin, interaction with, 1749<br />

inhibition of formation on prosthetic<br />

devices by proteolytic enzymes,<br />

2618<br />

BO-2727<br />

in vitro activity, 2756<br />

carbapenem resistance<br />

cephalosporinase, role in, 1387<br />

cefoperazone-sulbactam<br />

granulocytopenic mice, disseminated<br />

SUBJECT INDEX xxix<br />

infections in, 1927<br />

cefozopran<br />

urinary tract infection, 100<br />

ceftazadime, 308<br />

ceftazidime-amikacin, 308<br />

ciprofloxacin<br />

age <strong>and</strong> therapeutic outcome, 1856<br />

dose-ranging <strong>and</strong> fractionation, 1756<br />

in vitro model of infection, 1756<br />

increased susceptibility in the presence<br />

of vancomycin, 2506<br />

resistance to unrelated antibiotics, effects<br />

on, 1289<br />

clarithromycin<br />

biofilms, interaction with, 1749<br />

deglucoteicoplanin amide derivatives<br />

uptake, mechanism of, 453<br />

erythromycin<br />

sub-MICs, effect on serum sensitivity,<br />

675<br />

flurbiprofen<br />

age <strong>and</strong> therapeutic outcome, 1856<br />

gentamicin<br />

A b<strong>and</strong> <strong>and</strong> B b<strong>and</strong> lipopolysaccharides,<br />

interaction with, 715<br />

imipenem<br />

phenotypic resistance induced by salicylate,<br />

2743<br />

imipenem resistance<br />

mechanism of efficient elimination of<br />

protein D2, 2385<br />

imipenem-amikacin<br />

in vitro pharmacodynamic effects,<br />

1931<br />

interleukin-1-induced nonspecific resistance<br />

role of acute-phase proteins in studies<br />

with mice, 2527<br />

keratitis<br />

age <strong>and</strong> therapeutic outcome, 1856<br />

macrolides<br />

sub-MICs, effect on serum sensitivity,<br />

675<br />

panipenem, 322<br />

diffusion through outer membrane,<br />

role of OprD protein, 322<br />

phenotypic resistance induced by salicylate,<br />

2743<br />

postantibiotic effect<br />

tobramycin, prolongation by hyperoxia,<br />

role of reactive oxygen species,<br />

120<br />

prednisolone<br />

age <strong>and</strong> therapeutic outcome, 1856<br />

tobramycin<br />

postantibiotic effect, prolongation by<br />

hyperoxia, role of reactive oxygen<br />

species, 120<br />

vancomycin<br />

increased susceptibility to ciprofloxacin,<br />

2506<br />

Pseudomonas cepacia<br />

,-lactamase<br />

strain 249 chromosomal penicillinase,<br />

member of AmpC family, 667<br />

ceftazidime<br />

comparative evaluation, 123<br />

chloramphenicol<br />

comparative evaluation, 123<br />

ciprofloxacin<br />

comparative evaluation, 123<br />

co-trimoxazole<br />

comparative evaluation, 123

SUBJECT INDEX<br />

meropenem<br />

comparative evaluation, 123<br />

PD 127391<br />

comparative evaluation, 123<br />

PD 131628<br />

comparative evaluation, 123<br />

Pseudomonas pseudomallei<br />

ceftazidime resistance<br />

biofilm cells, 2000<br />

co-trimoxazole<br />

biofilm cells, 2000<br />

Pulsed-field gel electrophoresis<br />

enterococci<br />

characterization of glycopeptide-resistant<br />

isolates from U.S. hospitals,<br />

2311<br />

Pyrimethamine<br />

combinations<br />

azithromycin, 1993<br />

T. gondii, 1993<br />

creatinine secretion, renal<br />

inhibition of, 1056<br />

Pyrimido[1,6-a]benzimidazoles<br />

D. melanogaster<br />

effects on topoisomerase II <strong>and</strong> Kc<br />

cells, 2599<br />

Q-35<br />

L. interrogans<br />

five serogroups, 901<br />

M. pneumoniae<br />

in vitro <strong>and</strong> in vivo activities, 1826<br />

mice irradiated with long-wavelength<br />

UV<br />

reduced phototoxicity, 2217<br />

Q fever<br />

C. bumetii<br />

minireview, 1733<br />

treatment of<br />

minireview, 1733<br />

Quinapyramine<br />

T. congolense, resistant clone<br />

derivation <strong>and</strong> characterization, 1163<br />

Quinoline alkaloids<br />

2 substituted<br />

L. amazonensis, 859<br />

L. venezuelensis, 859<br />

leishmaniasis, cutaneous, 859<br />

L. amazonensis, 859<br />

L. venezuelensis, 859<br />

leishmaniasis, 859<br />

Quinolones<br />

1-8 bridged<br />

topoisomerase II, stereospecificity for<br />

the C-11 methyl group, 646<br />

AM-1155<br />

antimycobacterial activities, comparative<br />

evaluation, 1259<br />

Ames Salmonella TA102 assay<br />

bacterial mutagenicity, 213<br />

antibiotic carryover<br />

antibiotic-removal beads, elimination<br />

with, 1377<br />

anti-M. avium activities<br />

erratum, 2766<br />

B. fragilis<br />

in vivo efficacy, correlation with in<br />

vitro susceptibility, 997<br />

mice, 997<br />

Bay y 3118<br />

broth macrodilution assays, 2348<br />

C. jejuni resistance<br />

DNA gyrase mutations, characterization<br />

of, 457<br />

cefazolin-induced seizures<br />

DBA/2 mice, potentiation of, 1497<br />

CI-960<br />

C. trachomatis salpingitis, 8<br />

combinations<br />

Brucella spp., 1831<br />

comparative evaluation, 1831<br />

CP-115,953<br />

activities against mammalian systems,<br />

comparative evaluation, 2179<br />

DNA gyrases<br />

E. coli, mechanism of action, 839<br />

E. coli<br />

DNA gyrase, mechanism of action,<br />

839<br />

in vivo efficacy, correlation with in<br />

vitro susceptibility, 997<br />

mice, 997<br />

E. coli resistance<br />

plasmid complementation test, 2588<br />

M. avium<br />

in vitro activities, 1799<br />

structure-activity relationship studies,<br />

1807<br />

M. pneumoniae<br />

hamsters, 287<br />

NM394<br />

antibacterial activity, 793<br />

OPC 17116<br />

M. hominis, M. pneumoniae, <strong>and</strong> U.<br />

urealyticum, 1726<br />

P. carindi<br />

activity in vitro <strong>and</strong> in a mouse model,<br />

1543<br />

PD 138312<br />

in vitro activities, 2563<br />

PD 140248<br />

in vitro activities, 2563<br />

proconvulsant effects<br />

DBA/2 mice, 1497<br />

T-3761<br />

in vitro <strong>and</strong> in vivo activities, 384<br />

topoisomerase II<br />

stereospecificity for the C-11 methyl<br />

group, 646<br />

topoisomerase II <strong>and</strong> cultured cells, activities<br />

against, 2179<br />

R751<br />

integron<br />

multidrug resistance to antiseptics <strong>and</strong><br />

disinfectants, 761<br />

Ramoplanin<br />

gram-positive organisms<br />

bloodstream isolates, 896<br />

in vitro activity, 896<br />

vancomycin resistant, 1364<br />

"Red man syndrome"<br />

vancomycin<br />

skin tests to healthy volunteers, 2139<br />

Renal function<br />

creatinine secretion<br />

pyrimethamine, inhibition of, 1056<br />

Resorcinomycin<br />

M. avium-M. intracellulare complex<br />

in vitro activities, 2584<br />

M. tuberculosis<br />

in vitro activities, 2584<br />

ANTIMICROB. AGENTS CHEMOTHER.<br />

Respiratory pathogens<br />

ciprofloxacin<br />

adherence changes induced by subinhibitory<br />

concentrations, 885<br />

sparfloxacin<br />

adherence changes induced by subinhibitory<br />

concentrations, 885<br />

trimethoprim<br />

adherence changes induced by subinhibitory<br />

concentrations, 885<br />

Respiratory syncytial virus<br />

immune globulin<br />

prophylaxis for high-risk infants, evaluation<br />

of, 1655<br />

Respiratory tract infections<br />

cefozopran, 100<br />

K. pneumoniae<br />

cefozopran, 100<br />

Retroviruses<br />

acyclic nucleoside phosphonates<br />

(S) <strong>and</strong> (R) enantiomers, 332<br />

(R)-9-(2-phosphonomethoxypropyl)-2,6diaminopurine,<br />

332<br />

Reverse transcriptase inhibitors<br />

diarylsulfones<br />

human immunodeficiency virus, 754<br />

FTC<br />

human immunodeficiency virus, 1720<br />

human immunodeficiency virus<br />

diarylsulfones, mechanism of action,<br />

754<br />

FTC, 5'-triphosphates of (-) <strong>and</strong> (+)<br />

enantiomers, 1720<br />

L-696,229, activity against isolates resistant<br />

to related inhibitors, 947<br />

nonnucleoside inhibitors, 1037<br />

S-2720, 1659<br />

human immunodeficiency virus resistance<br />

mutant enzyme <strong>and</strong> viral variant assessment,<br />

1576<br />

human immunodeficiency virus type 1<br />

infectious amplification from lymphocytes<br />

<strong>and</strong> modulation, 2206<br />

L-696,229<br />

human immunodeficiency virus isolates<br />

resistant to related inhibitors,<br />

947<br />

S-2720<br />

human immunodeficiency virus, 1659<br />

thiazolo-iso-indolinones<br />

human immunodeficiency virus type 1<br />

resistance, 2612<br />

U-90152<br />

human immunodeficiency virus, 1127<br />

Rhinovirus<br />

WIN 54954<br />

prophylaxis, efficacy of, 297<br />

Rhodococcus equi<br />

penicillin-binding proteins<br />

imipenem resistance, potential role in,<br />

1406<br />

Ribavirin<br />

pharmacokinetics<br />

children with human immunodeficiency<br />

virus infection, 532<br />

safety <strong>and</strong> tolerance<br />

children with human immunodeficiency<br />

virus infection, 532<br />

Rickettsia spp.<br />

spotted fever group<br />

in vitro susceptibilities to clarithromycin,<br />

2633

VOL. 37, 1993<br />

Rifabutin<br />

combinations<br />

M. avium, prophylaxis in mice, 1690<br />

minocycline, 1690<br />

M. avium<br />

erratum, 2515<br />

prophylaxis in C57BL/6 mice, 1690<br />

M. avium complex<br />

rats treated with cyclosporine, 398<br />

M. haemophilum<br />

in vitro activities, 2323<br />

M. paratuberculosis<br />

systemic infection in mice, 1645<br />

Rifampin<br />

combinations<br />

Brucella spp., 1831<br />

doxycycline, 1831<br />

fleroxacin, 2132<br />

novobiocin, 1334<br />

ofloxacin, 1214, 1831<br />

S. aureus, methicillin resistant, eradication<br />

of, 1334<br />

Staphylococcus-infected orthopedic<br />

implants, 1214<br />

M. haemophilum<br />

in vitro activities, 2323<br />

M. leprae resistance<br />

molecular basis, 414<br />

minireview<br />

nonstaphylococcal, nonmycobacterial<br />

disease, 1<br />

N. brasiliensis<br />

inactivation of drug by glycosylation,<br />

1313<br />

nonstaphylococcal, nonmycobacterial<br />

disease<br />

minireview, 1<br />

pharmacokinetics<br />

fleroxacin, influence on, 2132<br />

S. aureus, 2132<br />

zidovudine, interaction with, 1426<br />

S. epidermidis<br />

diffusion through a biofilm, 2522<br />

staphylococcal bacteremia<br />

use with neonates, 2401<br />

synergy<br />

ethambutol, 1285<br />

M. malmoense, 1285<br />

zidovudine<br />

pharmacokinetic interaction with, 1426<br />

Rifapentine<br />

Brucella spp.<br />

in vitro activity, comparative evaluation,<br />

911<br />

M. avium complex<br />

rats treated with cyclosporine, 398<br />

Rimantadine<br />

influenza virus<br />

susceptibilities of subtypes A/HlN1<br />

<strong>and</strong> A/H3N2, 2239<br />

Ro 11-8958<br />

synergy<br />

dapsone, 1436<br />

P. caninii, 1436<br />

sulfamethoxazole, 1436<br />

Ro 40-6890<br />

antimicrobial susceptibility, 893<br />

disk diffusion susceptibility, 893<br />

S. aureus<br />

antibiotic activity <strong>and</strong> host defense<br />

mechanisms, 2622<br />

pharmacodynamic activity in human<br />

skin blister fluid, 2622<br />

Ro 41-3399<br />

metabolite<br />

antimicrobial susceptibility, 893<br />

disk diffusion susceptibility, 893<br />

Roxithromycin<br />

Brucella spp.<br />

in vitro activity, comparative evaluation,<br />

911<br />

gram-negative organisms<br />

outer membrane permeability barrier,<br />

354<br />

Mycobacterium spp.<br />

in vitro activity, 1560<br />

pH, effect on radiometric MICs, 1560<br />

RP 74501-RP 74502<br />

Legionella spp.<br />

in vitro activity, 908<br />

RP59500<br />

gram-positive organisms<br />

vancomycin resistant, 598<br />

RU-40555<br />

combinations<br />

clarithromycin, 692<br />

M. avium complex, 692<br />

M. avium complex, 692<br />

Rufloxacin<br />

comparative evaluation<br />

amoxicillin, 2298<br />

chronic bronchitis, 2298<br />

magnesium-aluminum hydroxide<br />

effects on absorption, 2212<br />

pharmacokinetics<br />

biliary excretion in humans, 2545<br />

patients with impaired renal function,<br />

637<br />

T-cell subsets <strong>and</strong> tumor necrosis factor<br />

production<br />

mice infected with B. fragilis, effect<br />

on, 1711<br />

S-1108<br />

pharmacokinetics, 1043<br />

safety of <strong>and</strong> carnitine status of patients,<br />

1043<br />

S-2720<br />

human immunodeficiency virus<br />

inhibition of reverse transcriptase <strong>and</strong><br />

viral replication, 1659<br />

Saccharomyces cerevisiae<br />

bleomycin<br />

cell wall anchorage of mannoproteins,<br />

disruption of, 1264<br />

Ro 09-1470<br />

inhibition of P-450 lanosterol C-14<br />

demethylase, 2662<br />

Saccharopolyspora erythraea<br />

avermectins <strong>and</strong> ivermectins, glycosylation,<br />

microbial conversion by, 1737<br />

Salmonella typhi<br />

ceftriaxone<br />

5 days, comparative evaluation, 1572<br />

chloramphenicol<br />

14 days, comparative evaluation, 1572<br />

Salmonella typhimurium.<br />

ciprofloxacin resistance<br />

isolates from two patients, 662<br />

isoniazid<br />

susceptibilities of oxyR regulon mutants,<br />

2251<br />

lactoferrin-porin interaction<br />

antibacterial activity, effect on, 240<br />

mutants<br />

SUBJECT INDEX xxxi<br />

supersusceptibility to antibiotics, 2255<br />

Salmonellae<br />

acyclovir, 106<br />

antimicrobial resistance<br />

Spanish hospital, 1200<br />

azithromycin<br />

in vitro activity, 1203<br />

2',3'-dideoxycytidine, 106<br />

2',3'-dideoxyinosine, 106<br />

zidovudine, 106<br />

Salmonellosis<br />

murine<br />

ciprofloxacin, 2293<br />

Salpingitis<br />

CI-960<br />

monkey model, 8<br />

SCE-2787<br />

pharmacokinetics<br />

healthy volunteers, 1835<br />

serum bactericidal activities, 1835<br />

side effects, 1835<br />

Screening assays<br />

anti-P. carinii agents<br />

development <strong>and</strong> characterization,<br />

1674<br />

Shell vial assay<br />

C. bumetii susceptibility<br />

shell vial assay, 491<br />

Shigella sonnei<br />

dysentery<br />

fluoroquinolones, 2486<br />

fluoroquinolones<br />

reduced susceptibilities of strains from<br />

patients with dysentery, 2486<br />

Shigella spp.<br />

azithromycin<br />

in vitro activity, 1203<br />

Simian immunodeficiency virus<br />

antibodies, neutralizing<br />

macrophages, comparative evaluation,<br />

360<br />

3'-azidothymidine<br />

macrophages, comparative evaluation,<br />

360<br />

protease inhibitors<br />

antiretroviral activity, 71<br />

Simian varicella virus<br />

(-)-9-[4-hydroxy-2-(hydroxymethyl)butyl]guanine<br />

African green monkeys, 1370<br />

Sinefungin<br />

Cryptosporidium parvum<br />

curative <strong>and</strong> preventive activities, 889<br />

immunosuppressed rat model, 889<br />

Skin infections<br />

piperacillin-tazobactam<br />

comparative evaluation, 1580<br />

ticarcillin-clavulanate<br />

comparative evaluation, 1580<br />

Sodium stibogluconate<br />

L. panamensis<br />

in vitro activities of fractions, 1842<br />

Soluble intercellular adhesion molecule 1<br />

picornavirus capsid binders<br />

detection of, 1693<br />

Sparfloxacin<br />

bite wound isolates<br />

aerobic <strong>and</strong> anaerobic, 1150<br />

C. pneumoniae<br />

in vitro <strong>and</strong> in vivo activities, 801<br />

C. psittaci<br />

in vitro <strong>and</strong> in vivo activities, 801<br />

C. trachomatis

xxxii SUBJECT INDEX<br />

in vitro <strong>and</strong> in vivo activities, 801<br />

H. influenzae<br />

adherence changes induced by subinhibitory<br />

concentrations, 885<br />

K pneumoniae<br />

adherence changes induced by subinhibitory<br />

concentrations, 885<br />

M. catarrhalis<br />

adherence changes induced by subinhibitory<br />

concentrations, 885<br />

M. haemophilum<br />

in vitro activities, 2323<br />

M. kansasii<br />

susceptibility testing, 1997<br />

M. tuberculosis, 407<br />

ophthalmitis<br />

rabbits with, efficacy in, 633<br />

pharmacokinetics<br />

ocular penetration in rabbits with ophthalmitis,<br />

633<br />

Spiramycin<br />

C. trachomatis<br />

comparative evaluation, 1373<br />

genital infections, treatment of, 1373<br />

Staphylococcus aureus<br />

abscesses<br />

cefazolin, ,-lactamase-mediated inactivation<br />

<strong>and</strong> efficacy, 203<br />

cefmetazole, 3-lactamase-mediated<br />

inactivation <strong>and</strong> efficacy, 203<br />

adherence<br />

teicoplanin, effect of subinhibitory<br />

concentrations on, 921<br />

vancomycin, effect of subinhibitory<br />

concentrations on, 921<br />

ampicillin-sulbactam<br />

P-lactamase-hyperproducing strain,<br />

507<br />

antimicrobial susceptibility<br />

fibronectin-coated surfaces, isolates<br />

on, 625<br />

azithromycin<br />

uptake by human monocytes, 2318<br />

B. fragilis, polymicrobial infection<br />

mice, 1531<br />

B. thetaiotaomicron, polymicrobial infection<br />

mice, 1531<br />

bacteremia<br />

use of intravenous rifampin with neonates,<br />

2401<br />

,-lactamase<br />

production, genes involved in regulation,<br />

1966<br />

P-lactamases<br />

blaI <strong>and</strong> blaRl, regulation of, 1144<br />

blaI <strong>and</strong> blaRI<br />

P-lactamase <strong>and</strong> PBP 2a regulation,<br />

1144<br />

cefazolin<br />

P-lactamase-mediated inactivation <strong>and</strong><br />

efficacy, 203<br />

cefmetazole<br />

P-lactamase-mediated inactivation <strong>and</strong><br />

efficacy, 203<br />

cefozopran, 100<br />

cephalosporins<br />

broad spectrum, 554<br />

ciprofloxacin<br />

dose-ranging <strong>and</strong> fractionation, 1756<br />

in vitro model of infection, 1756<br />

resistance to unrelated antibiotics, effects<br />

on, 1289<br />

dihydrofolate reductase, trimethoprim<br />

sensitive<br />

characterization of gene for, 1400<br />

enhanced intracellular antibacterial activity,<br />

2318<br />

fibronectin-coated surfaces, isolates on<br />

antimicrobial susceptibility, 625<br />

fleroxacin-rifampin<br />

pharmacokinetics, 2132<br />

fluoroquinolone resistance<br />

efflux mediated, 1086<br />

NorA, multidrug efflux transporter,<br />

128<br />

levofloxacin-oxacillin<br />

synergy, 339<br />

methicillin resistant<br />

13-lactam-1-lactamase inhibitor combinations,<br />

702<br />

P-lactams, 702<br />

blaI <strong>and</strong> blaRI regulate P-lactamase<br />

<strong>and</strong> PBP 2a production, 1144<br />

ciprofloxacin, resistance to unrelated<br />

antibiotics, effects on, 1289<br />

endocarditis, 2466<br />

fusidic acid, alone or in combination<br />

with vancomycin, 2466<br />

penicillin-binding protein 2A, role in<br />

cell wall synthesis, 342<br />

rifampin-novobiocin, 1334<br />

methicillin resistant <strong>and</strong> susceptible<br />

sequential acquisition of norfloxacin<br />

<strong>and</strong> ofloxacin resistance, 2278<br />

methicillin susceptible<br />

cephalosporins, broad spectrum, 554<br />

methicillin susceptible, borderline<br />

,B-lactam-13-lactamase inhibitor combinations,<br />

702<br />

P-lactams, 702<br />

mupirocin resistance<br />

detection <strong>and</strong> characterization, 2003<br />

mupirocin resistance, high level<br />

isoleucyl-tRNA synthetases, evidence<br />

for two distinct, 32<br />

NorA<br />

Bmr, comparison of substrate specificities,<br />

128<br />

multidrug efflux transporter, 128<br />

oxacillin<br />

,-lactamase-hyperproducing strain,<br />

507<br />

pefloxacin<br />

one 800-mg versus two 400-mg doses,<br />

737<br />

povidone iodine<br />

irrigation, 2754<br />

pristinamycin resistance<br />

isolates responsible for outbreak in<br />

Parisian hospital, 2159<br />

quinolone resistant<br />

levofloxacin-oxacillin synergy, 339<br />

rifampin<br />

use with neonates, 2401<br />

Ro 40-6890<br />

antibiotic activity <strong>and</strong> host defense<br />

mechanisms, 2622<br />

pharmacodynamic activity in human<br />

skin blister fluid, 2622<br />

teicoplanin<br />

adherence, effect of subinhibitory concentrations<br />

on, 921<br />

teicoplanin resistance<br />

expression of a novel membrane protein<br />

<strong>and</strong> increased expression of<br />

ANTIMICROB. AGENTS CHEMOTHER.<br />

penicillin-binding protein 2 complex,<br />

2432<br />

tetK<br />

E. coli, expression in, 191<br />

TetK, TetA(B), <strong>and</strong> TetA(C)<br />

substrate specificities, comparison of,<br />

191<br />

vancomycin<br />

adherence, effect of subinhibitory concentrations<br />

on, 921<br />

Staphylococcus epidermidis<br />

adherence<br />

teicoplanin, effect of subinhibitory<br />

concentrations on, 921<br />

vancomycin, effect of subinhibitory<br />

concentrations on, 921<br />

biofilms<br />

diffusion of rifampin, 2522<br />

diffusion of vancomycin, 2522<br />

inhibition of formation on prosthetic<br />

devices by proteolytic enzymes,<br />

2618<br />

teicoplanin<br />

adherence, effect of subinhibitory concentrations<br />

on, 921<br />

vancomycin<br />

adherence, effect of subinhibitory concentrations<br />

on, 921<br />

Staphylococcus spp.<br />

adherence<br />

teicoplanin, effect of subinhibitory<br />

concentrations on, 921<br />

vancomycin, effect of subinhibitory<br />

concentrations on, 921<br />

mec regulator genes<br />

distribution in methicillin-resistant<br />

strains, 1219<br />

methicillin resistant<br />

mec regulator genes, distribution of,<br />

1219<br />

orthopedic implant infections<br />

rifampin-ofloxacin, 1214<br />

rifampin-ofloxacin<br />

infected orthopedic implants, 1214<br />

teicoplanin<br />

adherence, effect of subinhibitory concentrations<br />

on, 921<br />

vancomycin<br />

adherence, effect of subinhibitory concentrations<br />

on, 921<br />

Stavudine<br />

pharmacokinetics<br />

cynomolgus monkeys, 1160<br />

Streptococcus mitis<br />

gentamicin<br />

chromosomally mediated high-level<br />

resistance, 2740<br />

Streptococcus mutans<br />

amoxicillin<br />

in vitro susceptibility, 1158<br />

cefuroxime<br />

in vitro susceptibility, 1158<br />

chlorhexidine<br />

in vitro susceptibility, 1158<br />

erythromycin<br />

in vitro susceptibility, 1158<br />

penicillin<br />

in vitro susceptibility, 1158<br />

tetracycline<br />

in vitro susceptibility, 1158<br />

trimethoprim-sulfamethoxazole<br />

in vitro susceptibility, 1158

VOL. 37, 1993<br />

Streptococcus pneumoniae<br />

cefotaxime breakpoint<br />

letter to the editor, 616<br />

ciprofloxacin<br />

mouse protection model, 234<br />

clarithromycin resistance<br />

cultures from Providence, R.I., 1742<br />

erythromycin resistance<br />

cultures from Providence, R.I., 1742<br />

meningitis<br />

penicillin <strong>and</strong> cephalosporin resistant,<br />

evaluation of treatment regimens,<br />

1630<br />

penicillin <strong>and</strong> cephalosporin resistant<br />

meningitis, evaluation of treatment<br />

regimens, 1630<br />

penicillin resistant<br />

otitis media, treatment with amoxicillin,<br />

1599<br />

penicillin-binding proteins 2B <strong>and</strong> 2X,<br />

genetic diversity of, 1938<br />

polymerase chain reaction<br />

heterogeneity of chloramphenicol acetyltransferase<br />

genes, 2593<br />

Streptococcus pyogenes<br />

poloxamer 188<br />

effects of scrubbing, 2754<br />

Streptococcus spp.<br />

ceftriaxone-netilmicin<br />

endocarditis, 207<br />

synergy, 207<br />

endocarditis<br />

ceftriaxone-netilmicin, 1971<br />

ceftriaxone-netilmicin synergy, 207<br />

group A<br />

antibiotic susceptibilities, hospital isolates,<br />

1717<br />

cefuroxime axetil suspension, comparative<br />

evaluation, 159<br />

group A, beta-hemolytic<br />

bacterial interference, role in infection<br />

management, 1452<br />

P-lactamase production, role in infection<br />

management, 1452<br />

tonsillopharyngitis<br />

cefprozil versus penicillin V, 1620<br />

viridans group<br />

activities of potential therapeutic <strong>and</strong><br />

prophylactic antibiotics against<br />

blood culture isolates, 2493<br />

neutropenic patients receiving ciprofloxacin,<br />

2493<br />

Streptogramin A acetyltransferases<br />

E. faecium<br />

identification of satA, 2119<br />

Streptogramins<br />

RP 74501-RP 74502<br />

Legionella spp., 908<br />

RP59500<br />

gram-positive organisms, vancomycin<br />

resistant, 598<br />

Streptomyces clavuligerus<br />

cephalosporin 7oa-hydroxylase<br />

cloning <strong>and</strong> expression in S. lividans,<br />

84<br />

Streptomyces spp.<br />

chromosomal DNA<br />

role in multiple antibiotic resistance,<br />

2379<br />

multiple antibiotic resistance<br />

chromosomal DNA in antibiotic preparations,<br />

2379<br />

Streptomycin<br />

combinations<br />

B. melitensis, 2333<br />

ciprofloxacin, doxycycline, <strong>and</strong> rifampin,<br />

2333<br />

E. coli resistance<br />

bleomycin, increase of, 1982<br />

Sulbactam<br />

combinations<br />

ampicillin, 251, 507, 610, 1447<br />

cefoperazone, 1927<br />

clavulanate, 2059<br />

comparative evaluation, 610<br />

E. coli, 1927, 2059<br />

E. coli intra-abdominal abscess model,<br />

610<br />

E. faecalis, P-lactamase producing,<br />

highly gentamicin resistant, 1447<br />

endocarditis, 507, 1447<br />

P. aeruginosa, 1927<br />

S. aureus, P-lactamase hyperproducing,<br />

507<br />

susceptibility testing with a predictor<br />

panel, 251<br />

tazobactam, 2059<br />

E. coli<br />

,B-lactamase, TEM type, resistant,<br />

2059<br />

oxidant-scavenging activities<br />

neutrophil functions, effect on, 950<br />

Sulfamethoxazole<br />

synergy<br />

dihydrofolate reductase inhibitors,<br />

1436<br />

P. carinii, 1436<br />

Ro 11-8958, 1436<br />

Suramin<br />

duck hepatitis B virus<br />

prevention of infection in vivo, 1539<br />

polymorphonuclear leukocyte bactericidal<br />

activity<br />

suppression of, 495<br />

Susceptibility testing<br />

agar dilution<br />

G. vaginalis, 2733<br />

amoxicillin<br />

blood culture isolates of viridans<br />

group streptococci from neutropenic<br />

patients receiving ciprofloxacin,<br />

2493<br />

ampicillin-sulbactam<br />

predictor panel, 251<br />

azlocillin<br />

blood culture isolates of viridans<br />

group streptococci from neutropenic<br />

patients receiving ciprofloxacin,<br />

2493<br />

broth microdilution<br />

multicenter evaluation, 39<br />

yeasts, 39<br />

C. neoformans<br />

current status of the st<strong>and</strong>ardization<br />

process, minireview, 2517<br />

C<strong>and</strong>ida spp.<br />

current status of the st<strong>and</strong>ardization<br />

process, minireview, 2517<br />

clarithromycin<br />

blood culture isolates of viridans<br />

group streptococci from neutropenic<br />

patients receiving ciprofloxacin,<br />

2493<br />

co-amoxiclav<br />

blood culture isolates of viridans<br />

SUBJECT INDEX xxxiii<br />

group streptococci from neutropenic<br />

patients receiving ciprofloxacin,<br />

2493<br />

dye uptake assay<br />

in vitro activity of clarithromycin<br />

against spotted fever group rickettsiae,<br />

2633<br />

erythromycin<br />

blood culture isolates of viridans<br />

group streptococci from neutropenic<br />

patients receiving ciprofloxacin,<br />

2493<br />

G. vaginalis<br />

agar dilution, 2733<br />

M. fermentans<br />

in vitro strains from AIDS patients,<br />

2500<br />

in vitro strains from non-AIDS patients<br />

with acute respiratory disease,<br />

2500<br />

tissue culture, 2500<br />

M. kansasii<br />

azithromycin, 1997<br />

clarithromycin, 1997<br />

fusidic acid, 1997<br />

ofloxacin, 1997<br />

sparfloxacin, 1997<br />

Nocardia spp.<br />

letter to the editor, 2514<br />

piperacillin-tazobactam<br />

predictor panel for evaluating methods,<br />

2578<br />

plaque assay<br />

in vitro activity of clarithromycin<br />

against spotted fever group rickettsiae,<br />

2633<br />

roxithromycin<br />

Mycobacterium spp., effect of pH on<br />

MICs, 1560<br />

yeasts<br />

broth macrodilution, 39<br />

multicenter evaluation, 39<br />

Synergy<br />

3'-azido-2',3'-deoxythymidine<br />

carbovir, 144<br />

human immunodeficiency virus type 1,<br />

144<br />

carbovir<br />

3'-azido-2',3'-deoxythymidine, 144<br />

human immunodeficiency virus type 1,<br />

144<br />

decimal assay for additivity, 260<br />

E. faecium<br />

penicillin-gentamicin, 2427<br />

ethambutol-amikacin<br />

M. malmoense, 1285<br />

ethambutol-ciprofloxacin<br />

M. malmoense, 1285<br />

ethambutol-rifampin<br />

M. malmoense, 1285<br />

levofloxacin-oxacillin<br />

S. aureus, quinolone resistant, 339<br />

M. malmoense<br />

ethambutol-amikacin, 1285<br />

ethambutol-ciprofloxacin, 1285<br />

ethambutol-rifampin, 1285<br />

microdilution checkerboard method<br />

measurement of, reproducibility of<br />

results, 613<br />

penicillin-gentamicin<br />

E. faecium, 2427

xxxiv SUBJECT INDEX<br />

T-3761<br />

in vitro <strong>and</strong> in vivo activities, 384<br />

Tazobactam<br />

1-lactamases<br />

kinetic interactions, 851<br />

combinations<br />

clavulanate, 2059<br />

E. coli, 2059<br />

piperacillin, 2578<br />

sulbactam, 2059<br />

E. coli<br />

P-lactamase, TEM type, resistant,<br />

2059<br />

Teicoplanin<br />

adherence<br />

Staphylococcus spp., effect of subinhibitory<br />

concentrations on, 921<br />

bactericidal activity<br />

albumin or serum, presence of, controlled<br />

pH <strong>and</strong> calcium, 605<br />

pharmacokinetics<br />

evaluation of a fluorescence polarization<br />

immunoassay, 1924<br />

prophylaxis in monolateral <strong>and</strong> bilateral<br />

total knee replacement procedures,<br />

2693<br />

S. aureus resistance<br />

expression of a novel membrane protein<br />

<strong>and</strong> increased expression of<br />

penicillin-binding protein 2 complex,<br />

2432<br />

Staphylococcus spp.<br />

adherence, effect of subinhibitory concentrations<br />

on, 921<br />

Temafloxacin<br />

B. fragilis<br />

evaluation of activity by an in vitro<br />

pharmacodynamic system, 2454<br />

bite wound isolates<br />

aerobic <strong>and</strong> anaerobic, 1150<br />

M. pneumoniae<br />

hamsters, 287<br />

postantibiotic effect<br />

repeated exposures, 1723<br />

Terbinafine<br />

C<strong>and</strong>ida spp.<br />

temperature, effect on activity, 685<br />

combinations<br />

Chagas' disease, murine, 1353<br />

ICI 195,739, 1353<br />

ketoconazole, 1353<br />

T. cruzi, 1353<br />

mevinolin<br />

T. cruzi, potentiation of antiproliferative<br />

effects, 580<br />

Terconazole<br />

C<strong>and</strong>ida spp.<br />

temperature, effect on activity, 685<br />

tet(Q)<br />

B. fragilis<br />

nucleotide <strong>and</strong> deduced amino acid<br />

sequences, 2037<br />

TetA(D)<br />

nucleotide <strong>and</strong> deduced protein sequences,<br />

1253<br />

relationship to other antimicrobial transport<br />

proteins, 1253<br />

TetK<br />

S. aureus<br />

E. coli, expression in, 191<br />

substrate specificities, comparison<br />

with those of TetA(B) <strong>and</strong><br />

TetA(C), 191<br />

Tetracycline<br />

C. jejuni resistance<br />

effect of mutational alteration of Asn-<br />

128, 2645<br />

resistance determinants<br />

TetA(D), nucleotide <strong>and</strong> deduced protein<br />

sequences, 1253<br />

S. mutans<br />

in vitro susceptibility, 1158<br />

Tet(O)<br />

effect of mutational alteration of Asn-<br />

128, 2645<br />

TetA(D)<br />

nucleotide <strong>and</strong> deduced protein sequences,<br />

1253<br />

relationship to other antimicrobial<br />

transport proteins, 1253<br />

Tetracycline-HCl<br />

synergy<br />

H. pylori, 1184<br />

metronidazole, 1184<br />

metronidazole, hydroxymetabolite of,<br />

1184<br />

Tetracyclines<br />

glycylcyclines<br />

comparative evaluation, 2270<br />

penetration into bacterial cells<br />

minireview, 1393<br />

screening assay, 1624<br />

Thiazolo-iso-indolinones<br />

human immunodeficiency virus type 1<br />

resistance, 2612<br />

Thiosemicarbazones<br />

Abelson murine leukemia virus<br />

v-abl protein, suppression of, 2483<br />

Ticarcillin<br />

combinations<br />

clavulanate, 1580<br />

clavulanic acid, 51<br />

comparative evaluation, 1580<br />

skin <strong>and</strong> skin structure infections,<br />

1580<br />

yeast colonization of the human gastrointestinal<br />

tract, effect on, 51<br />

Ticarcillin-clavulanic acid<br />

C. albicans<br />

colonization of the human gastrointestinal<br />

tract, effect on, 51<br />

pharmacokinetics<br />

healthy volunteers, 1860<br />

yeast colonization of the human gastrointestinal<br />

tract, effect on, 51<br />

Time-kill curves<br />

mathematical model for comparison of,<br />

1685<br />

Time-kill studies<br />

turbidimetric assay<br />

viable bacterial densities, quantitation<br />

of, 371<br />

Tinea unguium<br />

griseofulvin<br />

ultramicrosize, 2064<br />

itraconazole, 2064<br />

Tobramycin<br />

E. coli resistance<br />

3'-aminoglycoside phosphotransferase<br />

type I, overproduction of, 78<br />

postantibiotic effect<br />

hyperoxia, prolongation by, role of<br />

reactive oxygen species, 120<br />

P. aeruginosa, 120<br />

repeated exposures, 1723<br />

ANTIMICROB. AGENTS CHEMOTHER.<br />

Tonsillopharyngitis<br />

cefprozil<br />

comparative evaluation, 1620<br />

penicillin V<br />

comparative evaluation, 1620<br />

streptococcal<br />

cefprozil versus penicillin V, 1620<br />

Topoisomerase inhibitors<br />

P. carinii<br />

activity in vitro <strong>and</strong> in a mouse model,<br />

1543<br />

Topoisomerases<br />

quinolones<br />

1-8 bridged, stereospecificity for the<br />

C-11 methyl group, 646<br />

activities against mammalian systems,<br />

comparative evaluation, 2179<br />

Torulopsis glabrata<br />

fluconazole<br />

prophylaxis in neutropenic bone marrow<br />

transplant patients, 1847<br />

Tosufloxacin<br />

C. pneumoniae<br />

in vitro <strong>and</strong> in vivo activities, 801<br />

C. psittaci<br />

in vitro <strong>and</strong> in vivo activities, 801<br />

C. trachomatis<br />

in vitro <strong>and</strong> in vivo activities, 801<br />

Toxicity<br />

A77003<br />

preclinical evaluation, 115<br />

amphotericin B<br />

mono-methyl ester derivative, 419<br />

neurotoxicity, comparative evaluation,<br />

419<br />

3'-azido-3'-deoxythymidine<br />

time of administration, effect on, 1771<br />

gentamicin<br />

polyaspartic acid, protective effects,<br />

pharmacologic limits of, 347<br />

human renal proximal tubule cells<br />

use in studying foscarnet-induced<br />

nephrotoxicity in vitro, 2496<br />

LJC 10,627<br />

central nervous systems of rats, low<br />

levels of, 199<br />

nephrotoxicity<br />

isepamicin, 2042<br />

neurotoxicity<br />

amphotericin B, 419<br />

amphotericin B mono-methyl ester<br />

derivative, 419<br />

Toxoplasma gondii<br />

anticoccidial agents<br />

susceptibility <strong>and</strong> resistance, 2358<br />

atovaquone-clarithromycin<br />

in vitro <strong>and</strong> in vivo activities, 2371<br />

atovaquone-minocycline<br />

in vitro <strong>and</strong> in vivo activities, 2371<br />

atovaquone-pyrimethamine<br />

in vitro <strong>and</strong> in vivo activities, 2371<br />

atovaquone-sulfadiazine<br />

in vitro <strong>and</strong> in vivo activities, 2371<br />

azithromycin<br />

combinations, in vitro activities of,<br />

1993<br />

protein synthesis, inhibition of, 1701<br />

clindamycin<br />

infectivity, 2571<br />

intracellular replication, 2571<br />

protein synthesis, 2571<br />

dihydrofolate reductase<br />

inhibitors, identification of, 1914

VOL. 37, 1993<br />

poloxamers<br />

toxoplasmosis, 2265<br />

pyrimethamine<br />

combinations, in vitro activities of,<br />

1993<br />

toxoplasmosis<br />

poloxamers, 2265<br />

Toxoplasmosis<br />

poloxamers, 2265<br />

T. gondii, 2265<br />

Treponema pallidum<br />

clarithromycin<br />

hamsters, 864<br />

Triazino[5,6-b]indoles<br />

GR99060<br />

antifungal properties, 1243<br />

GR99062<br />

antifungal properties, 1243<br />

Triazoles<br />

D0870<br />

blastomycosis, murine, 1177<br />

pathogenic yeasts, 2126<br />

Tnchophyton mentagrophytes<br />

butenafine<br />

guinea pigs, 363<br />

Trimethoprim<br />

dihydrofolate reductase cassette<br />

integron on a Tn2l-like element, 1297<br />

H. influenzae<br />

adherence changes induced by subinhibitory<br />

concentrations, 885<br />

K pneumoniae<br />

adherence changes induced by subinhibitory<br />

concentrations, 885<br />

M. catarrhalis<br />

adherence changes induced by subinhibitory<br />

concentrations, 885<br />

resistance<br />

dihydrofolate reductase cassette inserted<br />

on an integron on a Tn2llike<br />

element, 1297<br />

Trimethoprim-sulfamethoxazole<br />

pharmacokinetics<br />

12/60 mg/kg/day, multiple dose, 448<br />

healthy volunteers, 448<br />

S. mutans<br />

in vitro susceptibility, 1158<br />

Tritrichomonas foetus<br />

zinc<br />

electron microscopic study, 2722<br />

Trypanosoma brucei brucei<br />

N-n-alkyl-3,4-dihydroxybenzamide<br />

in vitro <strong>and</strong> in vivo activities, 1082<br />

G418 resistance phenotype<br />

in vivo system to select for bloodstream-form<br />

transfectants, 1167<br />

Trypanosoma congolense<br />

Boran cattle<br />

diminazine pharmacokinetics, effect of<br />

infection on, 1050<br />

quinapyramine resistant<br />

derivation <strong>and</strong> characterization, 1163<br />

Trypanosoma cruzi<br />

N,N'-bis(benzyl)-substituted polyamine<br />

analogs<br />

inhibition of host cell invasion <strong>and</strong><br />

intracellular replication, 2235<br />

ICI 195,739-terbinafine<br />

murine model, 1353<br />

ketoconazole-terbinafine<br />

murine model, 1353<br />

Trypanosoma (Schizotrypanum) cruzi<br />

mevinolin<br />

ketoconazole <strong>and</strong> terbinafine, potentiation<br />

of antiproliferative effects, 580<br />

Tuberculosis<br />

multidrug resistant<br />

studies with mice, 2344<br />

Tumor necrosis factor<br />

murine models<br />

amphotericin B, 2228<br />

receptors<br />

relation to therapy of typhoid fever,<br />

2418<br />

Tumor necrosis factor alpha<br />

amphotericin B, 1958<br />

C. albicans, 1958<br />

Turbidimetric assays<br />

viable bacterial densities, quantitation of<br />

E. coli, 371<br />

Typhoid fever<br />

ceftriaxone<br />

5 days, comparative evaluation, 1572<br />

chloramphenicol<br />

14 days, comparative evaluation, 1572<br />

ciprofloxacin<br />

severe, in children, 1197<br />

interleukin-6, gamma interferon, <strong>and</strong> tumor<br />

necrosis factor receptors<br />

relation to outcome of antimicrobial<br />

therapy, 2418<br />

severe<br />

ciprofloxacin, 1197<br />

U-90152<br />

human immunodeficiency virus type 1<br />

replication, inhibition of, 1127<br />

Ureaplasma diversum<br />

antimicrobial susceptibilities, 317<br />

Ureaplasma urealyticum<br />

OPC 17116<br />

susceptibility in vitro, 1726<br />

Ureidopenicillins<br />

F. oryzihabitans<br />

in vitro activities against clinical isolates<br />

from patients with cancer,<br />

2504<br />

Urinary tract infections<br />

acute uncomplicated<br />

lomefloxacin, 3 days, comparative<br />

evaluation, 574<br />

norfloxacin, 3 days, comparative evaluation,<br />

574<br />

cefozopran, 100<br />

enoxacin<br />

cefuroxime axetil, more rapid than,<br />

1558<br />

rapid symptom alleviation, 1558<br />

lomefloxacin<br />

3 days, comparative evaluation, 574<br />

nitrofurazone<br />

catheter associated, 2033<br />

norfloxacin<br />

3 days, comparative evaluation, 574<br />

P. aeruginosa<br />

cefozopran, 100<br />

recurrent<br />

enoxacin, rapid symptom alleviation,<br />

1558<br />

rapid symptom alleviation, 1558<br />

Vancomycin<br />

adherence<br />

Staphylococcus spp., effect of subin-<br />

SUBJECT INDEX xxxv<br />

hibitory concentrations on, 921<br />

B. burgdorfeni<br />

in vitro activity, 1115<br />

E. faecalis<br />

1-lactamase producing, highly gentamicin<br />

resistant, 1447<br />

endocarditis, 1447<br />

E. faecalis resistance gene<br />

homology with vanB, vanA, <strong>and</strong><br />

vanC, 1604<br />

E. faecium resistance, 1904<br />

endocarditis, 2069<br />

E. faecium resistance gene<br />

homology with vanB, vanA, <strong>and</strong><br />

vanC, 1604<br />

gram-positive organism resistance<br />

ramoplanin, 1364<br />

gram-positive organisms, resistance<br />

RP59500, 598<br />

pharmacokinetics<br />

obesity, effect on, 436<br />

pulmonary lining fluid, penetration<br />

into, 281<br />

serum protein-binding characteristics,<br />

1132<br />

pulmonary lining fluid<br />

penetration into, 281<br />

"red man syndrome"<br />

skin tests to healthy volunteers, 2139<br />

S. epidermidis<br />

diffusion through a biofilm, 2522<br />

Staphylococcus spp.<br />

adherence, effect of subinhibitory concentrations<br />

on, 921<br />

Visna virus<br />

acyclic nucleoside phosphonate analogs<br />

inhibition of replication, 2540<br />

2' ,3'-dideoxynucleosides<br />

inhibition of replication, 2540<br />

WIN 54954<br />

coxsackievirus<br />

group B diabetogenic strain in mice,<br />

1593<br />

rhinovirus<br />

prophylaxis, efficacy of, 297<br />

WIN 57273<br />

E. faecalis<br />

activity against high-level gentamicinresistant<br />

strains, 2470<br />

Yeasts<br />

D0870<br />

in vitro activities, 2126<br />

susceptibility testing<br />

broth macrodilution, 39<br />

multicenter evaluation, 39<br />

Zalcitabine<br />

salmonellae<br />

in vitro activities, 106<br />

Zidovudine<br />

embryos, implantation of<br />

prevention of, 1610<br />

human immunodeficiency virus resistance<br />

pol mutations, multiple resistance,<br />

1480<br />

human immunodeficiency virus type 1<br />

sensitivity<br />

discontinuation of zidovudine treatment,<br />

effects on, 1525<br />

pharmacokinetics

xxxvi SUBJECT INDEX ANTIMICROB. AGENTS CHEMOTHER.<br />

effects of st<strong>and</strong>ard breakfast in patients<br />

with AIDS, 2153<br />

granulocyte-macrophage colony-stimulating<br />

factor, administration with,<br />

512<br />

prodrugs, enhanced levels in brain tis-<br />

sue, 818<br />

rifampin, interaction with, 1426<br />

prodrugs<br />

pharmacokinetics, enhanced levels in<br />

brain tissue, 818<br />

rifampin<br />

Statement of Ownership,<br />

Management <strong>and</strong><br />

Circulation<br />

(Required by 39 U.S.C. 3685)<br />

IA. Title of Publication 1S. PUBLICATION NO. 2. Date of Filing<br />

pharmacokinetic interaction with, 1426<br />

salmonellae<br />

in vitro activities, 106<br />

Zinc<br />

T. foetus<br />

electron microscopic study, 2722<br />

<strong>Antimicrobial</strong> Aqents <strong>and</strong> <strong>Chemotherapy</strong> 0 0 6 161 41 81 0 4 10-12-93<br />

3. Frequency of Issue No. of Issues Published 38. Annual Subscription Price<br />

Annually<br />

Monthly 12 $49 mbr, $250 nonmbr<br />

4. Complete Mailing Address of Known Office ol Publication (Strre City, Cse,.<br />

American Society for Mlicrobiology<br />

1325 Massachusetts Ave., N.W., Washinqton, D.C.<br />

ad ZIP+4 Code) (No<br />

20005-4171<br />

priaters)<br />

5. Complete Mailing Address of the Headquarters of General Business Offices of the Publisher (Not priaer)<br />

(Same as above)<br />

6. Full Names <strong>and</strong> Complete Mailing Address of Publisher, Editor, end Wanaging Editor (In Now MUST NOT be lank)<br />

Publisher (Name <strong>and</strong> Complete Mailing Address)<br />

(Same as above)<br />

Editor (Name <strong>and</strong> Complete Mailing Address)<br />

Robert C. Moellering, Jr.<br />

(Address same as above)<br />

Managing Editor (Name <strong>and</strong> Complete Mailing Adress)<br />

Linda M. Illig<br />

(Address same as above)<br />

7. Owner (if sohned bv a corporation. its name <strong>and</strong> address et be stated aed also imledately thereunder the nams o<strong>and</strong> addresses of stosckholders owning or holding<br />

I per ent sJr mnore of total amount of stck. If nor owned by a cotpoaton. the nams nd addresses of the ildindual owners must be gisen. If otrned bh a partners/ip<br />

or other unincorporated firn. its nomw <strong>and</strong> address, as swll at that of eac* diWdl erst be given. If the publication is published by a nonprofit organizatissn. its<br />

name <strong>and</strong> address must be stated.) (Item must be coepleted.)<br />

FuN Name Complete MelIng Address<br />

%merican Society for Microbiology 1325 Massachusetts Ave., N.W.<br />

Washington. D.C. 20005-4171<br />

8. Known Bondholders, Mortgagees, <strong>and</strong> Other Security Holders Owning or HoldIng 1 Percent or More of Total Amount of Bonds, Mortgages or Other<br />

Securities (if there are none, so state)<br />

FuN Nam Complete MeIUng Address<br />

None<br />

9. For Completion by Nonprofit Organizations Authorized To MaN at Specil Rates (DIM Secdon 424.12 only)<br />

The purpose, function, <strong>and</strong> nonprofit status of this organization <strong>and</strong> the exempt atatus for Federal income tax purposes (Chesi osse)<br />

Ill 121<br />

W Has Not Changed During Has Changed During (if changed, publisher must submit explanation of<br />

LAlPreceding 12 Months I Preceding 12 Months chagewith this statement.)<br />

10. Extent <strong>and</strong> Nature of Circulation Averae No. Copies Each Issue During Actual No. Copies of Single Issue<br />

(See instructions on reverse side) Proceding 12 Months Published Nearest to Filing Date<br />

A. Total No. Copies (Net Press Run) 8,775 8,800<br />

B. Paid <strong>and</strong>/or Requested Circulation<br />

1. Sales through dealers <strong>and</strong> carriers, street vendors <strong>and</strong> counter sWas<br />

2. Mail Subscription<br />

(Paid <strong>and</strong>/or requested) 7,171 7, 751<br />

C. Total Paid <strong>and</strong>/or Requested Circulation<br />

1Sum of 10I11 <strong>and</strong> /082/ 7,171 7,751<br />

D. Free Distribution by Mail, Carrier or Other Means<br />

Samples, Complimentary, <strong>and</strong> Other Free Copies 1 10 1 10<br />

E. Total Distribution (Sum of C<strong>and</strong>D7,D86 7,28<br />

F. Copies Not Distributed<br />

1. Office ise, left over, unaccounted, spoiled after printing 1 ,494 939<br />

2 Return from News <strong>Agents</strong><br />

G. TOTAL (Sum sf E, Fl <strong>and</strong> 2-should equal ne press unR shoun in A) 8,775 8,800<br />

I certify that the statements made by<br />

me above are correct <strong>and</strong> complete<br />

Signature <strong>and</strong> Titie of Editor, Publisher, Businhss Manager, or Owner<br />

A . K Director, Journals<br />

PS PS<br />

Form Form<br />

3526, 3526.<br />

Januarv January<br />

1991 M-f instmWtroa on reverse)<br />

1991 (See instructions on reverse)~~~~~~~~~~~~~~~~~<br />

--I

logo

products

Resources

Company

Terms of service
Privacy policy
Cookie policy
Cookie settings
Imprint
Change language
Made with love in Switzerland
© 2024 Yumpu.com all rights reserved

Hooray! Your file is uploaded and ready to be published.

Saved successfully!

Ooh no, something went wrong!